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Abstract 
 
Functional Domain Contributions to Signaling 
Specificity Between the Non-Receptor Tyrosine 
Kinases c-Src and c-Yes 
 
Justin Summy 
 
 c-Src and c-Yes are two widely expressed and highly homologous members of the 
Src family of non-receptor tyrosine kinases and are involved in a diverse range of cellular 
signaling pathways.  They are frequently activated in human cancers, and thus represent 
potential targets for anti-tumor drug design.  The high level of homology between these 
two kinases includes not only sequence similarity, but also overlapping regulation and 
function.  Despite the redundancies between c-Src and c-Yes, however, specificity in 
signaling has been demonstrated between the two proteins.  It was hypothesized in these 
studies that differences in the signaling capacities of c-Src and c-Yes could be attributed 
to functional domain differences.  In order to test this hypothesis, chimeric proteins were 
created in which the SH4, Unique, SH3, or SH2 domains of c-Src or the constitutively 
activated Src527F, were replaced by those of c-Yes, either individually or in combinations.  
Differences in the signaling capacities of these proteins were assessed at the levels of 
protein/protein interactions, downstream gene induction, and cell biology.   It was 
demonstrated that both the SH3 and SH2 domains were capable of directing differential 
protein/protein interactions between c-Src and c-Yes.  While no differences in substrate 
selection were evident, the c-Yes SH3 domain failed to efficiently bind the Src SH3 
binding partner AFAP-110 and several additional tyrosine-phosphorylated binding 
partners.  Additionally, the c-Yes SH2 domain facilitated stable complex formation 
between Src527F/c-Yes chimeras and an unidentified 87 kDa tyrosine-phosphorylated 
protein, pp87.  Differences in downstream gene induction and cell biology were mediated 
by the amino terminal region (including the SH4 and Unique domains), as Src527F/c-Yes 
amino terminal chimeras failed to induce efficient upregulation of Heme Oxygenase 1 
expression and were unable to induce actin filament rearrangement or changes in cell 
morphology upon expression in chicken embryo fibroblasts.  These results occurred 
concomitant with a failure of these chimeras to induce activation of the PI3K/Akt 
pathway and inactivation of RhoA.  Taken together, these results indicate that each of the 
non-catalytic functional domains may contribute to signaling specificity between c-Src 
and c-Yes.  These results may contribute to the overall knowledge of biological 
differences between c-Src and c-Yes and how Src family kinases in general are able to 
achieve signaling specificity. 
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I.  Introduction and Significance 
p62 c-Yes and p60 c-Src are two of the nine members of the Src family of non-
receptor tyrosine kinases (c-Src, c-Yes, Fyn, Lyn, Lck, Hck, Blk, Fgr, and Yrk).  Src 
family kinases are linked by a common structural architecture, each with four Src 
homology domains (SH1-4) and a Unique domain.  The Src family kinases have been 
implicated in signaling pathways that regulate a vast array of cellular processes, including 
cytokine and growth factor responses, cytoskeleton dynamics, cell proliferation, survival 
and differentiation (Rev. in Thomas and Brugge, 1997).  While c-Src has been 
extensively studied, comparatively little is known of the biological functions of c-Yes.  c-
Yes and c-Src are two of the most widely expressed and homologous members of the Src 
family.  Both kinases are present in many of the same tissues and are activated in 
response to many of the same stimuli.  The frequent activation of c-Src and c-Yes in 
human cancers, coupled with the tumorigenic potential of their viral homologues, v-Src 
and v-Yes, suggests that they may contribute to the onset or progression of the malignant 
phenotype.  Thus c-Src and c-Yes represent potential targets for rational drug design.  In 
order to optimize the value of these kinases as chemotherapeutic targets, it will not only 
be important to understand the biological functions of c-Yes and c-Src, both in normal 
and cancerous tissues, but also to understand how they are capable of sending specific 
signals.  As the biology and functions of c-Src have been extensively studied and 
reported, this literature review will focus on the functions of c-Yes and how c-Yes may 
be able to participate in specific signaling pathways.  
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II.  v-Yes and v-Src 
The Yes kinase was originally discovered as the oncogenic protein encoded by the 
Yamaguchi 73 and Esh sarcoma viruses (Ghysdael et al., 1981; Rev. in Toyoshima et al., 
1987; Wang and Hanafusa, 1988).  Initial interest in v-Yes arose as a result of its 
similarity to v-Src.  Both oncoproteins are tyrosine kinases capable of inducing sarcomas 
in chickens and transforming fibroblasts in culture (Toyoshima et al., 1987).  v-Src and 
v-Yes are 82% homologous, with particularly strong homology (90%) within the tyrosine 
kinase domain (Kitamura et al., 1982).  The amino acid homology between the two 
kinases allows immunorecognition of v-Yes by monoclonal antibodies raised against v-
Src (McCarley et al., 1987), and the two proteins release overlapping subsets of tyrosine-
phosphorylated peptides upon tryptic digestion and two-dimensional electrophoresis 
(Erikson and Erikson, 1983).  In addition to their structural homology, biochemical and 
functional similarities have been observed between v-Src and v-Yes in chicken embryo 
fibroblast culture.  Both proteins fractionate with the detergent-insoluble cytoskeleton 
and localize to focal contacts, where the cell and extracellular matrix meet (Loeb et al., 
1987; Gentry and Rohrschneider, 1984).  Many of the same proteins are phosphorylated 
in cells transformed by either v-Src or v-Yes (Kamps and Sefton, 1988; Kanner et al., 
1990).  v-Src and v-Yes also appear to utilize shared downstream signaling pathways, as 
both proteins induce activation of PI3 kinase and require the activator protein 1 (AP-1) 
transcription factor complex (composed of heterodimers of various isoforms of the c-Jun 
and c-Fos transcription factors) for cell transformation (Fukui et al., 1991; Suzuki et al., 
1994).    
Homology between v-Src and v-Yes can be extended further to include the 
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mechanisms by which these kinases have been rendered transformation-competent.  Both 
kinases are constitutively active due to loss or replacement of sequence in their carboxy-
termini (Rev. in Brown and Cooper, 1996).  Src family kinases contain a conserved 
tyrosine residue (Tyr527 in c-Src, Tyr535 in c-Yes) in their carboxy-terminal tail sequence.  
This tyrosine residue is phosphorylated by members of the Csk (C-terminal Src kinase) 
family and forms an intramolecular interaction with the SH2 domain (Okada et al., 1991).   
The SH2/tail interaction forms the linchpin of the “closed” or “assembled” conformation 
(Xu et al., 1997; Sicheri et al., 1997).  The SH3 domain contributes to the stability of the 
closed conformation through formation of an intramolecular interaction with the kinase 
linker, a short stretch of amino acids bridging the SH2 and kinase domains (Xu et al., 
1997; Sicheri et al., 1997).  In the assembled state, the conformation of the kinase active 
site is such that ATP and substrates are prevented from entering, resulting in repressed 
kinase activity (Xu et al., 1999).  Although recent evidence indicates that 
autophosphorylation within the active site (Tyr416 in Src, Tyr424 in Yes) may allow kinase 
activity in the presence of phosphorylation at the regulatory tyrosine (Sun et al., 1998; Xu 
et al., 1999), Src family kinases must be released from the closed conformation in order 
to achieve their full transforming potential.  The ability of v-Src, v-Yes, Src527F (in which 
Tyr527 is mutated to Phe), and various SH3 and SH2 domain mutants of c-Src to 
transform cells illustrates this point (O’brien et al., 1990; Superti-Furga et al., 1993; 
Brown and Cooper, 1996).   
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III.  c-Yes Expression Patterns: Comparison and Contrast with c-Src 
            The c-yes gene, localized to chromosome 18 at locus q21.3 in humans (Yoshida et 
al., 1985), was discovered as the cellular homologue of the v-yes oncogene (Yoshida et 
al., 1980; Sukegawa et al., 1987; Sudol et al., 1988b).  The c-yes gene encodes a 62 kDa 
tyrosine kinase that displays extensive homology with the c-Src protein and, like c-Src, is 
expressed across a wide range of normal cells and tissues (Sudol and Hanafusa, 1986).  c-
Yes expression is found in epithelial tissues (lung, kidney, gastrointestine, liver, skin, 
etc.), connective tissue, vascular endothelial cells, and smooth muscle; expression levels 
are particularly high in platelets, neurons (particularly Purkinje cells of the cerebellum), 
and spermatid acrosomes (Sudol et al., 1989; Zhao et al., 1990; Sugawara et al., 1991; 
Zhao et al., 1991; Walaas et al., 1993).  While c-Src is also expressed in many of these 
tissues, the expression patterns of the two proteins are not identical, thus providing 
evidence that c-Yes may perform functions unique from those of c-Src.   Gessler and 
Barnekow observed that the c-yes and c-src genes were differentially expressed during 
chicken embryogenesis (Gessler and Barnekow, 1984).  In these studies, c-src message 
was expressed at high levels in brain throughout embryogenesis and displayed an age-
dependent decrease in muscle tissue.  Message levels of c-yes were initially low in brain, 
muscle, and heart, but increased throughout embryogenesis.  Bixby and Jhabvala noted 
differential developmental expression of c-Src and c-Yes in the brain (Bixby and 
Jhabvala, 1993).  Peak c-Src expression was observed between days 10 and 12, followed 
by a gradual decrease in expression, whereas c-Yes expression did not peak until day 20 
and remained at high levels into adulthood.  Sudol et al. noted a similar age-dependent 
decrease in chicken cerebellar c-Src expression, in contrast to increased c-Yes expression 
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(Sudol et al., 1988a).  Collectively, these data imply that c-Src and c-Yes may perform 
different functions in the developing embryo and adult.   
IV.  Involvement of c-Yes in Cellular Signaling Pathways 
  While c-Yes has not been studied as exhaustively as c-Src, several studies over 
the past decade have examined the biological functions of cellular Yes.  The ability of v-
Yes to induce cellular transformation suggests that c-Yes may be involved in the control 
of cell proliferation.  However, the fact that many of the cells in which c-Yes is highly 
expressed are post-replicative (i.e. neurons, platelets) and fully differentiated suggests a 
possible role in differentiation or the facilitation of cell-specific processes.  In fact, 
evidence exists for involvement of c-Yes, and Src family kinases in general, in a variety 
of signal transduction pathways, including those that regulate cell division, 
differentiation, survival, motility, adhesion, spreading, and vesicular transport (Thomas 
and Brugge, 1997).  In serum-starved NIH 3T3 fibroblasts, serum stimulation results in 
activation of c-Yes, along with c-Src and Fyn, during the G2/M cell cycle transition 
(Roche et al., 1995).  c-Yes and c-Src are both activated during proliferation and 
differentiation of rat trophoblast cells (Kamei et al., 1997).  In keratinocytes, calcium 
treatment results in decreased c-Yes kinase activity, coinciding with a shift from cellular 
proliferation to differentiation (Zhao et al., 1993).  Owens et al. demonstrated that, upon 
calcium treatment of epithelial cells, c-Yes, c-Src, and Fyn localize to sites of cell/cell 
contact, where their kinase activity is necessary for disruption of cell/cell junctions 
(Owens et al., 2000).  In cultured neuronal cells, c-Yes, c-Src, and Fyn are concentrated 
and activated in growth cones (Meyerson and Pahlman, 1993).  c-Yes is also activated in 
response to stimulation of receptor tyrosine kinases (PDGF-R, CSF-1-R, Neu, FGF-R, 
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Sky, Flt 1) (Kypta et al., 1990; Courtneidge et al., 1993; Muthuswamy and Muller, 1995; 
Landgren et al., 1995; Toshima et al., 1995; Waltenberger et al., 1994), G-protein 
coupled receptors (angiotensin II receptor, thrombin receptor, endothelin receptor) 
(Tsygankova et al., 1998; Chen et al., 1994; Kovacic et al., 1998), cytokine receptors 
(oncostatin M, interleukin-11, GM-CSF) (Schieven et al., 1992; Fuhrer and Yang, 1996a; 
Corey et al., 1993), the FcεRI receptor, and the polyimmunoglobulin (pIg) receptor 
(Eiseman and Bolen, 1992; Luton et al., 1999). 
V.  Specificity in Signaling Between c-Yes and Other Src Family Kinases 
            While the above list represents what is likely to be only a sampling of the 
pathways in which c-Yes is involved, it illustrates the potential for diversity in the 
function of this kinase.  However, as c-Src and other Src family kinases are activated in 
response to many of the same cellular signals, it is not always clear where c-Yes performs 
unique functions and where it functions redundantly with other Src family kinases.  The 
answer appears to vary from system to system.  c-Yes may function redundantly with c-
Src and Fyn in serum-induced fibroblast cell cycle progression.  Microinjection of 
antibodies immunoreactive against all three proteins induces a cell cycle block at the 
G2/M phase transition, whereas microinjection of a c-Src-specific antibody does not 
interfere with cell cycle progression unless no other Src family kinases are expressed 
(Roche et al., 1995).  c-Yes may also function redundantly with c-Src and Fyn in PDGF-
receptor signaling (Mori et al., 1993; Twamley-Stein et al., 1993).   
 The phenotypes of the Src family kinase knockout mice provide further evidence 
for shared functions between Src family members.  Whereas c-src -/-, fyn -/-, and c-yes -/- 
individual knockout mice develop distinct phenotypes, they typically survive for 
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extended periods after birth. The loss of both the c-src and c-yes genes, however, 
invariably leads to perinatal lethality (Stein et al., 1994).  Mice lacking both the fyn and 
c-yes genes develop degenerative renal damage, leading to diffuse segmental 
glomerulosclerosis (Stein et al., 1994).  Interestingly, mice harboring a disruption of the 
c-yes gene do not display significant abnormalities in the cells or tissues in which c-Yes 
is most highly expressed (platelets, neurons, and spermatid acrosomes), suggesting that c-
Src and/or Fyn are capable of compensating for the lack of c-Yes activity in these cells.   
            Despite the evidence for functional overlap, data also exist that indicate c-Yes- 
specific signaling.  Much of this data is obtained from studies of c-src -/- mice and cells 
derived from them.  Several of these studies indicate that c-Yes is unable to compensate 
for c-Src in processes that are dependent on the dynamic regulation of the actin 
cytoskeleton.  Osteoclasts from c-src -/- mice are unable to reabsorb bone, resulting in an 
osteopetrotic phenotype (Soriano et al., 1991).  This deficiency correlates with an 
inability of the osteoclasts to form membrane ruffles and actin ring structures (Boyce et 
al., 1992).  Additionally, cells from the c-src -/- mice fail to spread properly on 
fibronectin and demonstrate reduced motility (Kaplan et al., 1995; Hall et al., 1996).  
Neuronal cells derived from c-src -/- mice are deficient in neurite extension on NCAM-
L1 (Ignelzi, Jr. et al., 1994). Mice lacking the c-src gene also fail to develop Middle T 
antigen-induced mammary tumors, whereas c-yes -/- mice develop mammary tumors at a 
normal rate (Guy et al., 1994).  Despite the apparent deficiency of c-Yes in eliciting these 
actin-dependent processes, active variants of Yes are localized to detergent insoluble 
cytoskeletal fractions (Loeb et al., 1987).  It is possible that c-Yes may associate with 
and/or regulate other components of the cytoskeleton.  Indeed, it was observed by 
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Ciesielski-Treska et al. that c-Yes co-localizes specifically with vimentin intermediate 
filaments in amoeboid microglia (Ciesielski-Treska et al., 1995).     
            The inability of c-Yes to function as a “molecular backup” for c-Src is not limited 
exclusively to regulation of the actin cytoskeleton.  In rat aortic smooth muscle cells, c-
Src specifically is necessary for angiotensin II-induced phosphorylation of p120 Ras 
GAP and p190 Rho GAP (Schieffer et al., 1996).  In rat ventricular myocytes, c-Yes, c-
Src, and Fyn are activated in response to endothelin, however, only c-Src is able to drive 
elevated transcription from the atrial natriuretic peptide promoter, a hallmark of 
hypertrophy in ventricular cardiomyocytes (Kovacic et al., 1998).  c-Src and c-Yes also 
differ in their respective abilities to participate in the hypoxia response.  Of the three 
ubiquitously expressed Src family members, c-Src exclusively is activated under hypoxic 
conditions (Mukhopadhyay et al., 1995).  This is in agreement with recent data that 
indicates that Src527F/c-Yes chimeras with the c-Yes SH4 and Unique domains are 
deficient in upregulation of Heme Oxygenase 1 expression, as normally occurs in 
response to cellular stresses, including hypoxia (Hoey et al., 2000).   
            Specificity between c-Yes and c-Src is not limited to pathways in which c-Yes 
fails to compensate for c-Src.  While both c-Yes and c-Src are able to induce 
phosphorylation of the adapter protein Cbl when overexpressed in COS cells, only c-Yes 
is able to efficiently co-immunoprecipitate with Cbl (Feshchenko et al., 1998).  During 
trophoblast cell proliferation, c-Yes associates with several tyrosine-phosphorylated 
proteins that are not found in complex with other Src family kinases (Kamei et al., 1997).  
As mentioned above, c-Yes is inactivated in keratinocytes upon calcium and phorbol 
ester treatment (Zhao et al., 1993).  In this system, c-Yes inactivation correlates with 
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association with unknown proteins of 110 and 220 kDa (Zhao et al., 1993).  In 3T3 L1 
mouse pre-adipocytes, both c-Src and c-Yes are activated upon IL-11 stimulation; 
however, only c-Yes is detected in a receptor-associated signaling complex including 
JAK2, PP2A, and gp130 (Fuhrer and Yang, 1996b).  In angiotensin II-treated pulmonary 
vein endothelial cells, of the three ubiquitously expressed Src family kinases, only c-Yes 
induces phosphorylation of and associates with the calcium-sensitive kinase Pyk2 (Tang 
et al., 2000).  Unfortunately, the importance of co-association between c-Yes and the 
proteins mentioned above remains unknown.  They do however, illustrate that c-Yes is 
capable of forming distinct protein/protein interactions and is thus capable of initiating or 
participating in unique signaling pathways.   
In addition to differences in intermolecular interactions, signaling specificity 
between c-Src and c-Yes has been observed at the level of kinase activation.  c-Yes is the 
predominant Src family kinase activated upon engagement of the Fcε receptor in the TF-
1 mast cell line (Eiseman and Bolen, 1992) and upon stimulation of neutrophils with 
oncostatin M (Schieven et al., 1992).  By virtue of its localization to lipid raft fractions, 
c-Yes may be selectively involved in the renal tubular cell internalization of Shiga toxin 
(Stx), produced by Shigella dysenteriae and enterohemorrhagic Escherichia coli.   c-Yes 
associates with the globotriaosylceramide Gb3, to which Stx binds.  Association of Stx 
with Gb3 induces c-Yes-specific kinase activation (Katagiri et al., 1999).  The 
importance of c-Yes activity for Stx entry was not determined.  In rat liver epithelial 
cells, c-Yes and Fyn are specifically activated in response to angiotensin II (Tsygankova 
et al., 1998).  In this system, c-Yes and Fyn are essential for the induction of DNA 
synthesis and c-Fos expression, as both responses are inhibited by microinjection of 
 11 
antibodies against either protein (Tsygankova et al., 1998).  Both c-Src and c-Yes, but not 
Fyn, appear to be required for VEGF-induced vascular permeability in mice, as cells 
lacking either protein are deficient in this response (Eliceiri et al., 1999).   Finally, c-Yes 
specifically associates with the pIg receptor and is activated upon receptor engagement 
(Luton et al., 1999).  c-Yes appears to be required for pIg receptor-mediated transcytosis, 
as mice lacking the c-yes gene are deficient in transcytosis of IgA (Luton et al., 1999).  
Taken together, these results indicate that in normal cells, c-Yes is able to send unique 
signals. 
VI.  c-Yes in Cancer and Disease 
            The ability of v-Yes to induce cell transformation piqued interest in the study of 
the normal cellular homologue, as it was inferred that c-Yes might be involved in the 
onset or progression of human cancers.  As with c-Src, several lines of evidence have in 
fact pointed to this possibility.   The evidence is largely circumstantial, however, and 
consists primarily of observations that c-Yes is activated in several transforming, 
cancerous, and pre-cancerous conditions.  Nevertheless, the data discussed below have 
laid the groundwork for future studies of c-Yes in human cancers.  Both c-Yes and c-Src 
are frequently activated in human colon carcinoma cells and pre-malignant lesions of the 
colon (Cartwright et al., 1989; Park et al., 1993; Cartwright et al., 1994; Pena et al., 
1995).  The degree of c-Yes and/or c-Src kinase activation in these cells correlates with 
their malignant potential (Cartwright et al., 1994; Pena et al., 1995).  In colorectal 
carcinoma liver metastases, the kinase activity of either c-Src or c-Yes decreases relative 
to the parent tumor (Han et al., 1996).  However, activation of c-Yes in colon carcinoma 
liver metastases is associated with more aggressive disease and a poorer prognosis than c-
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Src activation (Han et al., 1996).  Interestingly, Park and Cartwright demonstrated that 
while c-Src activity increases during mitosis of human colon carcinoma cells, c-Yes 
protein expression and activation decrease (Park and Cartwright, 1995).  c-Yes protein 
levels and kinase activity are elevated 5-10 fold in malignant melanoma cells, in 
comparison to normal melanocytes, whereas c-Src activity and expression are unchanged 
(Loganzo, Jr. et al., 1993).  c-Yes kinase activity correlates with the brain metastatic 
potential of melanoma cell lines, as the most highly metastatic melanoma cell lines 
display the highest levels of c-Yes kinase activity (Marchetti et al., 1998).  c-Yes activity 
is further elevated upon stimulation with NGF or neurotrophin 3 (Marchetti et al., 1998).  
The neurotrophin-induced activation is specific for c-Yes, as c-Src activity is not 
affected.  Despite the apparent dispensability of c-Yes kinase activity for Middle T 
antigen-induced murine breast tumors, the ability of Middle T to transform cells 
correlates well with its ability to associate with and activate both c-Src and c-Yes 
(Courtneidge, 1985; Kornbluth et al., 1987; Kornbluth et al., 1990; Glenn and Eckhart, 
1993).  While c-Yes activity does not appear to be necessary for transformation of 
fibroblasts by Middle T, it is important for Middle T-induced transformation of 
endothelial cells (Reported in Guy et al., 1994).  In human breast cancer cells, 
overexpression of members of the EGFR family, specifically erbB-2 (Neu), is associated 
with poor clinical prognosis.  When expressed in mice, under control of the mouse 
mammary tumor virus (MMTV) promoter, the Neu protein induces transformation of 
breast epithelial cells.  In this system, the Neu protein associates with and activates both 
c-Src and c-Yes through SH2 domain interactions (Muthuswamy and Muller, 1995).  
Moasser et al. demonstrated up-regulation of c-Src and/or c-Yes kinase activity in a panel 
 13 
of human breast cancer cell lines, and inhibition of Src family kinase activity in this 
system resulted in cell cycle arrest during mitotic prophase (Moasser et al., 1999).    
Together, the above data illustrate that not only is c-Yes activated in select human 
cancers, but its contributions to the transformed phenotype may differ from those of c-
Src.   Furthermore, the differential activation of c-Yes and c-Src in some human cancers 
suggests that it may be beneficial to selectively target these kinases individually using 
rational drug design.  In order to accomplish this, however, it is necessary to understand 
how these kinases send specific signals.  
VII.  Contributions of the c-Yes Functional Domains to Signaling Specificity 
As a member of the Src family, c-Yes shares the functional domain architecture 
common to all Src family kinases.  As mentioned above, this consists of four homologous 
domains and a Unique domain.  While the c-Yes functional domains, specifically, have 
not been studied extensively, a great deal has been learned about the roles of Src family 
functional domains in general, and this knowledge will be important in the elucidation of 
how the c-Yes functional domains are likely to contribute to signaling specificity.     
 
 
 
 
 
 
 
 
SH4 Unique SH3 SH2 PTK Reg Y 
A Prototypical Src Family Kinase Sub-Divided into the Functional Domains 
 14 
VII.A.  SH4 Domain 
The amino terminal 7-14 amino acids are referred to as the SH4 domain (Rev. in 
Resh, 1994).  This region is necessary and sufficient for localization to cellular 
membranes.  All Src family members contain a glycine in the second position from the 
amino terminus.  This glycine is myristoylated co-translationally and targets Src family 
members to cellular membranes.  While the addition of myristic acid is necessary for 
membrane localization, it is not sufficient (Resh, 1994).  All Src family members, with 
the exception of c-Src and Blk, additionally undergo palmitoylation at one or more 
cysteine residues downstream of the myristoylation site (Resh, 1994).  Palmitoylation 
occurs post-translationally, and potentially spontaneously, as cysteine-acylation has been 
shown to occur spontaneously in the presence of acyl-CoA in vitro (Bano et al., 1998).  
However, prior myristoylation is required for palmitoylation (Koegl et al., 1994).  It has 
been suggested that palmitoylation is a dynamic process and may serve as a means of 
regulating the sub-cellular localization of Src family members and their access to 
substrates (Yurchak and Sefton, 1995).  Palmitoylation targets Src family members to 
lipid rafts, regions of the plasma membrane rich in glycolipids, sphingolipids, cholesterol, 
and glycosylphosphatidyl inositol-linked proteins, that can be isolated by flotation on 
sucrose gradients (Shenoy-Scaria et al., 1993; Robbins et al., 1995).  The importance of 
the SH4 domain in raft localization has not been demonstrated specifically for c-Yes but 
has been shown for other Src family members, including Lck and Hck (Shenoy-Scaria et 
al., 1993).  However, since c-Yes is palmitoylated and is found in lipid rafts (Sargiacomo 
et al., 1993; Arreaza et al., 1994), it is likely that palmitoylation also serves to target c-
Yes to these membrane microdomains.   
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Several recent studies have revealed the importance of palmitoylation and lipid 
raft localization in Src family kinase signaling.  A functional palmitoylation signal is 
required for the ability of Src family kinases to efficiently transduce signals from the T 
cell receptor and Fc receptors (Kabouridis et al., 1997; Honda et al., 2000; Suzuki et al., 
2000).  It has been speculated that the presence of c-Yes in lipid raft fractions in MDCK 
cells may be indicative of a role for c-Yes in vesicular trafficking or proper sorting of 
GPI-linked proteins (Sargiacomo et al. 1993; Arreaza et al., 1994).   
VII.B.  Unique Domain 
Following the SH4 domain is the Unique domain, a 60 to 90 amino acid sequence 
that is completely heterogeneous across the Src family.  Very little is known about the 
role of the Unique domain in c-Yes signaling, and due to the lack of sequence homology 
in this region, it is difficult to infer a function for the c-Yes Unique domain based upon 
what is known of other Src family kinases.  c-Src is phosphorylated on serine and 
threonine residues in the Unique domain during mitosis, and these phosphorylation 
events correlate with elevated kinase activity (Gould and Hunter, 1988; Morgan et al., 
1989; Shenoy et al., 1989).  Upon stimulation of the PDGF receptor in fibroblasts, Fyn is 
phosphorylated on tyrosine residues in its Unique domain, via both autophosphorylation 
and PDGF receptor phosphorylation (Hansen et al., 1997).  As with the c-Src Unique 
domain, phosphorylation of the Fyn Unique domain also correlates with increased kinase 
activity.  An in vitro autophosphorylation site was mapped to tyrosine 32 in the c-Yes 
Unique domain, however, the importance of this phosphorylation event remains unclear 
(Ariki et al., 1997).  Phosphorylation of Unique domain residues may serve to facilitate 
protein/protein interactions or to alter the global conformation of the protein in such a 
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fashion that the inactive “closed” conformation is destabilized, thus increasing kinase 
activity.  In addition to serving as a site of phosphorylation, the Unique domain may also 
direct protein/protein interactions.  The Unique domain is responsible for association of 
Lck with CD4 and CD8 in T cells, and association of Lyn with the Fcε receptor (Shaw et 
al., 1989; Vonakis et al., 1997).  
VII.C.  SH3 Domain 
Following the Unique domain are two modular domains that serve to direct 
protein/protein interactions: the SH3 and SH2 domains.  There are several ways in which 
protein/protein interactions mediated by the SH3 and SH2 domains may direct c-Yes- 
specific signaling.  SH3 and SH2 domain binding partners may disrupt the intramolecular 
interactions maintaining the protein in the assembled or inactive conformation.  
Destabilization of the closed conformation enhances the accessibility of the kinase active 
site for ATP and substrates, thus increasing the specific activity of the kinase (Alonso et 
al., 1995; Moarefi et al., 1997).  Additionally, association of c-Yes with SH3 or SH2 
domain binding partners may serve to present these proteins for tyrosine phosphorylation.  
Thus the SH3 and SH2 domains may contribute to signaling specificity through 
differential substrate selection and presentation for processive phosphorylation (Kanner 
et al., 1991; Mayer and Baltimore, 1994; Weng et al., 1994; Guappone and Flynn, 1997; 
Pellicena et al., 1998).  Finally, stable association between c-Yes and SH3 or SH2 
domain binding partners may allow the formation of c-Yes-specific signaling complexes 
that serve as sites of activation or inactivation of downstream signaling pathways or 
target c-Yes to distinct sub-cellular localizations (Fukui et al., 1991).   
The SH3 domain is approximately 60 amino acids in length and directs 
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protein/protein interactions through association with left-handed type II helical proline-
rich sequences within SH3 domain binding partners (Yu et al., 1992; Yu et al., 1994; 
Rev. in Brown and Cooper, 1996).  Domain swapping studies and in vitro binding assays 
have demonstrated overlapping ligand specificity between Src family SH3 domains 
(Weng et al., 1994; Erpel et al., 1996).  However, these studies have also illustrated 
differences in Src family kinase SH3 domain specificity.  Studies utilizing phage display 
analysis have revealed subtle differences in the ligands selected by Src family kinase SH3 
domains, including c-Src and c-Yes (Rickles et al., 1995; Sparks et al., 1996).  It is 
important to note, however, that actual SH3 domain binding partners do not always 
contain the consensus binding motifs defined by peptide-binding assays.  In support of 
the peptide-binding data, however, differential protein binding has been demonstrated 
between the c-Yes and c-Src SH3 domains in vitro and in vivo.  In comparison to the c-
Src SH3 domain, the c-Yes SH3 domain is deficient in binding the 110 kDa actin 
filament associated protein (AFAP-110) in vitro (Summy et al., 2000).  In agreement 
with the in vitro binding data, Src527F/c-Yes chimeras with the c-Yes SH3 domain were 
deficient in stable complex formation with AFAP-110 in vivo, as demonstrated by a lack 
of co-immunoprecipitation between the proteins (Summy et al., 2000).  Conversely, the 
c-Yes SH3 domain readily binds the 65 kDa Yes Associated Protein (YAP 65), a weak c-
Src SH3 domain binding partner (Sudol, 1994).  Association of c-Yes with YAP 65 
appears to contribute to the apical localization of c-Yes in airway epithelia, through 
association with EBP50 (Mohler et al., 1999).   
VII.D.  SH2 Domain 
Immediately following the SH3 domain is the SH2 domain.  The SH2 domain is 
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comprised of 90-100 amino acids that form a modular phosphotyrosine-binding motif 
(Rev. in Brown and Cooper, 1996).  SH2 domain interactions are high affinity, with 
dissociation constants in the nanomolar range.  The SH2 domain is comprised of a central 
β-barrel structure, flanked by two α-helices and a smaller β-sheet (Waksman et al., 1992; 
Eck et al., 1993).  The tertiary structure of the SH2 domain forms two binding pockets, 
the first for phosphotyrosine and the second for the pY+3 amino acid (Waksman et al., 
1992; Eck et al., 1993).  SH2 domain binding specificity is dictated by the sequence of 
amino acids surrounding the phosphorylated tyrosine residue, particularly those on the 
carboxy-terminal side (Bibbins et al., 1993; Songyang et al., 1993). The optimal c-Yes 
SH2 domain ligand sequence has not been specifically determined, however, all Src 
family SH2 domains appear to select the sequence pYEEI with maximal affinity 
(Songyang et al., 1993).  In support of the peptide-binding data, SH2 domain redundancy 
has also been demonstrated with regard to full-length protein binding.  c-Src, Fyn, and c-
Yes bind the same sites within the PDGF and CSF-1 receptors via their SH2 domains 
(Alonso et al., 1995), and the c-Yes and c-Src SH2 domains appear to bind the same sites 
within the Neu protein (Muthuswamy and Muller, 1995).  
Little data exists to suggest signaling specificity between Src family members at 
the level of the SH2 domain, however, it was recently noted that Src527F/c-Yes chimeras 
with the c-Yes SH2 domain display enhanced co-immunoprecipitation with an unknown 
phosphoprotein of approximately 87 kDa (pp87) (Summy et al., 2000).  As the identity of 
this protein is currently unknown, the significance of complex formation between pp87 
and the c-Yes SH2 domain is unclear.  It does illustrate, however, that c-Yes-specific 
signaling events may be generated through SH2 domain interactions.  A recent study by 
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Bradshaw et al. revealed that SH2 domain specificity between Src family members may 
arise as a result of differences within the phosphotyrosine binding pocket (Bradshaw et 
al., 1999).  It was noted in this study that the amino acid in the βC3 position of the pTyr-
binding pocket contributes considerable energy to phosphotyrosine binding.  c-Src 
contains a cysteine in this position, whereas all other Src family kinases, including c-Yes, 
contain a serine in this position.  Mutation of the cysteine to serine resulted in a four-fold 
increase in binding affinity for pTyr.  This may have implications for the relative abilities 
of Src family kinase SH2 domains to associate with their cognate regulatory 
phosphotyrosines or intermolecular binding partners. 
VII.E.  SH2/Kinase Linker 
Following the SH2 domain is a short stretch of 15 amino acids that spans the gap 
between the SH2 and tyrosine kinase domains, referred to as the SH2/kinase linker.  The 
primary function of the linker sequence is association with the SH3 domain in the closed 
conformation.  In the closed conformation, the linker takes on the left-handed helical 
structure characteristic of SH3 domain binding partners.  Mutations in this region can 
enhance kinase activity through destabilization of the closed conformation (Briggs and 
Smithgall, 1999).  Thus any contributions to signaling specificity made by the linker 
sequence would likely be reflected in the ease of enzymatic activation.  Only one amino 
acid difference exists between the linker sequences of c-Yes and c-Src: the fourth 
position in the sequence is occupied by a serine residue in c-Src and a valine in c-Yes.  
The role of this amino acid in maintenance of the closed conformation has not been 
investigated, and thus, at this point no accurate assessment of its contribution to c-Yes 
signaling specificity can be made.   
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VIIf.  Tyrosine Kinase Domain 
Following the linker sequence is the tyrosine kinase domain.  This is the most 
highly conserved region across the Src family.  As mentioned above, the kinase domains 
of c-Yes and c-Src are approximately 90% homologous.  The extremely high homology 
between c-Yes and c-Src, and members of the Src family in general, in the kinase domain 
suggests that this region contributes little to signaling specificity.  Differences in the 
optimal substrate sequences phosphorylated by Src and Lck have been demonstrated 
(Songyang et al., 1995), however, these differences were subtle, and Src and Hck have 
been demonstrated to select the same peptide sequences for phosphorylation in vitro 
(Sicilia et al., 1998).  
VIII.  Summary and Goals 
While the information available on c-Yes still lags behind that of c-Src and other 
members of the Src family, over the past decade, knowledge of the regulation and 
functions of the c-Yes tyrosine kinase have increased dramatically.  It has become clear 
that c-Yes is capable of sending specific signals, however, the manner by which c-Yes 
accomplishes this remains a mystery.  The work presented in this dissertation has begun 
to investigate the issue of signaling specificity between c-Src and c-Yes, with particular 
emphasis placed on the contributions of the functional domains to specificity in signaling 
between these closely related proteins.  The studies presented in this thesis have focused 
on the roles of the non-catalytic functional domains in signaling specificity between c-Src 
and c-Yes at three levels: (1) protein/protein interactions, including substrate selection 
and stable complex formation, (2) downstream gene activation, as determined by 
differential display analysis, and (3) cell biology, with emphasis placed on understanding 
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why c-Yes is apparently unable to compensate for c-Src in regulation of the actin 
cytoskeleton.  The overriding hypothesis driving these studies was that differences in 
signaling specificity between c-Src and c-Yes could be attributed to individual functional 
domains, and that utilization of Src/Yes chimeric constructs would allow determination 
of the contributions of the various functional domains to signaling events or pathways 
that were representative of the three general categories listed above.  These studies may 
shed light, not only on the biology of c-Yes, but also on how specificity is generated 
between Src family kinases.  Knowledge of the roles of the functional domains in 
directing c-Yes signaling specificity may contribute to the design of inhibitory drugs, 
which selectively disrupt signals sent by c-Yes, as opposed to other Src family members.  
Such compounds would not only aid in the elucidation of c-Yes-specific signaling 
pathways but could potentially be of therapeutic use in the treatment of cancers in which 
c-Yes is abnormally activated. 
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Abstract 
The c-src and c-yes proto-oncogenes encode 60,000 and 62,000 Dalton non-
receptor tyrosine kinases of the Src family, pp60c-src and pp62c-yes, respectively.  These 
kinases are over 80% homologous outside of their unique amino termini, yet several 
studies suggest that differences exist in the regulation, activation, and function of c-Src 
and c-Yes.  The determinants of specificity in signaling between these proteins, however, 
remain unclear.  In order to investigate the roles of the Src Homology (SH) 3 and 2 
domains in mediating signaling specificity between c-Src and c-Yes, chimeras were 
created in which the SH3 and/or SH2 domains of c-Src or the fully activated variant 
Src527F were replaced by the corresponding domains of c-Yes. These constructs were used 
to assess the effects of the c-Yes SH3 and SH2 domains on the ability of activated Src to 
form stable complexes with and induce tyrosine phosphorylation of c-Src SH3 and SH2 
domain binding partners in vivo.  Differences were demonstrated between c-Src and c-
Yes in the specificity of both the SH3 and SH2 domains.  The c-Yes SH3 domain was 
unable to affinity absorb the Src SH3/SH2 binding partner AFAP-110 from COS-1 cell 
lysates, and chimeric constructs of Src527F containing the c-Yes SH3 domain were unable 
to efficiently co-immunoprecipitate with AFAP-110 from chicken embryo fibroblasts.  
Interactions with the Src SH2 binding partner pp130cas were unaffected.  Additionally, 
only chimeras containing the c-Yes SH2 domain were able to co-immunoprecipitate with 
an unidentified 87kDa tyrosine-phosphorylated protein. These results indicate that the 
SH3 and SH2 domains are capable of directing specificity in substrate binding between c-
Src and c-Yes, indicating potential mechanisms for generating specificity in signaling 
between these two highly related non-receptor tyrosine kinases. 
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Introduction 
The Src family of non-receptor tyrosine kinases is comprised of nine members (c-
Src, c-Yes, Fgr, Fyn, Lyn, Lck, Hck, Blk, and Yrk) that share amino acid homology and a 
common domain architecture, consisting of four regions of Src homology (SH1-4) and a 
Unique domain (Brickell, 1992).  Src family kinases are involved in many signal 
transduction pathways, influencing such diverse cellular processes as cell division, 
differentiation, survival, adhesion, and motility (Thomas and Brugge, 1997).  pp60c-src 
and pp62c-yes are of particular interest due to their frequent activation in several human 
cancers, most notably colon carcinoma, in which the activity of both kinases is 
commonly up-regulated (Cartwright et al., 1994; Cartwright et al., 1989; Park et al., 
1993; Pena et al., 1995).  pp60c-Src and pp62c-yes are two of the most highly homologous 
members of the Src family.  They share greater than 80% amino acid homology outside 
of their Unique domains (Erikson and Erikson, 1983; Kitamura et al., 1982; Sudol et al., 
1988b) and are both expressed throughout several vertebrate tissues, with particularly 
high levels in brain and platelets (Bixby and Jhabvala, 1993; Brown and Cooper, 1996; 
Gessler and Barnekow, 1984; Horne et al., 1992; Sugawara et al., 1991; Zhao et al., 
1990).  c-Src and c-Yes are also activated in response to many of the same extracellular 
stimuli (Courtneidge et al., 1993; Di Domenico et al., 1996; Eiseman and Bolen, 1992; 
Fuhrer and Yang, 1996; Kypta et al., 1990; Muthuswamy and Muller, 1995; Schieffer et 
al., 1996; Tsygankova et al., 1998), at the same points in the cell cycle (Roche et al., 
1995), and are at least partially able to functionally compensate for each other in the 
event that one of the kinases is missing or non-functional (Roche et al., 1995; Stein et al., 
1994).  
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Despite the similarities between c-Src and c-Yes, differences in expression, 
regulation, and function have been demonstrated between the two proteins (Fuhrer and 
Yang, 1996; Loganzo et al., 1993; Marchetti et al., 1998; Park and Cartwright, 1995; 
Zhao et al., 1993). Single gene knockouts of either the c-src or c-yes gene in mice 
provide strong evidence for specific roles performed by c-Src and c-Yes, as the loss of 
either gene results in a unique phenotype.  The loss of the c-src gene results in 
osteopetrosis due to a defect in the ability of the osteoclasts to reabsorb bone (Soriano et 
al., 1991), and the loss of the c-yes gene results in a reduction in IgA levels in secreted 
fluids, as c-Yes has been demonstrated to play a key role in IgA transcytosis mediated by 
the polyimmunoglobulin receptor (Luton et al., 1998).  
To date, the establishment of functional and regulatory differences between c-Src 
and c-Yes have not revealed which functional domain or domains are responsible for 
directing signaling specificity between these two highly related, non-receptor tyrosine 
kinases.  Two potential candidates for mediating specificity in signaling between c-Src 
and c-Yes are the SH3 and SH2 domains. The SH3 domain directs specific interactions 
by binding to proline-rich sequences in target proteins, while the SH2 domain recognizes 
a phosphotyrosine moiety and the surrounding 3 or 4 amino acids  (Anderson et al., 1990; 
Moran et al., 1990; Pawson and Scott, 1997; Ren et al., 1993; Songyang et al., 1992; 
Sudol et al., 1998). It has been demonstrated that c-Src will phosphorylate many 
substrates on tyrosine residues that represent potential SH2 binding motifs, indicating that 
c-Src may select substrates for stable complex formation ( Songyang et al., 1995; Zhou 
and Cantley, 1995). Weng et al. demonstrated that phosphorylation of some SH3 domain 
binding partners was dependent upon a functional Src SH3 domain, indicating a potential 
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role for SH3 interactions in presenting substrates for tyrosine phosphorylation (Weng et 
al., 1994).   
 The Src-binding partners pp130cas and AFAP-110 are two well-characterized 
tyrosine phosphorylated substrates that form a stable complex with activated forms of 
Src, e.g., Src527F (Schaller et al., 1993). Stable complex formation between pp130cas and 
activated forms of Src are dependent upon the integrity of the SH2 domain (Kanner et al., 
1991; Sakai et al., 1994). However, interactions between AFAP-110 and Src527F are 
modulated by both the SH3 and SH2 domains, and disruption of either interaction is 
sufficient to abrogate stable complex formation between these two proteins (Reynolds et 
al., 1989; Kanner et al., 1991; Guappone and Flynn, 1997; Guappone et al., 1998).  
Additionally, deletions in the SH2 domain of Src can inhibit phosphorylation of pp130cas 
(Kanner et al., 1991), while mutations in the Src SH3 domain or the SH3-binding motif 
of AFAP-110 inhibit phosphorylation of AFAP-110 by Src in vivo (Kanner et al., 1991; 
Guappone and Flynn, 1997).  v-Yes is unable to induce high levels of phosphorylation of 
either of these proteins in vivo (Kanner et al., 1990), and thus one possible explanation of 
this data is that v-Yes is unable to form sufficiently high affinity SH3 and/or SH2 domain 
interactions with AFAP-110 and pp130cas to allow efficient substrate presentation in 
vivo.  
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Results 
In order to explore this possibility, the relative affinities of the c-Src and c-Yes 
SH3 domains for AFAP-110 were compared, in vitro. The SH3 and SH2 domains are 
well conserved between c-Yes and v-Yes, thus the c-Yes SH3 and SH2 domains were 
used throughout this report.  Lysates from Cos-1 cells overexpressing AFAP-110 were 
incubated with GST, GST-SH3Src or GST-SH3Yes fusion proteins immobilized on 
glutathione-coated sepharose beads.  AFAP-110 was efficiently absorbed by GST-SH3Src, 
however, the levels of AFAP-110 absorbed by GST-SH3Yes more closely approximated 
background levels absorbed by GST alone (Figure 1A).   c-Src and c-Yes SH3 
absorbtions were performed from aliquots of the same cell lysates, thus differences in the 
amount of AFAP-110 absorbed were not due to differences in AFAP-110 expression.  In 
contrast, tyrosine phosphorylated AFAP-110 from Cos-1 cell lysates overexpressing 
AFAP-110 and Src527F was efficiently affinity absorbed by both GST- SH2Src and GST-
SH2Yes (Figure 1A).  These data indicate that c-Yes has the potential to bind AFAP-110 
through SH2, but not SH3 interactions. Fusion proteins were quantitated via Coomassie 
staining to verify that equal amounts were used in the absorptions. In order to confirm 
that the inability of the c-Yes SH3 domain to absorb AFAP-110 reflected differential 
specificity and not a defect in the folding or function of the GST-SH3Yes construct, 
western blot analysis with an antibody directed against the c-Yes SH3 binding partner 
p65 YAP was performed (Sudol 1994). p65 YAP was identified through the use of an 
anti-idiotypic antibody and was subsequently demonstrated to bind to the c-Yes SH3 
domain in vitro (Sudol 1994).  However, p65 YAP is not a tyrosine-phosphorylated 
substrate and is not readily co-immunoprecipitated with c-Yes in vivo (Sudol, Unpubl. 
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Data).  Western blot analysis confirmed that p65 YAP was specifically absorbed by the c-
Yes SH3 domain and not the c-Src SH3 domain or GST alone (Figure 1B).  Thus, the 
inability of the c-Yes SH3 domain to affinity absorb AFAP-110 did not appear to be due 
to a functional defect in the GST-SH3Yes construct. These results demonstrate that there is 
ligand specificity between the c-Src and c-Yes SH3 domains and raises the possibility 
that SH3 domain selectivity may serve as a general mechanism for directing signaling 
specificity between c-Src and c-Yes.      
In order to assess the ability of the SH3 or SH2 domains to affect substrate 
selection, chimeric Src527F constructs were created in which the c-Src SH3 domain 
(Y3527F), SH2 domain (Y2527F) or both domains (Y32527F), were replaced by the 
corresponding domains of c-Yes.  These same chimeras were also generated within the 
context of c-Src (Y3, Y2 and Y32).  Swapping of functional domains was enabled by the 
generation of novel restriction sites that define the boundaries separating the SH3 and 
SH2 domains.  Point mutations were verified, and DNA sequence analysis confirmed that 
no secondary mutations were encumbered. These chimeras were expressed in CEF cells 
using the Rous Sarcoma Virus vector, along with c-Src and Src527F (Figure 2).  Relative 
expression levels were determined by western blot analysis of whole cell lysates with the 
rabbit anti-Src antibody that recognizes a common epitope in the carboxy terminus of c-
Src or Src527F.  As shown in Figures 3A and 3B, all constructs were expressed at 
comparable levels.  The inclusion of normal CEF cell lysates in these and all subsequent 
western blots demonstrated the contribution of the overexpressed proteins to the observed 
results, as compared to endogenous Src family kinases.  Western blots of total cell lysates 
were also probed with a polyclonal anti-Yes antibody (Figure 3C and 3D).  This antibody 
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showed strong reactivity with the Y3, Y32, Y3527F, and Y32527F constructs and some 
limited cross-reactivity with constructs containing the c-Src SH3 domain.  The anti-Yes 
antibody was raised against a region of Yes encompassing the SH3 and SH2 domains and 
appears to have specificity for the c-Yes SH3 domain (Sudol and Hanafusa, 1986).  No 
antibody was available to discriminate between the c-Src and c-Yes SH2 domains, 
however, restriction enzyme digests of the plasmid cDNA's encoding these constructs, as 
well as sequence analysis, verified the presence of the c-Yes SH2 domain coding 
sequence (data not shown). These data demonstrate that the c-Src/c-Yes and the Src527F/c-
Yes chimeras can be expressed in CEF cells by Rous sarcoma virus. 
In order to explore the possibility that SH3 and/or SH2 domain interactions may 
have been responsible for the previously observed inefficient phosphorylation of AFAP-
110 and pp130cas by v-Yes, the ability of activated Src with the c-Yes SH3 and/or SH2 
domains to form stable complex with and induce tyrosine-phosphorylation of these 
proteins was analyzed. The steady-state levels of pp130cas and AFAP-110 tyrosine-
phosphorylation were assessed from lysates of cells expressing Src527F and the 
corresponding chimeras.  As seen in Figure 4, Src527F and each of the Src527F/c-Yes 
chimeras induced comparable levels of pp130cas and AFAP-110 tyrosine 
phosphorylation (Figure 4A and 4B, top panels). In order to assess the effects of the c-
Yes SH3 domain on the ability of Src527F chimeras to form stable complex with either 
AFAP-110 or pp130cas, in vivo, Src527F/c-Yes chimeras were immunoprecipitated with 
the mAb EC10 and western blot analysis was performed with monoclonal antibodies 
directed against either pp130cas (anti-pp130cas) or AFAP-110 (mAb 4C3).  Although no 
significant reduction in pp130cas binding to the Src527F/c-Yes chimeras was detected 
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(Figure 4C, top panel), Y3527F and Y32527F, demonstrated a 2.5 fold reduction in their 
ability to co-immunoprecipitate with AFAP-110, compared to Src527F and Y2527F (Fig. 
4D, top panel).  This correlated well with previous data that indicated SH3 interactions 
are necessary for stable complex formation between Src527F and AFAP-110 (Kanner et 
al., 1991; Reynolds et al., 1989, Guappone and Flynn, 1997).  These results indicate that 
differential SH3 domain specificity can direct differences in steady-state levels of stable 
complex formation between AFAP-110 and c-Src and c-Yes, in vivo.  These results also 
indicate that the previously observed inefficient tyrosine-phosphorylation of AFAP-110 
and pp130cas by v-Yes do not appear to be the result of inefficient SH3 or SH2 domain 
mediated substrate presentation, as these proteins were efficiently phosphorylated in vivo 
by the Y3527F, Y2527F and Y32527F chimeras.  This result is particularly interesting in the 
case of AFAP-110, as SH3 domain interactions have been demonstrated to be required 
for phosphorylation of AFAP-110 by Src in vivo, and the c-Yes SH3 domain clearly 
demonstrates a low affinity for AFAP-110, both in vitro and via co-immunoprecipitation.  
However, even the low affinity of the c-Yes SH3 domain for AFAP-110 may allow a 
transient interaction between the Y3527F and Y32527F chimeras and AFAP-110 in vivo 
that, coupled with the overexpression of the chimeras in comparison to AFAP-110, may 
be sufficient to achieve stoichiometric levels of phosphorylation in vivo.  
In order to assess the roles of the SH3 and SH2 domains in directing binding to 
additional substrates, the profile of tyrosine-phosphorylated proteins in complex with 
Src527F and each of the Src527F/c-Yes chimeras was examined.  Src527F, Y3527F, Y2527F, and 
Y32527F were immunoprecipitated with the rabbit anti-Src antibody, and co-
immunoprecipitating tyrosine-phosphorylated proteins were resolved by SDS-PAGE and 
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visualized by western blotting with an antibody directed against phosphotyrosine.  As 
seen in Figure 5, a phosphorylated protein of approximately 87 kDa specifically co-
immunoprecipitated with constructs containing the c-Yes SH2 domain, Y2527F and 
Y32527F, while the presence of the c-Yes SH3 domain in the Y3527F construct did not 
permit binding of pp87.  Thus, the c-Yes SH2 domain may also direct specificity in 
binding cellular proteins.  
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Discussion 
The data presented here indicate that specificity exists between both the SH3 and 
SH2 domains of c-Src and c-Yes.  It is not surprising that differences were observed in 
the ligand specificity of the c-Src and c-Yes SH3 domain in regard to their ability to bind 
to AFAP-110.  Previous reports by others indicate differences in the ligand binding 
capacities of Src family members.  In vitro analyses of the optimal peptide sequences 
bound by SH3 domains of multiple Src family members, including c-Src and c-Yes, have 
revealed subtle differences in the sequences surrounding the core PXXP motif preferred 
by each family member (Rickles et al., 1994; Rickles et al., 1995; Sparks et al., 1996).  
Weng et al. demonstrated that the c-Src, Fyn, and Lyn SH3 domains bound overlapping 
yet distinct profiles of proteins in vitro (Weng et al., 1995).  It has also been shown that 
the Lck SH3 domain is unable to functionally compensate for the c-Src SH3 domain in 
allowing c-Src to transduce signals from the PDGF receptor that result in DNA synthesis 
(Erpel et al. 1996).  Thus, there is precedent for differential SH3 domain specificity 
between Src family members.  Little prior data existed however, to suggest differences in 
the binding specificity of the SH2 domains of Src family members.  In vitro studies have 
shown that Src family members optimally bind cognate ligands having the sequence 
pYEEI (Songyang et al., 1993; Sicilia et al., 1998).  However, this is merely an 
optimized sequence obtained using short peptides as cognate ligands, and thus cannot 
take into account how the sequence is presented in the context of a complete protein.  The 
ability of both the c-Yes and c-Src SH2 domains to efficiently bind AFAP-110 in vitro, 
and the ability of the Y2527F and Y32527F constructs to co-immunoprecipitate with AFAP-
110 and pp130cas suggests that there is functional redundancy between the c-Src and c-
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Yes SH2 domains.  However, the fact that pp87 co-immunoprecipitates only with 
constructs with the c-Yes SH2 domain suggests strongly that it is associated, either 
directly or indirectly, with the c-Yes but not the c-Src SH2 domain.  This in turn points 
toward ligand specificity between the c-Src and c-Yes SH2 domains.  Future studies will 
determine the significance of stable complex formation with AFAP-110 and pp87, and if 
the differential abilities of activated Src and Yes to associate with these proteins 
correlates with any of the known functional differences between c-Src and c-Yes.  The 
molecular determinants of specificity between the SH3 and SH2 domains of c-Src and c-
Yes, and the remaining Src family members, remain unclear.  Elucidation of the 
contribution of specific amino acids toward SH3 and SH2 domain specificity between c-
Src and c-Yes may lead to the design of rational drugs capable of specifically blocking 
the unique signaling pathways utilized by these kinases.  Such drugs would be ideal for 
studying the biological pathways affected by individual Src family members and may 
prove beneficial in the treatment of cancers in which c-Src or c-Yes is abnormally 
activated, as they could avoid the potentially deleterious effects of inhibiting the function 
of multiple Src family members.    
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Figure 1.  Affinity absorption of AFAP-110 by fusion proteins expressing the c-Src or c-
Yes SH3 or SH2 domains.  (A). Cos-1 cells transiently expressing AFAP-110 or tyrosine 
phosphorylated AFAP-110 (co-expressed with Src527F) were grown to confluence and 
lysed in RIPA buffer.  Twenty µg of GST, GST-SH3Src or GST-SH3Yes were incubated 
with 250 µg of Cos-1 cell lysates containing AFAP-110, while GST, GST-SH2Src, and 
GST-SH2Yes were incubated with 250 µg of Cos-1 cell lysates containing tyrosine 
phosphorylated AFAP-110, as previously described (Guappone et al., 1996).  Bound 
proteins were eluted by boiling in Laemmli's sample buffer, resolved by 8% SDS-PAGE, 
and subjected to western blot analysis with the polyvalent anti-AFAP-110 antibody F1 
GST-SH3 and GST-SH2 
Absorptions 
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(Guappone et al., 1996).  Lanes 1 and 4 = GST; Lane 2 = GST-SH3Src; Lane 3 = GST-
SH3Yes; Lane 5 = GST-SH2Src; Lane 6 = GST-SH2Yes (B) Affinity absorption from 500 
µg of CEF cellular lysates with GST, GST-SH3Src or GST-SH3Yes, followed by western 
blot analysis with an anti-p65YAP polyclonal antibody.  Lane 1 = GST; Lane 2 = GST-
SH3Src; Lane 3 = GST-SH3Yes. 
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Figure 2.  Generation of Src/Yes chimeras.   An Acy I site was engineered into the avian 
c-yes gene (GGTGly90GTTVal91→GGC GTC) immediately 5’ to the SH3 domain coding 
sequence.  This matched a pre-existing site in the avian c-src gene (GGCGly82GTCVal83).  
A PinA I restriction site was engineered into both the c-src (ACGThr129 GGCGly130 →ACC 
GGT) and c-yes (ACAThr137GGCGly138→ACC GGT) genes, immediately 3’ to the SH3 
domain coding sequences.  An Mlu I site was engineered into the c-yes gene 3’ to the 
SH2 domain and kinase linker coding sequence (GATAsp267GCCAla268TGGTrp269→GAC 
GCG TGG).  This again matched a pre-existing site in the avian c-src gene 
(GACAsp258GCGAla259TGGTrp260).  Mutations were engineered using the Quickchange 
Site-directed Mutagenesis kit (Stratagene).  All mutations were engineered such that the 
corresponding amino acid sequence remained intact.  All sequences were verified, along 
with the absence of second site mutations, by DNA sequencing.  The newly engineered 
restriction enzyme sites were used to facilitate sub-cloning of the SH3 and SH2 domain 
coding sequences of c-yes into the c-src or Src527F backbone. The SH3, SH2, or SH3 and 
c-Yes  
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SH2 domains of c-Src and Src527F were replaced with those of c-Yes, resulting in 
constructs of c-Src, c-Src/c-Yes SH3 (Y3), c-Src/c-Yes SH2 (Y2), c-Src/c-Yes SH3/SH2 
(Y32), Src527F, Src527F/c-Yes SH3 (Y3527F), Src527F/c-Yes SH2 (Y2527F), and Src527F/c-
YesSH3/SH2 (Y32527F).  Gray boxes: c-Src domains; White boxes: c-Yes domains.   
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Figure 3. Expression levels of chimeric constructs.  Mock transfected CEF cells, as well 
as CEF cells expressing the c-Src/c-Yes chimeras (A and C) or Src527F/c-Yes chimeras (B 
and D) were lysed in NP40 or RIPA buffer, respectively, and 25 µg total cell proteins 
were resolved by 8% SDS-PAGE.  Western blot analysis with the rabbit anti-Src 
antibody (1:1000 dil.), reactive against a conserved domain in the carboxy-terminus of 
Src, common to all constructs, was used to demonstrate the expression levels of (A) c-
Src, Y3, Y2 and Y32, (B) as well as Src527F, Y3527F, Y2527F and Y32527F. Western blot 
analysis with the rabbit anti-Yes antibody (1:2000), that recognizes a motif specific to the 
c-Yes SH3 domain, was used to demonstrate the identity of the chimeric constructs (C) 
A B 
Rabbit Anti-Src Blot 
Cell lysates 
C D 
Anti-Yes Blot 
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←60 kDa ←60 kDa
←60 kDa 
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Y3 and Y32, (D) as well as the Y3527Fand Y32527F constructs. (A and C) Lane 1 = CEF; 
Lane 2 = c-Src; Lane 3 = Y3; Lane 4 = Y2; Lane 5 = Y32.  (B and D) Lane 1 = CEF; 
Lane 2 = Src527F; Lane 3 = Y3527F; Lane 4 = Y2527F; Lane 5 = Y32527F.  Results are 
representative of three independent experiments. 
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Figure 4.  Effects of the c-Yes SH3 and SH2 domains on in vivo steady-state tyrosine 
phosphorylation levels and stable complex formation with pp130cas and AFAP-110 from 
lysates of cells expressing Src527F/c-Yes chimeras.  Five hundred µg of CEF lysates from 
mock-transfected cells or cells expressing Src527F, Y3527F, Y2527F or Y32527F were 
immunoprecipitated with either a polyclonal anti-pp130cas antibody (1:300 dil.) (A) or 
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the polyclonal anti-AFAP-110 antibody F1 (B).  Bound proteins were eluted by boiling in 
Laemmli’s sample buffer and resolved by 8% SDS-PAGE.    Immunoprecipitated 
proteins were subjected to western blot analysis using a polyvalent antibody against 
phosphotyrosine (A and B, top panels).  The blot was stripped and re-probed with the 
anti-pp130cas antibody (A, bottom panel) or the anti-AFAP-110 antibody (B, bottom 
panel). C and D: Stable complex formation between Src527F/c-Yes chimeras and pp130cas 
or AFAP-110.  Five hundred µg of CEF lysates from mock-transfected cells or cells 
expressing Src527F, Y3527F, Y2527F, or Y32527F were immunoprecipitated with mAb EC10.  
Bound proteins were eluted by boiling in Laemmli’s sample buffer and resolved by 8% 
SDS-PAGE.  Immunoprecipitated proteins were subjected to western blot analysis using 
a polyvalent antibody against p130cas (C, top panel) or anti-AFAP-110 monoclonal 
antibody 4C3 (1:2000 dil.) (D, top panel). The anti-pp130cas blot and AFAP-110 blots 
were stripped and reprobed with rabbit anti-Src antibodies (C and D, bottom panels).  (A-
D) Lane 1 = CEF; Lane 2 = Src527F; Lane 3 = Y3527F; Lane 4 = Y2527F; Lane 5 = Y32527F.  
Results are representative of two independent experiments.  Western blots were 
quantitated using the Stratagene Eagle Eye II scanning densitometry software. 
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Figure 5.  Stable complex formation between Src527F/c-Yes chimeras and tyrosine 
phosphorylated proteins.  Mock-transfected CEF, or CEF expressing Src527F, Y3527F, 
Y2527F, or Y32527F, were grown to confluence in 100 mm dishes and lysed in RIPA 
buffer.  Five hundred µg of each cell lysate was immunoprecipitated with the rabbit anti-
Src antibody.  Co-immunoprecipitated proteins were eluted by boiling in Laemmli’s 
sample buffer, resolved by 8% SDS-PAGE, and subjected to western blot analysis using 
a polyclonal antibody against phosphotyrosine.  Lane 1 = CEF; Lane 2 = Src527F; Lane 3 
= Y3527F; Lane 4 = Y2527F; Lane 5 = Y32527F.  Results are representative of three 
independent experiments.   
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Abstract 
 
 c-Src and c-Yes are the two most homologous members of the Src family of non-
receptor tyrosine kinases.  These kinases perform redundant signaling functions in cells; 
however, there is also evidence to support specificity in signaling.  In this report, 
specificity in signaling between activated forms of the c-Src and c-Yes oncoproteins was 
examined at the level of downstream gene expression.  Here, pp60c-src527F (Src527F) and 
chimeric constructs of Src527F containing combinations of the SH4/Unique/SH3/SH2 
domains of c-Yes were generated to determine whether the individual modular domains 
of c-Src or c-Yes could direct distinct cellular signals leading to differential gene 
expression.  A biased, differential display analysis approach was used to analyze changes 
in gene expression.  The data indicate that Src527F is capable of upregulating heme 
oxygenase-1 (HO-1) in CEF cells at the level of transcription and protein expression.  
Chimeric constructs containing the SH4/Unique domains of c-Yes were less efficient in 
upregulating HO-1 expression.  Activation of c-Src and expression of the HO-1 gene 
product are each induced under conditions of hypoxia.  We hypothesize that activated c-
Src can direct upregulation of HO-1 while activated c-Yes may be less efficient in 
stimulating signal transduction pathways that direct expression of HO-1. 
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Introduction 
 The Src family of non-receptor tyrosine kinases comprises nine members (Src, 
Yes, Fgr, Fyn, Lyn, Lck, Hck, Blk, and Yrk), all of which share a common functional 
domain structure, consisting of four Src homology domains (SH1, SH2, SH3, and SH4) 
and a Unique domain [1].  The SH1 or tyrosine kinase domain provides the enzymatic 
function specific to these tyrosine kinases and is regulated via intramolecular interactions 
[2].  The kinase domain can be further segregated into 11 subdomains, which are highly 
conserved among all the non-receptor tyrosine kinases [1,2].  The amino terminal SH3 
and SH2 domains appear to play a central role in substrate selection and kinase regulation 
[3,4].  The SH3 and SH2 domains form intramolecular interactions with Src family 
kinases when they are in the repressed or inactivated state.  However, upon activation of 
the enzyme, the SH3 and SH2 domains are released from intramolecular binding, thus 
becoming accessible for modulation of protein-protein interactions with a variety of 
SH2/SH3 binding partners [2]. 
 c-Src and c-Yes are the two most homologous members of the Src family [5-7].  
There is very high homology within the SH2 and SH3 domains.  In addition, the 11 
subdomains within the SH1 domain that define its function are virtually identical between 
c-Yes and c-Src.  It has been demonstrated that cellular and viral homologues of these 
two kinases phosphorylate many of the same substrates [8,9].  c-Src and c-Yes are 
expressed at relatively high levels in the same cell types and tissues [2,10-14], and they 
localize to the same subcellular region [10,15-18].  In addition, knockouts of either the c-
Src or c-Yes gene are not embryonic-lethal; however, knocking out both genes is 
embryonic-lethal, indicating the capacity of these two genes to compensate for each other 
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during development [19].  These data indicate that these two kinases may have redundant 
functions. 
 The most significant differences between c-Src and c-Yes exist in the SH4 and 
Unique domains.  The amino terminal SH4 domain modulates interactions with the 
cytoplasmic face of the cell membrane [20].  The SH4 domains of c-Src and c-Yes are 
both myristoylated at Gly2 and this modification is important for membrane association.  
However, unlike c-Src, the SH4 domain of c-Yes is also palmitoylated at Cys3 [20].  It 
has been hypothesized that the additional palmitoylation signal in the amino terminus of 
c-Yes may help to direct it to specific subcellular membrane domains, such as caveolae 
[21].  The Unique domains share little conservation in primary amino acid sequence 
among Src family members and their function is poorly understood; however, there is 
evidence to indicate that the Unique domain of pp56lck can mediate protein interactions 
with the CD4 receptor or the CD45 tyrosine phosphatase [22-24].  Furthermore, the 
Unique domain of pp56lck can also mediate membrane-associated localization [25].  
Therefore, the Unique domains of the Src family tyrosine kinases may function by 
facilitating protein interactions, which could influence subcellular membrane association. 
 There is some evidence for specificity in signaling between c-Src and c-Yes.  
Although c-Src and c-Yes are expressed in many of the same cells and tissues, 
differences in expression can be documented over the course of development [17,26].  
There is also some evidence for specificity in protein/protein interactions.  Activated c-
Yes will associate with an 87 kDa protein by virtue of its SH2 domain [9].  Also, the SH3 
domain of c-Yes fails to bind to the Src SH3 binding partner AFAP-110, and chimeric 
constructs containing the c-Yes SH3 domain fail to form a stable complex with AFAP-
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110 [9].  Specificity in signaling between c-Src and c-Yes is also evident in cells isolated 
from genetic knockout mice.  The osteoclasts from c-src -/- mice show abnormalities in 
formation of lamellipodia [27,28], and fibroblasts from c-src -/- mice are also deficient in 
cell spreading, despite normal expression levels of c-Yes [29].  Thus, c-Yes cannot 
compensate for the ability of c-Src to effect these cytoskeletal changes.  In addition, c-yes 
-/- mice have deficiencies in the ability to transcytose IgA from the blood to the bile 
despite normal expression levels of c-Src [30].   
 In this report, we sought to determine whether specificity in signaling between c-
Src and c-Yes could result in changes in transcriptional activation of specific gene 
products, and whether these changes could be attributed to a specific functional domain.  
Here, we demonstrate that signals modulated by activated Src (Src527F) direct 
upregulation of heme oxygenase 1 (HO-1) mRNA and protein levels; while chimeric 
constructs containing the c-Yes SH4/Unique domains within the context of Src527F were 
less efficient in stimulating an increase in HO-1 expression. 
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Materials and Methods 
Generation of Src/Yes chimeras 
 Site-directed mutagenesis was used to generate restriction enzyme sites flanking 
the c-src and c-yes SH3 and SH2 domains.  All mutations were designed so that the 
resulting amino acid sequences remained unchanged (see Table 1).  These restriction sites 
resulted in SH3 and SH2 domain cassettes in c-Src and c-Yes that could be easily 
exchanged (Fig. 1).  An Acy I site was introduced at position 393 in the chicken c-yes 
sequence, just 5’ of the SH3 domain.  This corresponded to a pre-existing Acy I site at 
position 355 in chicken c-src.  Unique PinA I restriction sites were engineered at the 3’ 
ends of the SH3 domains in c-src (position 496) and c-yes (position 534).  The coding 
sequence for the c-src SH3 domain was replaced with that of c-yes via a two-part Acy I to 
PinA I ligation.  To facilitate SH2 domain replacement, a unique Mlu I site was 
engineered at position 922 just downstream of the c-yes SH2 domain and kinase linker 
sequence.  Again, this site corresponded to a pre-existing Mlu I site in c-src at position 
884.  All mutagenesis was performed using the Stratagene Quickchange Site-Directed 
Mutagenesis protocol and reagents.  Prior to sub-cloning, DNA sequencing was 
performed after each round of mutagenesis in order to ensure that the desired mutation 
was present and to ensure that no second-site mutations had arisen.  Restriction enzyme 
digests were performed to verify the presence of the correct sequence from c-yes.  All 
Src527F/c-Yes chimeras were created in the Rous Sarcoma Virus (RSV) Sac∆ vector, a 
deletion variant of RSV that lacks the Gag, Pol, and Env sequences [9].  Full-length RSV 
constructs encoding c-src with the c-yes SH3, c-yes SH2, or c-yes SH3 and SH2 domains 
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were generated by linearizing the RSV Sac∆ vectors with Sac I and sub-cloning RSV 
digested with Sac I, as previously described [9].  Fully activated versions of the c-src 
chimeras were generated by replacing the c-src kinase domain, from the Mlu I site 
mentioned above, to a Cla I site downstream of the c-src coding sequence in RSV, with 
that of Src527F, a fully active Src variant in which the regulatory tyrosine residue has been 
mutated to phenylalanine.  The nomenclature uses Y to represent c-Yes sequence, 4 = 
SH4 domain, 3 = SH3 domain, 2 = SH2 domain, and U = Unique domain (Fig. 1b).  The 
superscript 527F indicates an activated tyrosine kinase analogous to Src527F.  Thus, 
Y32527F indicates a chimera of Src527F containing SH3/SH2 domains of c-Yes in place of 
the same domains found in c-Src.  The SH1 or kinase domains are virtually identical 
between c-Src and c-Yes in the 11 subdomains that define a tyrosine kinase domain [9] 
and can be used interchangeably.  Thus, Y4U32527F would be analogous to activated c-
Yes.  Site-directed mutagenesis was used to change the Cys3→Ser and the Ile4→Ser, to 
create a c-Src SH4 domain using the Y4U527F construct, generating YU527F.  Conversely, 
the Src527F SH4 domain was mutated by changing Ser3→Cys and Ser4→Ile to represent 
the c-Yes SH4 domain, generating Y4527F.       
Cell culture, antibodies, and western blot analysis 
 Chicken embryo fibroblasts (CEF) were prepared as described previously and 
cultured in 100-mm dishes in DMEM containing 4% fetal calf serum, 1% chicken serum, 
4% tryptose phosphate broth, 2 mM glutamine, and 1% penicillin/streptomycin.  CEF 
were transfected via CaCl2 as described previously at 50% cell-confluence with 5 µg of 
RSV plasmid DNA encoding Src527F or the Src527F/c-Yes chimeras and passaged 1:4 
every 48 hr with 0.25% trypsin.  After 10-12 days, confluent plates were lysed with RIPA 
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(1% NP-40; 0.25% deoxycholate; 50 mM Tris, pH 7.5, 150 mM NaCl; 2 mM sodium 
vanadate; 2 mM PMSF; 50 µg/ml aprotinin; 2 mM EGTA), and total cellular proteins 
were quantitated via the Bicinchoninic acid (BCA) assay (Pierce).  
 Western blot analysis was performed as described previously, using the antibody 
concentrations previously described and quantitated by chemiluminescence and scanning 
densitometry using the Stragene Eagle Eye II software [9].  Rabbit anti-Src is a 
polyclonal antibody raised against an epitope in the carboxy-terminus [9].  Rabbit anti-
Src was used at a 1:1000 dilution for probing western blots.  The anti-phosphotyrosine 
antibody is a polyclonal antibody from Transduction Laboratories (250 µg/ml) and was 
used for western blotting at a 1:1000 dilution.  Anti-heme oxygenase-1 antibodies 
specific for an amino terminal epitope in HO-1 and not immunoreactive with HO-2 were 
obtained from StressGen (Vancouver, British Columbia) and used according to 
manufacturer’s instructions. 
RNA isolation and Northern blot analysis 
 Total RNA was isolated from cultured cells using TRI REAGENT (Molecular 
Research Center, Cincinnati, OH) according to manufacturer’s recommendations.  Total 
RNA was fractionated on a 1% agarose/formaldehyde gel and transferred to a Zeta-probe 
GT membrane (Bio-Rad, Hercules, CA).  Following UV cross-linking using the 
Stratalinker 2400 (Stratagene, La Jolla, CA), the membrane was hybridized to cDNA 
probes random-prime labeled with [α-32P] using the HotPrime kit (Genhunter, Nashville, 
TN). 
 For removal of chromosomal DNA from total RNA, the MessageClean kit 
(Genhunter, Nashville, TN) was used according to the manufacturer’s recommended 
 65 
protocol.  Fifty µg total cellular RNA was incubated for 30 min at 37°C with 10 units of 
Dnase I in 10 X Reaction buffer consisting of 100 mM Tris-Cl, pH 8.4, 500 mM KCl, 15 
mM MgCl2, and 0.01% gelatin.  Following extraction with phenol/CHCl3, the upper 
phase was ethanol precipitated by adding 0.1 vol 3M NaOAc and 2.5 vol 100% EtOH.  
Following centrifugation at 4°C, the RNA pellet was washed twice with 80% EtOH.  The 
pellet was air dried and redissolved in Milli-Q H2O.  RNA concentration was determined 
using a GeneQuant II DNA/RNA calculator (Pharmacia Biotech, Inc.).  RNA integrity 
was assessed by analyzing a 1µg aliquot on a 1% (TBE) agarose gel.   
Differential display PCR, cDNA amplification, cloning and sequence analysis 
 Differential display was performed essentially as described [31,32], except that 
0.2 µg of total RNA was used for reverse transcription in a 20 µl reaction volume.  A 
two-base anchored oligodeoxy adenylic acid primer T11AA (Display Systems Biotech) 
was used to reverse transcribe total RNA into first-strand cDNA, which was subsequently 
amplified by PCR using the Zn2 upstream primer (5’-
GTCGTCGAATTCCA(CT)AC(ACT)GG(AG)GAAAAGCC-3’) as previously described 
[33].  PCR conditions followed the suggested instructions in the Display Systems 
Differential Display Kit (Display Systems Biotech).  PCR products were resolved on a 
6% nondenaturing polyacrylamide gel (Gibco BRL, NY) using [α-33P]dATP (3000 
Ci/mmol).   
 For re-amplification of differentially expressed cDNAs, autoradiograms with 
cDNAs of interest (i.e., those with bands that appeared to be differentially expressed) 
were overlayed onto the dried gel.  cDNA bands were cut from the dried gel using a 
sterile blade, and put into 100 µl of sterile H2O.  Samples were boiled for 10 min and an 
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aliquot was taken for PCR.  The PCR primers used for reamplification were identical to 
those that generated the original differential display cDNA.  The reamplified cDNA 
bands were subcloned into pCR 2.1 plasmid vector using the TA cloning kit (Invitrogen, 
San Diego, CA).  Competent E. coli (INVαF’) were transformed by the heat shock 
method.  Plasmids were sequenced using Sequenase 7-deaza-dGTP sequencing reagents 
with [α33P]dATP (3000 Ci/mmol) and vector-specific sequencing primers.  
 For preparation of mRNA and cloning by PCR amplification, poly (A)+ RNA was 
purified using the Poly(A) Pure mRNA preparation kit (Ambion, Austin, TX).  Double-
strand cDNA synthesis was carried out with the Marathon cDNA amplification kit 
(Clontech Laboratories, Inc., Palo Alto, CA) according to the manufacturer’s 
recommended protocol.  The PCR amplification was carried out using a forward primer 
corresponding to the ligated adaptor in combination with a reverse primer, 5’-
GCTCCGGAGCTGCATAGTTCTGAGGCA-3’ designed against the Zn2A-1 
differential display PCR cDNA.   
 The PCR products were run on a 1% (TAE) agarose gel.  A 1.0-kb PCR product 
corresponding to the expected size of the full-length Zn2A-1 cDNA was cut from the gel 
and purified using the QIAquick gel extraction kit (Qiagen, Valencia, CA).  The PCR 
product was ligated into pCR 2.1 vector (Invitrogen, San Diego, CA) using the TA 
cloning kit (Invitrogen, San Diego, CA) for sequence analysis using Sequenase 7-deaza-
dGTP sequencing reagents with [α-33P]dATP (3000 Ci/mmol).  The full-length Zn2A-1 
5’RACE cDNA was sequenced using vector-specific and internal sequencing primers as 
shown diagrammatically in Fig. 4b. 
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Results 
Expression of Src527F/c-Yes chimeric constructs in CEF cells 
 Chimeric constructs were generated as described in materials and methods (Fig. 
1a and b, Table1).  The chimeras were expressed in CEF cells by transfection using the 
Rous Sarcoma Virus and lysed at confluence after 10-12 days in culture, as previously 
described [9].  Twenty-five µg of total cellular proteins were resolved by SDS-PAGE and 
transferred to PVDF.  Relative expression levels were determined by western blot 
analysis with a polyclonal rabbit anti-Src antibody, which recognizes an epitope in the 
carboxy-terminus of c-Src and Src527F that is conserved among all chimeric constructs 
(Fig. 2a).  Western blot analysis with anti-c-Yes specific antibodies confirmed the 
presence of the c-Yes SH3 domain [9].  The presence of the c-Yes SH2 domain was 
verified by cDNA restriction enzyme digest, as no antibody was available to discriminate 
between the c-Src and c-Yes SH2 domains.  Most constructs were expressed at 
comparable levels; however, Y4U32527F and Y4U527F demonstrated reduced expression 
levels relative to the other chimeric constructs.  Western blot analysis of total cell lysates 
with polyclonal rabbit anti-phosphotyrosine demonstrated similar steady-state levels of 
tyrosine phosphorylation (Fig. 2B).  These data indicate that the constructs were active 
and catalytic and that the chimeric constructs induced steady-state levels of tyrosine 
phosphorylation similar to Src527F and significantly higher than in untransfected CEF 
cells. 
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Differential display analysis 
 CEF cells expressing the Src527F, Y4U32527F, Y32527F, Y2527F, Y3527F, or mock-
transfected CEF cells, were lysed and total RNA isolated as described in materials and 
methods.  A biased, differential display analysis was applied whereby RT-PCR of the 
isolated poly A+ RNA was performed using primers that hybridized with the poly-A tail 
at the 3’ end of the transcripts, as well as a consensus 5’ primer (Zn2) for members of the 
C2H2 family of Zinc-finger transcription factors, as previously described [33].  The bias 
toward a Zn-finger transcription factor was applied as a means to identify induction of 
related transcription factors.  The [33P]-labeled PCR products were resolved by 6% 
acrylamide gel electrophoresis and differential expression noted by changes in intensity 
of PCR products in each lane.  As demonstrated in Fig. 3, a PCR product was identified 
(Zn2A-1) that was 325 bp in size and was amplified from poly A+ RNA isolated from 
CEF cells expressing Src527F, Y32527F, Y3527F, and Y2527F.  However, this same 325-bp 
RT-PCR product was less efficiently detected from CEF cells expressing Y4U32527F or 
from untransfected CEF cells (Fig. 3a).  Northern blot analysis using the Zn2A-1 PCR 
product as a probe confirmed the differential display results and indicated that Zn2A-1 
hybridizes to a 1.2-kb poly A+ RNA product that could be detected in CEF cells 
expressing Src527F and Y32527F.  The Zn2A-1 probe hybridized less efficiently with RNA 
from CEF cells expressing Y4U32527F, and was not able to detect this 1.2-kb poly A+ 
RNA in untransfected CEF cells (Fig. 3b).  Analysis of ethidium bromide stained gels 
indicated equivalent loading efficiency (data not shown). 
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Zn2A-1 is representative of HO-1 
 Sequence analysis of Zn2A-1 revealed a novel sequence that was not homologous 
with any known sequence in the cDNA databases.  A 5’ RACE strategy was employed to 
obtain additional sequence 5’ and upstream of Zn2A-1 in order to identify this putative 
gene product (Fig. 4a).  A 1.0-kb amplified cDNA product (called Zn2A-1 5’RACE) was 
isolated, cloned and the 5’ and 3’ ends sequenced.  There was a 134-bp overlap between 
the 3’ end of Zn2A-1 5’RACE and the 5’ end of Zn2A-1, indicating that Zn2A-1 
5’RACE product contained cDNA sequence that was identical to the 5’ end of the Zn2A-
1 RT-PCR product (Fig. 4b).  BLAST analysis [34] demonstrated that the 5’ end of the 
Zn2A-1 5’RACE clone was 97% homologous with the reported sequence for chicken 
heme oxygenase-1 (HO-1; Fig. 4c).  This homologous sequence represented the region of 
HO-1 from bp 1 to 329.  The 3’ end of the original Zn2A-1 PCR product was not 
homologous with the reported cDNA sequence for HO-1.  These data indicate that the 
Zn2A-1 5’RACE cDNA sequence may contain additional 3’ sequence information from 
HO-1 that was not previously reported, or it could represent an alternatively processed 
form of HO-1. 
 To confirm that the Zn2A-1 5’RACE product was representative of the original 
Zn2A-1 PCR product identified by differential display, Northern analysis was also 
performed using the 1.0-kb Zn2A-1 5’RACE cDNA as a probe.  The data indicated that a 
major 1.2-kb band was also detected among poly A+ RNAs isolated from CEF cells 
expressing Src527F, Y32527F, Y2527F, Y3527F, and Y4U32527F (Fig. 5a).  In untransfected 
CEF, significantly less HO-1 poly-A+ RNA was detected.  The size of the poly A+ RNA 
was consistent with the reported size of the HO-1 message [35] and is consistent with the 
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size of the poly A+ RNA that hybridized with Zn2A-1.  In addition, Zn2A-1 5’RACE 
hybridized less efficiently to a second poly A+ RNA that was approximately 2.8 kb and 
was detected equally in each sample.  Y2527F appeared to induce a higher level of the 1.2-
kb poly A+ RNA.  The reason for this increase in hybridization efficiency in that 
particular sample was not clear, and could represent either an increase in the ability to 
upregulate transcription or an anomaly of sample loading.  These data demonstrate that 
like Zn2A-1, the Zn2A-1 5’RACE cDNA product also hybridized to a Src527F-inducible 
1.2-kb transcript.  However, unlike the original Zn2A-1 cDNA, the Zn2A-1 5’RACE 
cDNA also efficiently hybridized to a 2.8-kb transcript that was not induced by Src527F or 
the Src527F/c-Yes chimeras.  In order to calibrate the samples for loading efficiency, a 
cDNA representative of ubiquitin was used as a probe.  The data indicated some 
differences in loading (Fig. 5b and c).  Densitometry analysis was performed to 
determine the relative amounts of the 1.2-kb poly A+ RNA compared to ubiquitin (Fig. 
5c).  When normalized to loading controls, densitometry analysis indicated that the 1.2-
kb poly A+ RNA isolated from CEF cells expressing Y4U32527F was less efficiently 
induced, relative to Src527F or the other chimeras.  Collectively, these data are consistent 
with the differential display and the Northern analysis using Zn2A-1 and indicate that (1) 
both the Zn2A-1 and Zn2A-1 5’RACE probes hybridize with an inducible 1.2-kb poly 
A+ RNA, (2) the Y4U32527F kinase is less efficient at inducing expression of this 1.2-kb 
RNA, (3) the 1.2-kb RNA is consistent with the size of the HO-1 transcript and (4) 
Zn2A-1 5’RACE contains sequence homologous to HO-1. 
Src527F induces HO-1 protein expression more efficiently than Y4U527F or Y4U32527F. 
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 To determine whether the protein expression levels of HO-1 were affected, CEF 
cells expressing c-Src, c-Yes, Src527F, Y4U32527F, Y4U527F, Y4527F, YU527F, and Y32527F 
were lysed and processed for western blot analysis using an antibody specific for the 
amino terminus of HO-1 (StressGen, Vancouver, BC).  As demonstrated in Fig. 6, the 
protein expression levels of HO-1 were undetectable in CEF cells and very low in CEF 
cells expressing c-Src and c-Yes.  Src527F induced relatively high expression levels of 
HO-1, as did Y32527F, Y4527F, and YU527F.  However, Y4U32527F and Y4U527F were only 
able to induce relatively low levels of HO-1 protein compared to the other chimeras.  
Expression levels of Src527F and the chimeric constructs were also quantitated and 
matched to these lysates (see Fig. 2).  The relative steady-state levels of tyrosine 
phosphorylation (see Fig. 2b), suggest that, although there were differences between 
expression levels of the chimeric constructs, each was capable of inducing comparable 
steady-state levels of tyrosine phosphorylation, indicating that the kinases were 
functional and equivalently catalytic.  These data demonstrate that: (1) c-Src and c-Yes 
are unable to induce efficient upregulation of HO-1 expression; (2) although Src527F and 
Y4U527F expression levels are equivalent, the expression levels of HO-1 are reduced for 
Y4U527F, as they are for Y4U32527F, indicating that the c-Yes SH4/Unique domains, in 
the context of a fully activated Src, do not permit efficient upregulation of HO-1 protein 
expression by these chimeric constructs; (3) Y4U32527F was also less efficient in 
upregulating expression of the 1.2-kb poly A+ RNA; and (4) Y32527F induced relatively 
high expression levels of HO-1 indicating that the SH3/SH2 domains of c-Yes are 
capable of transmitting cellular signals for these chimeric constructs that result in 
increased HO-1 expression.  Collectively, these data indicate that Src527F can upregulate 
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HO-1 and that the presence of the c-Yes SH4/Unique domains restricts the ability of 
Src527F to upregulate HO-1.     
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Discussion 
 In an effort to elucidate mechanisms for specificity in signaling between c-Src and 
c-Yes, chimeric constructs containing the c-Yes SH4/Unique/SH3/SH2 domains were 
subcloned within the context of the Src527F tyrosine kinase.  Each of these chimeric 
constructs contained the SH1, or tyrosine kinase domain, of Src527F.  In this study, we 
hypothesized that c-Src and c-Yes may modulate specific signaling cascades that the 
other could not activate and that a mechanism for differential signaling may be due to 
differences in the functional domains.  These differences could direct these chimeric 
constructs to activate different signaling cascades, which could be qualitatively measured 
by differential gene expression.  Here, a biased, differential display analysis was used as 
a technique to look for differences in gene expression between the chimeric constructs.  
One PCR product, Zn2A-1, was generated from poly A+ RNA isolated from cells 
expressing Src527F and was less prevalent in CEF cells expressing the Y4U32527F chimera, 
while undetected in untransfected CEF cells.  Zn2A-1 was also detectable in the CEF 
cells expressing Y32527F, indicating that the SH4 and/or Unique domains may have 
prevented Y4U32527F from efficiently inducing Zn2A-1.    
 Sequence analysis of Zn2A-1indicated that it was not homologous with any 
known sequences in the DNA database.  A probe was created for a 5’RACE analysis 
using sequences within Zn2A-1 which resulted in the isolation of a 1-kb RT-PCR 
product, Zn2A-1 5’RACE.  This Zn2A-1 5’RACE cDNA contained 5’ cDNA sequence 
information that predicted an amino acid sequence that was 97% homologous to the 
chicken heme oxygenase-1 gene (HO-1) [35]; while the 3’ sequence was identical to 
Zn2A-1.  It is possible that Zn2A-1 sequence may represent previously unreported 3’ 
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avian HO-1 sequence or it could represent an alternatively processed variant of HO-1 
with different 3’ sequence.  Although it is possible that the Zn2A-1 5’RACE product 
could represent a PCR artifact, we consider this to be less likely in light of the northern 
and western blot analysis.  Northern analysis demonstrated that both the Zn2A-1 and 
Zn2A-1 5’RACE cDNA products were able to hybridize with a 1.2-kb poly A+ RNA, 
which is consistent with the reported size of the HO-1 mRNA [35].  However, unlike 
Zn2A-1, the Zn2A-1 5’RACE cDNA was also able to hybridize to a 2.8-kb poly A+ 
RNA, which is inconsistent with the reported size of the HO-1 mRNA [35].  This 
indicates that there could be alternatively processed forms of HO-1 represented by both 
the 1.2 and 2.8 kb mRNAs.  Western blot data demonstrated that Src527F could also 
induce expression of the HO-1 protein, as did most of the chimeric constructs.  However, 
chimeric constructs containing the c-Yes SH4/Unique domains were unable to upregulate 
HO-1 protein levels efficiently, consistent with reduced detection of the 1.2-kb poly A+ 
RNA from Northern analysis with Zn2A-1 or Zn2A-1 5’RACE probes.  These data 
indicate that these kinases, in the absence of the c-Yes SH4/Unique domains, may be able 
to effect expression of the HO-1 gene product at the level of transcription.  It is clear that 
Src527F, Y4U32527F, and Y4U527F each induced equivalent levels of tyrosine 
phosphorylation.  These data suggest that the presence of the c-Yes SH4/Unique domains 
do not position c-Yes or the chimeric constructs to upregulate expression of the HO-1 
protein efficiently.   
 It has been shown that the SH4 domains of the Src family can effect subcellular 
localization along the cell membrane.  Both c-Src and c-Yes are myristoylated at Gly2, 
which is required for membrane association; however, unlike c-Src, c-Yes is also 
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palmitoylated at the Cys3 position [20].  Palmitoylation has been predicted to direct 
proteins to specific membrane microdomains such as caveolae [21].  Previously reported 
data indicate that palmitoylation influences the localization of the Src family member 
pp56lck.  In NIH 3T3 cells, pp56lck localized primarily with the plasma membrane; 
however, when Cys5 was mutated to lysine (abrogating one of two palmitoylation signals 
in pp56lck), pp56lck co-localized with both the plasma membrane and golgi region.  
Interestingly, mutations that changed the palmitoylation site at Cys3 to a Ser induced a 
subcellular localization that was indistinguishable from wild-type pp56lck, occurring 
primarily at the plasma membrane [25].  These data indicate that palmitoylation can 
regulate specific membrane associations in at least one Src family member. 
 Interestingly, expression of either the SH4 or Unique domain of c-Yes 
individually in the chimeric constructs Y4527F or YU527F permitted intermediate 
expression levels of HO-1, indicating that the SH4/Unique domains may operate 
cooperatively.  It is possible that the Unique domain may direct specific protein 
interactions that assist in sequestering c-Yes away from signaling proteins that activate 
HO-1 expression.  For example, pp56lck forms functional protein interactions via its 
Unique domain [22-24].  Also, Bijlmakers et al. demonstrated that the Unique domain of 
pp56lck, when tethered to green fluorescent protein (GFP), was able to target GFP to the 
cell membrane [25].  Although the work of Resh and colleagues have clearly 
demonstrated a role for myristoylation in targeting Src family kinases to the cell 
membrane [20], it is possible that the targeting of pp56lck to specific subcellular 
localizations along the cell membrane may be influenced by both palmitoylation in the 
SH4 domain and by protein interactions modulated by the Unique domain.  Therefore, we 
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hypothesize that it is also possible that specificity in signaling by c-Yes may be regulated 
by the SH4/Unique domains, and that these two domains may work cooperatively simply 
by positioning c-Yes in specific subcellular regions that do not permit it to interact 
efficiently with signaling proteins that modulate HO-1 expression.  Conversely, these 
chimeric constructs may exist in subcellular domains concomitant with Src527F; however, 
the SH4/Unique domains of c-Yes may modulate interactions with other signaling 
proteins, which in turn sequester the chimeras away and prevent them from activating 
signaling pathways that efficiently modulate HO-1 expression.   
 Although this is the first report that we are aware of demonstrating that activated 
c-Src can upregulate expression of HO-1, several reports from other labs indirectly 
support this hypothesis.  Under conditions of hypoxia, it has been demonstrated that c-Src 
becomes activated while c-Yes does not [36,37].  These data indicate that hypoxia 
directly affects upstream regulatory components that regulate c-Src activation.  In 
addition, hypoxia results in the expression of HO-1 [38].  It has also been demonstrated 
that v-Src will induce expression of hypoxia-inducible transcription factor-1 (HIF-1) 
[39].  Ectopic expression of HIF-1 has been shown to upregulate HO-1 expression levels 
[40,41].  Lastly, Masuya et al. demonstrated that inhibitors of tyrosine kinases block the 
induction of HO-1 expression by hemin, sodium arsenite, or cadmium chloride [42].  
Thus, the results presented in this report are consistent with a prediction that activated c-
Src would be capable of upregulating HO-1 expression, possibly via a signal transduction 
cascade that includes HIF-1. 
 Several signal transducing proteins that become activated during hypoxia have 
been identified, and are also known to become activated or upregulated in response to 
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activated c-Src.  These include focal adhesion kinase [43], Ras [37], NFκB [44], MAP 
kinases [44,45], AP-1 [46], c-Fos [47], and HIF-1 [39].  It is possible that activated c-Src 
may modulate upregulation of HO-1 via one or more of these signaling proteins as part of 
a signal transduction cascade, and that activation of c-Yes is less efficient in modulating 
this same cascade.  The ability of activated c-Src to upregulate HO-1 may enhance tumor 
cell survival under conditions of hypoxia.  HO-1 can cleave heme into Fe, biliverdin, and 
CO.  Biliverdin can provide some protection against oxidative damage [38], indicating 
that one function of HO-1 might be to aid cell survival in the face of oxidative stress.  
These data are consistent with a prediction that c-Yes might not become activated during 
hypoxia simply because it is unable to efficiently modulate signal transduction pathways 
necessary to effect changes in gene expression that are required for survival under 
conditions of cellular stress. 
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Figure 1.  Engineering of restriction sites into c-Src and c-Yes for generation of chimeras. 
(A)  Pre-existing restriction sites in the c-src cDNA include the Nco I, Acy I, and Mlu I 
sites, as shown.  The c-yes cDNA had an analogous Nco I restriction site.  Matching sites 
were engineered into the cDNAs to permit swapping of sequences encoding the modular 
domains, as detailed in materials and methods.  (B)  Nomenclature for chimeric 
constructs, as detailed in materials and methods.  Y indicates c-Yes sequence and the 
following 4, 3, 2 and/or U indicate the SH4, SH3, SH2, and Unique domains derived 
from c-Yes and placed within the context of Src527F.  White boxes indicate c-Yes 
sequence; shaded boxes indicate Src527F derived sequences. 
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Figure 2.  Expression of chimeric constructs in CEF cells and analysis of steady-state 
levels of tyrosine phosphorylation.  (A)  Twenty-five µg of CEF lysates expressing the 
chimeric constructs were resolved by SDS PAGE and western blot analysis performed 
using a rabbit anti-Src antibody that reacts with a conserved epitope in the carboxy 
terminus.  (B)  Twenty-five µg of CEF lysates expressing the chimeric constructs were 
resolved by SDS-PAGE and western blot analysis performed using the rabbit anti-
phosphotyrosine antibody.  Results are representative of three independent experiments. 
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Figure 3.  Src527F induces expression of a 1.2-kb poly A+ RNA from CEF cells.  (A)  
Differential display analysis.  Resolution of amplified cDNAs demonstrate a 325 bp, 
[33P]-labeled PCR product, called Zn2A-1, that is detected from amplified mRNAs 
isolated from Src527F, Y3527F, Y2527F, and Y32527F, but not identified in Y4U32527F 
expressing CEF cells or CEF cells alone.  (B)  Northern analysis with Zn2A-1.  The 
Zn2A-1 probe was used to hybridize against poly A+ RNA from CEF cells expressing 
Src527F, Y4U32527F, Y32527F, or CEF cells alone. 
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Figure 4.  cDNA sequence generated upstream of Zn2A-1 is homologous to heme 
oxygenase-1.  (A)  Sequence analysis of 325 bp Zn2A-1 differential display PCR 
product.  The underlined sequences are those used as primers for the differential display 
PCR.  The double underlined region corresponds to the putative poly A+ signal sequence.  
For 5’RACE PCR, a 27-bp antisense primer (5’ 
ACGGAGTCTTGATACGTCGAGGCCTCG 3’) was designed against the region shown 
by bold type.  (B) 5’RACE using a primer generated from Zn2A-1 sequence.  A primer 
designed from Zn2A-1 was used for 5’RACE as a technique to identify upstream 5’ 
sequence.  The diagram shows the relationship between the reported avian HO-1 
sequence compared to the Zn2A-1 PCR product generated by differential display (Zn2A-
1) and Zn2A-1 5’RACE product sequences.  Dark shaded areas indicate sequences that 
are identical to the avian HO-1 sequence.  Hatched boxes indicate unsequenced cDNA 
and the gray-shaded boxes indicate identity between the Zn2A-1 clone used for 
differential display and the Zn2A-1 5’RACE cDNA.  The arrows indicate sites for 
primers used for sequencing and for the 5’RACE PCR.  (C)  The 5’ end of the Zn2A-1 
5’RACE cDNA product exhibits significant  homology with the reported avian HO-1 
sequence.  Blast analysis showing the alignment between HO-1 cDNA sequence and the 
5’RACE product.  The Zn2A-1 5’RACE product exhibits 97% homology with 2% gaps 
to a portion of the reported chicken heme oxygenase 1 sequence (gi: 62923; embl: 
X56201.1). 
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Figure 5.  Zn2A-1 5’RACE cDNA also hybridizes to an inducible 1.2-kb poly A+ RNA.  
(A)  Total cellular RNA was isolated from the cell lines indicated, and Northern blot 
analysis performed using [α-32P] dATP-labeled Zn2A-1 5’RACE cDNA as a probe.  A 
major poly A+ RNA of approximately 1.2-kb hybridizes to the labeled cDNA in each of 
the lanes except the lane containing CEF RNA, while a minor 2.8-kb message was also 
detected.  (B)  Loading control of Northern analysis using a cDNA which hybridizes to 
ubiquitin.  [α-32P] dATP-labeled ubiquitin probe was used to quantitate the amounts of 
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RNA loaded for each construct.  Detection was accomplished by autoradiogram.  (C)  
Relative amounts of the 1.2-kb poly A+ RNA representative of HO-1.  Scanning 
densitometry analysis was performed by quantitating the relative amount of the 1.2-kb 
poly A+ RNA detected and shown in (A), with the Zn2A-1 5’RACE probe, divided by 
the densitometric analysis of ubiquitin shown in (B).   The quotients were normalized to 
“1” for the CEF sample and all other quotients normalized against the CEF sample, 
giving a relative induction of the 1.2-kb poly A+ RNA compared to untransfected CEF 
cells. 
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Figure 6.  Steady-state protein expression levels of HO-1 in CEF cells expressing Src527F 
and chimeric constructs.  Twenty-five µg of CEF cell lysates were resolved by 12% SDS 
PAGE, transferred to PVDF membrane, and probed with an antibody raised against an 
epitope in the amino terminus of HO-1 (StressGen).  Results are representative of two 
independent experiments. 
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Abstract 
 c-Src and c-Yes are highly homologous members of the Src family of non-
receptor tyrosine kinases.  The sequence similarity between c-Src and c-Yes allows them 
to perform overlapping functions.  However, the phenotypes of the c-src and c-yes 
knockout mice, and cells derived from them, are quite different, suggesting functional 
specificity between the two proteins.  In particular, c-src -/- cells are deficient in several 
processes that require dynamic regulation of the actin cytoskeleton.  In order to begin to 
understand why c-Yes is unable to compensate for c-Src in the regulation of the actin 
cytoskeleton, we have utilized a series of Src/Yes chimeras in which the non-catalytic 
functional domains of Src527F were replaced by those of c-Yes.  Using Src527F-induced 
chicken embryo fibroblast (CEF) cytoskeletal rearrangements as a model system, our 
results indicate that the c-Yes amino terminus, including the SH4 and Unique domains, is 
sufficient to inhibit the ability of Src527F to alter cell morphology and induce actin 
filament rearrangements.  Furthermore, we have found that the inability of chimeric 
proteins with the c-Yes amino terminus to induce the cytoskeletal rearrangements and 
changes in cell morphology that occur concomitant with cell transformation correlates 
with an inability to induce activation of the downstream Src effector, 
phosphatidylinositol-3-kinase (PI3K). 
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Introduction 
 The Src family of non-receptor tyrosine kinases is composed of nine members: c-
Src, c-Yes, Fyn, Lyn, Lck, Hck, Blk, Fgr, and Yrk.  Src family kinases make important 
contributions to a variety of cellular signal transduction pathways, including those that 
govern such diverse processes as cell division, differentiation, survival, motility, and 
vesicular trafficking (Thomas and Brugge, 1997).  Members of the Src family are defined 
by their amino acid homology and functional domain architecture.  All Src family 
members are comprised of an amino-terminal membrane-localization domain (Src 
Homology 4 or SH4 domain), a poorly conserved Unique domain, an SH3 domain, an 
SH2 domain, a tyrosine kinase or SH1 domain, and a short carboxy-terminal regulatory 
sequence (Thomas and Brugge, 1997).  c-Src and c-Yes are two of the most ubiquitously 
expressed and  highly homologous members of the Src family (Sudol and Hanafusa, 
1986; Sudol et al., 1988; Zhao et al., 1990; Sugawara et al., 1991), sharing over 80% 
homology outside of their Unique domains (Kitamura et al., 1982).   
Given the high homology between these two kinases and their widely overlapping 
tissue distributions, it is of little surprise that they are capable of performing redundant 
functions.  c-Src and c-Yes are both activated downstream of a variety of cell surface 
receptors, including receptor tyrosine kinases, G-protein-coupled receptors, and cytokine 
receptors (Kypta et al., 1990; Courtneidge et al., 1993; Waltenberger et al., 1994; 
Muthuswamy and Muller, 1995; Landgren et al., 1995; Fuhrer and Yang, 1996a).  
Additionally, both kinases are activated during the cell cycle transition from G2 to M 
phase.  Roche et al. provided strong evidence for functional overlap between c-Src, c-
Yes, and Fyn, in demonstrating that inhibition of all three Src family kinases blocked cell 
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cycle progression at the G2/M transition (Roche et al., 1995).  Inhibition of c-Src alone 
did not block cell cycle progression unless c-Src was the only Src family member 
expressed (Roche et al., 1995).  Further evidence for functional redundancy between c-
Src and c-Yes has been derived from the c-src and c-yes knockout mice.  While the loss 
of neither gene individually is embryonic lethal, mice lacking both genes fail to survive 
after birth (Stein et al., 1994).   
 Despite the evidence for functional overlap, several studies have also indicated 
specificity between c-Src and c-Yes.  The two kinases differ in their sub-cellular 
localization (Sargiacomo et al., 1993; Zhao et al., 1993; Arreaza et al., 1994; Ciesielski-
Treska et al., 1995), intermolecular binding partners (Fuhrer and Yang, 1996b; Kamei et 
al., 1997; Feshchenko et al., 1998; Tang et al., 2000), activation in response to cellular 
stimulation (Schieven et al., 1992; Zhao et al., 1993; Mukhopadhyay et al., 1995; Park 
and Cartwright, 1995; Marchetti et al., 1998; Tsygankova et al., 1998), and ability to 
mediate downstream signaling (Schieffer et al., 1996; Kovacic et al., 1998).   
The inactivation of the c-src and c-yes genes has provided the most compelling 
evidence for functional specificity.  The c-yes -/- mice display no overt phenotype, 
however, mice lacking the c-src gene develop osteopetrosis due to an inability of the 
osteoclasts to reabsorb bone (Soriano et al., 1991).  The only observed deficiency in cells 
from c-yes -/- mice is reduced efficiency in transcytosis of the polyimmunoglobulin (pIg) 
receptor (Luton et al., 1999).  Cells from c-src -/- mice display a host of deficiencies, 
including inefficient motility (Hall et al., 1996), fibroblast spreading (Kaplan et al., 
1995), neurite extension (Ignelzi, Jr. et al., 1994), and formation of membrane ruffles and 
actin ring structures in osteoclasts (Boyce et al., 1992).  Additionally, induction of 
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mammary tumors by middle T antigen is impaired in c-src -/- cells, whereas tumor 
formation occurs normally in c-yes -/- mice (Guy et al., 1994).  A common feature of the 
cellular processes mentioned above is their shared requirement for dynamic regulation of 
the actin cytoskeleton.  Given that c-Yes is present in c-src -/- cells, we hypothesize that 
c-Yes is unable to compensate for c-Src in signaling pathways that control these 
cytoskeletal processes as a result of functional domain differences between the two 
proteins. 
 Each functional domain may contribute to signaling specificity between c-Src and 
c-Yes, and functional domain specificity may result from subtle differences in amino acid 
composition.  Previous studies have indicated minor differences in the ligand specificity 
of the c-Src and c-Yes SH3 domains in vitro (Rickles et al., 1995; Sparks et al., 1996).  
Data obtained in our laboratory indicate that the c-Yes SH3 domain is incapable of 
efficiently binding several c-Src SH3 domain binding partners, including the actin 
filament associated protein AFAP-110 (Summy et al., 2000 and unpublished data).  In 
contrast to the SH3 domain, little data exists to suggest specificity between c-Src and c-
Yes, or other Src family members, at the level of the SH2 domain.  However, we recently 
demonstrated co-immunoprecipitation of an 87 kDa tyrosine-phosphorylated protein 
(pp87) with Src527F/c-Yes chimeras containing the c-Yes SH2 domain, indicating that 
specificity between the two kinases may also be derived from SH2 domain differences 
(Summy et al., 2000). 
 Several recent studies have pointed to the role of the Src family amino terminus in 
dictating signaling specificity.  All Src family members with the exception of c-Src and 
Blk contain one or more cysteine residues downstream of the myristoylated glycine 
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residue at amino acid position two (Resh, 1994).  These cysteine residues are sites of 
palmitoylation, and incorporation of one or more palmitate residues facilitates 
localization to detergent-resistant membrane fractions, also known as lipid rafts (Shenoy-
Scaria et al., 1994; Resh, 1994; Robbins et al., 1995).  Localization to lipid rafts is 
important for Src family kinase participation in Fcε receptor and T cell receptor signaling 
(Kabouridis et al., 1997; Honda et al., 2000; Suzuki et al., 2000).  Hoey et al. recently 
demonstrated that replacement of the Src527F amino terminus (including the SH4 and 
Unique domains) with that of c-Yes prevented upregulation of heme oxygenase 1 (HO-1) 
message and protein (Hoey et al., 2000).  Thus it is evident that multiple functional 
domains may contribute to specificity in signaling, and hence function, between c-Src 
and c-Yes.  In the present study, we have sought to gain a better understanding of why c-
Yes is unable compensate for c-Src in the dynamic regulation of the actin cytoskeleton.  
In order to accomplish this, we have replaced the non-catalytic functional domains of 
Src527F with those of c-Yes and assessed the ability of the resulting chimeras to induce the 
morphological and cytoskeletal changes associated with overexpression of constitutively 
active c-Src.  
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Materials and Methods 
Plasmids 
 cDNA constructs encoding LA29 v-Src, c-Src, Src527F, Y3527F, Y2527F, Y32527F, 
Y4U32527F, Y4U527F, Y4527F, and YU527F were generated within the Rous Sarcoma Virus 
(RSV) as described previously (Felice et al., 1990; Hoey et al., 2000; Summy et al., 
2000). 
Cells 
 Chicken embryo fibroblasts (CEF) were prepared as described previously from 
day 10 eggs (Spafas) (Flynn et al., 1993).  Cells were passed 1:4 every 48 hours in Falcon 
100 mm tissue culture dishes or Falcon 250 ml vented-cap tissue culture flasks.  CEF 
were transfected at one half confluence with 15 µg of plasmid DNA using the Clontech 
Calphos kit, as per the protocol.  Confluent cells were viewed through a Nikon Phase 
Contrast II microscope at 40x total magnification (Plan 2 filter) and photographed with a 
Nikon N 2000 camera using Kodak TMax 400 black and white film. 
Antibodies 
 The rabbit polyclonal anti-Src antibody was raised against an epitope in the Src 
carboxy-terminus as described previously (Summy et al., 2000).  This antibody was used 
at a 1:1000 dilution for western blot analysis.  The anti-phosphotyrosine antibody was 
obtained from BD Transduction and was used at a 1:1000 dilution for western blot 
analysis.  The rabbit anti-phospho-Y416 was obtained from Upstate Biotechnology and 
used at a dilution of 1:1000.  The anti-Shc antibody is a rabbit polyclonal antibody 
commercially available from BD Transduction.  It was used at a 1:1000 dilution for 
western blot analysis and a 1:200 dilution for immunoprecipitation.  The anti-Grb2 
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antibody was obtained from BD Transduction and used at a 1:5000 dilution for western 
blot analysis.  The anti-phospho-c-Raf antibody was obtained from Biosource 
International.  It recognizes c-Raf phosphorylated on tyrosines 340 and 341.  It was used 
at a 1:1000 dilution for western blot analysis.  The rabbit anti-c-Raf-1 antibody was 
obtained from BD Transduction.  It was used at a 1:1000 dilution for western blot 
analysis.  The monoclonal anti-phospho-MAP kinase antibody was obtained from 
Upstate Biotechnology.  It is reactive against Erk 1 and Erk 2 phosphorylated at the pT-
E-pY motif and was used at a dilution of 1:1000 for western blot analysis.  The 
monoclonal anti-MAP kinase antibody was obtained from Upstate Biotechnology.  This 
antibody recognizes Erk 1 and 2 and was used at a 1:1000 dilution for western blot 
analysis.  The rabbit anti-phospho-Akt antibody was obtained from Upstate 
Biotechnology.  This antibody recognizes Akt1 phosphorylated at threonine 308.  This 
antibody was used at a 1:1000 dilution for western blot analysis.  The monoclonal anti-
Akt antibody was obtained from BD Transduction and used at a 1:500 dilution for 
western blot analysis.  The rabbit anti-rat PI3K p85 antibody was obtained from Upstate 
Biotechnology and used at a dilution of 1:1000 for western blot analysis and 1:50 for 
immunoprecipitation.  Anti-rabbit and anti-mouse horseradish peroxidase-conjugated 
secondary antibodies were obtained from Amersham Life Science and used at a dilution 
of 1:1000. 
Immunofluorescence 
 Immunofluorescence was carried out as described previously (Qian et al., 1998).  
Briefly, CEF were split onto cover slips and fixed in 3.7% formaldehyde at 50% 
confluence.  The cells were washed three times in PBS, permeablized in 0.4% Triton X-
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100, washed, and stained with rhodamine-conjugated phalloidin (2 µg/µl in 5% 
BSA/PBS).  Cells were stained for 20 min, washed three times in PBS, and mounted on 
cover slips using Flouromount G (Southern Biotechnology Associates Inc).  Cells were 
visualized using a Zeiss LSM 510 confocal microscope (63x objective). 
Western blot analysis 
 Cells were lysed at confluence in RIPA buffer as described previously (Hoey et 
al., 2000).  Cell lysates were quantitated for total protein content using the Pierce BCA 
assay as per the protocol.  Thirty or fifty µg of cell lysates were boiled in Laemmli’s 
sample buffer (LSB) and resolved by 8% SDS PAGE.  The proteins were transferred to 
PVDF membrane and washed as described previously (Hoey et al., 2000).  The 
membranes were blocked overnight in 1% BSA formulated in Tris buffered saline with 
1% Tween 20 (TBS-T) at 4°C or 5% non-fat milk in TBS-T for 30 min at room 
temperature.  The membranes were probed with primary antibody (diluted in TBS-T) for 
1 hour at room temperature or overnight in 5% milk/TBS-T at 4°C.  Secondary antibodies 
were applied for 45 min in TBS-T.  Bound antibodies were visualized by incubation with 
ECL reagents (Amersham Pharmacia), followed by X-ray film (Kodak) exposure (Hoey 
et al., 2000).  Quantitation of western blots was performed using the Stratgene Eagle Eye 
II scanning densitometry software.  
Immunoprecipitation   
 Five hundred µg of RIPA lysates were incubated with antibody for 1.5 hr at 4°C 
with rotating.  Twenty µl of Protein A/G agarose (Santa Cruz) was added for an 
additional 1.5 hr at 4°C with rotation.  The beads were centrifuged for 30 s at room 
temperature, followed by two washes in RIPA and two washes in TBS.  Bound proteins 
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were eluted by boiling in LSB and resolved by SDS-PAGE.  Western blot analysis was 
carried out as described above. 
Cell Fractionation 
 Cells were fractionated into membrane and cytosolic fractions as described 
previously (Resh and Erikson, 1985).  Briefly, cells were rinsed twice with STE buffer 
(150 mM NaCl, 50 mM Tris, 1mM EDTA, pH 7.2).  Cells were scraped off in STE buffer 
using a rubber policeman and collected by low speed centrifugation. Cells were then 
resuspended in 800 µl/100 mm dish hypotonic buffer (10 mM Tris, 0.2 mM MgCl2) and 
lysed with a Dounce homogenizer.  The homogenate was adjusted to 0.2 mM sucrose and 
1mM EDTA and spun at 1000 g for 10 min at 4°C.  The supernatant was removed and 
saved, and the pellet was resuspended in 0.25 M sucrose, 1 mM EDTA, 10 mM Tris, pH 
7.4 via Dounce homogenization.  The homogenate was re-spun at 1000 g for 10 min, and 
the supernatant was removed and pooled with that of the previous spin.  The supernatants 
were then spun at 100,000 g for 30 min at 4°C, separating the cellular material into 
cytosolic (S100 or supernatant) and membranous (P100 or pellet) fractions. 
 Cells were also separated into triton X-100 soluble and insoluble fractions as 
described previously (Hamaguchi and Hanafusa, 1987).  Briefly, cells were washed twice 
with cold Tris buffered saline.  Cells were then incubated with 1 ml of cold CSK buffer 
(10 mM Pipes, ph 6.8, 100 mM KCl, 2.5 mM MgCl2, 1 mM CaCl2, 0.3 M sucrose, 1 mM 
phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 1% triton X-100) on ice with gentle 
rocking for 1, 4, or 10 min.  The soluble material was removed, and the remaining 
material was solubilized in 1 ml of RIPA buffer as described previously.  Lysates were 
clarified by 5 min centrifugation at 10,000 rpm and 4°C in a Hermle Z 360 K bench-top 
 99 
centrifuge, and supernatants were quantitated for total protein content.  Samples were 
prepared for western blot analysis as described above.  Triton-soluble fractions were 
equilibrated to RIPA by addition of 1% sodium deoxycholate and 10 mM Tris-HCl, pH 
8.0 prior to protein quantitation.    
PI3 Kinase Assay 
 The PI3K assay was performed as described elsewhere (Jiang et al., 1998).  
Briefly, CEF were scraped from tissue culture flasks in cold PBS and pelleted at 1000 
rpm and 4°C for 5 min in a Sorvall RT6000B bench-top centrifuge.  Cells were then 
lysed and total protein concentration was determined.  Four hundred µg of lysate were 
pre-cleared with 20 µl of Protein A/G agarose for 1 hr at 4°C.  Lysates were 
immunoprecipitated with 2 µl of anti-PI3K antibody for 1 hr at 4°C.  Twenty-five µl of 
protein A/G agarose beads were added and incubated with rotation for an additional 1 hr 
at 4°C.  The immunoprecipitations were washed with TNE buffer (20 mM Tris, pH 7.5, 
100 mM NaCl, 1mM EDTA), centrifuged, and the pellet was then resuspended in 50 µl 
of PI3K assay buffer (20 mM Hepes pH7.5, 10 mM MgCl2, 0.2 mg/ml phosphoinositol, 
60 µM ATP, 2 µCi [γ-32P] ATP).  The reactions were incubated at room temperature for 
15 min.  Following the reaction, the products were extracted by addition of 80 µl 1M HCl 
and 160 µl chloroform/methanol.  The upper phase was removed, and the lower phase, 
containing the lipid products, was dried.  The pellets were then resuspended in 
chloroform and spotted on thin layer chromatography (TLC) plates.  Once the buffer 
front had migrated to the top of the plate, the plates were removed, dried, and exposed via 
phosphorimaging.   
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Results 
Expression of Src527F/c-Yes chimeric constructs in CEF 
Chicken embryo fibroblasts were transfected at 50% confluence with RSV 
constructs expressing Src527F, Y3527F, Y2527F, Y32527F, or Y4U32527F (Figure 1).  After 10 
days, cells were lysed in RIPA, 30 µg of cell lysates were resolved by SDS-PAGE, and 
expression of the constructs was verified by western blot analysis using an anti-Src 
antibody, reactive against all chimeras, as described previously.  As seen in Figure 2A, all 
constructs were expressed successfully in CEF (Figure 2A, bottom panel); however, the 
Y4U32527F chimera was expressed at somewhat lower steady-state levels than Src527F or 
the other Src527F/c-Yes chimeras.  In order to assess the functionality of these constructs, 
steady-state levels of phosphotyrosine were assessed by western blot analysis with a 
polyclonal anti-phosphotyrosine antibody.  As seen in Figure 2A, all of the constructs 
induced comparable levels of phosphotyrosine (Figure 2A, top panel), with the exception 
of Y4U32527F, which induced somewhat lower levels of phosphotyrosine.  These blots 
were stripped and re-probed with an antibody that binds specifically to the 
phosphorylated form of tyrosine 416, the c-Src autophosphorylation site. 
Immunoreactivity with this antibody is used as an indicator of kinase activation.  As seen 
in Figure 2A, all chimeras were immunoreactive with the anti-phospho-Y416 antibody, 
although, the Y4U32527F construct displayed reduced immunoreactivity (Figure 2A, 
middle panel).  However, the reduced immunoreactivity with anti-phospho-Y416 
correlated with and was likely due to the reduced expression levels of this chimera, 
relative to the other constructs.  Collectively, these data indicate that these constructs 
displayed equivalent in vivo catalytic activity 
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The Y4U32527F chimera does not induce morphological changes or rearrangement of 
cytoskeletal actin. 
We hypothesized that differences in one or more of the functional domains were 
responsible for the inability of c-Yes to compensate for c-Src in regulation of cellular 
pathways controlling actin cytoskeletal dynamics.  We chose the chicken embryo 
fibroblast as a model system in these studies, as CEF have a well-defined system of actin 
filament stress fibers that undergo a characteristic rearrangement upon overexpression of 
constitutively active Src.  Transfected cells were evaluated for the Src-transformed 
phenotype, the hallmarks of which include a rounded morphology, the lack of a well-
organized monolayer, and an absence of contact-dependent inhibition of cell growth.  As 
seen in Figure 2B, the Y4U32527F chimera failed to induce changes in cell morphology, as 
the morphology of these cells was difficult to distinguish from that of mock-transfected 
cells.   Y32527F, however, induced morphological changes similar to those induced by 
Src527F (Figure 2B), as did Y3527F and Y2527F (data not shown).   
The change in cell morphology induced by constitutively active Src occurs 
concomitant with rearrangement of the actin cytoskeletal structure.  Src-transformed cells 
display a loss of actin stress fibers and focal adhesions, with the actin repositioning into 
rosettes, lamellipodia, and filopodia.  In order to determine the effects of the c-Yes 
functional domains on the ability of Src527F to exert its influence on the actin-based 
cytoskeleton, cells were fixed on cover slips, stained with rhodamine-conjugated 
phalloidin, and visualized via confocal laser microscopy.  As can be seen in Figure 2C, 
cells expressing Src527F appeared more rounded, and actin staining was present largely in 
punctate rosette structures or in actin-based motility structures such as lamellipodia or 
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filopodia.  Similar actin staining was detected in cells expressing each of the Src527F/c-
Yes chimeras, again with the exception of Y4U32527F (Figure 2C).  Cells expressing this 
construct retained long, well-organized actin stress fibers, comparable to those in non-
transfected cells (Figure 2C).  Additionally, in contrast to Src-transformed cells, the cells 
appeared elongated with intact focal adhesion structures.   
The c-Yes SH4 and Unique domains are sufficient for the ablation of morphological 
and cytoskeletal changes induced by Src527F.   
These initial results indicated that Src527F/c-Yes chimeras with the c-Yes SH4, 
Unique, SH3, and SH2 domains were unable to induce the actin filament rearrangements 
that typically occur concomitant with Src-transformation.  The next question we sought 
to address was which functional domain or domains were responsible for the inability of 
Y4U32527F to induce changes in the actin cytoskeleton.  As the Y32527F construct induced 
morphological changes similar to those of Src527F, we hypothesized that the SH4 and/or 
Unique domains of c-Yes were responsible for the inability of Y4U32527F to induce 
changes in actin filament integrity.  In order to determine if the c-Yes SH4 and Unique 
domains, either together or individually, were sufficient to prevent cytoskeletal and 
morphological changes, CEF were transfected with Src527F/c-Yes chimeras in which the 
SH4 and Unique domains (Y4U527F), the SH4 domain alone (Y4527F), or the Unique 
domain alone (YU527F) of Src527F were replaced by those of c-Yes.  Rabbit anti-Src 
western blot analysis was again used to verify expression of the chimeric constructs 
(Figure 3A).  As seen in Figure 3B, replacement of either the Src527F SH4 or Unique 
domain individually with the corresponding c-Yes domain did not affect the ability of 
Src527F to induce morphological changes as extensively as did replacement of both 
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domains.  Cells expressing Y4527F and YU527F demonstrate a loss of contact-dependent 
inhibition of cell growth and a loss of organization of the monolayer, however, the 
morphological changes are not as dramatic as those induced by Src527F (Figure 3B).   The 
Y4U527F chimera, however, did not induce significant morphological changes in CEF 
(Figure 3B).  Y4U527F transfectants grew into a confluent, well-organized monolayer and 
retained contact-dependent inhibition of cell growth.  The ability of these chimeras to 
effect repositioning of actin to rosettes and motility structures was also assessed through 
immunofluorescent confocal microscopy.  Cells were fixed on cover slips, and stained 
with rhodamine-conjugated phalloidin.  In Figure 3C, it can be seen that cells transfected 
with the Y4527F and YU527F constructs were more rounded and demonstrated actin 
staining in rosette structures, although they retained some actin stress fibers.  In cells 
transfected with Y4U527F, actin was predominantly present in stress fibers and along the 
plasma membrane (Figure 3C).  These results indicate that while both the c-Yes SH4 and 
Unique domains contribute, neither domain alone is sufficient to completely ablate the 
ability of Src527F to induce morphological changes and effect the repositioning of actin 
from stress fibers to rosettes and membranous motility structures.   
Src527F/c-Yes amino terminal chimeras are associated with the triton-insoluble 
cytoskeletal fraction. 
We next set out to address why Src527F/c-Yes amino terminal chimeras (including 
both the SH4 and Unique domains) were unable to induce changes in the actin-based 
cytoskeletal architecture.  Although Y4U32527F produced relative autophosphorylation 
and total cellular phosphotyrosine levels that approached those induced by Src527F, the 
reduced steady-state expression levels of Y4U32527F were considered as a possible 
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explanation for the lack of morphological or cytoskeletal changes associated with this 
chimera.   However, we observed that steady-state levels of the Y4U32527F chimera were 
higher than those of LA29 v-Src, a temperature-sensitive variant of v-Src that is 
transformation competent at the permissive temperature of 36° C but does not transform 
cells at 41° C (Poste and Flood, 1979) (Figure 4).  Thus, reduced steady-state expression 
alone may not be sufficient to account for the inability of Y4U32527F to induce changes in 
the integrity of the actin cytoskeleton.  
 In order to investigate the mechanisms associated with the inability of Y4U32527F 
and Y4U527F to alter actin filament integrity, we next examined the subcellular 
distribution of these chimeric proteins.  One of the hallmarks of transformation-
competent variants of Src is that they are associated with cellular membranes via their 
SH4 domains.  Fractionation of cells into membrane and cytosolic preps revealed that 
Src527F and all Src527F/c-Yes chimeras were associated predominantly with the membrane 
fraction (data not shown).    Thus the inability of Y4U32527F to induce cytoskeletal 
rearrangements is not due to an inability to localize with cellular membranes.  Another 
feature of transformation-competent variants of Src is that they associate predominantly 
with the triton X-100 insoluble cytoskeletal fraction, whereas endogenous c-Src is 
primarily triton-soluble.  Thus, in order to determine if Src527F/c-Yes amino terminal 
chimeras were able to associate with the triton-insoluble fraction, mock-transfected CEF 
or cells expressing c-Src, Src527F, Y4U32527F, or Y4U527F were separated into triton-
soluble and triton-insoluble fractions.  Both endogenous c-Src from mock-transfected 
cells and overexpressed c-Src displayed a shift in solubility from the triton insoluble 
fraction to the triton soluble fraction after four minutes of incubation in CSK buffer, 
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whereas Src527F and Y4U32527F remained predominantly associated with the triton-
insoluble fraction, even after 10 minutes of incubation.  Similar results were obtained 
with Y4U527F (data not shown).  These results indicate that the inability of Y4U32527F to 
effect actin redistribution is not due to an inability of the protein to partition into the 
triton-insoluble cytoskeletal fraction.   
The c-Yes amino terminal region does not prevent activation of the MAP kinase 
pathway.  
The inability of Src527F/c-Yes amino terminal chimeras to induce rearrangement 
of the actin cytoskeleton may likely be attributed to failure to activate one or more 
downstream pathways that are normally upregulated in response to oncogenic Src.  Thus, 
we next investigated the activation status of signaling proteins that function downstream 
of Src.  The proteins chosen in this study can broadly be classified into two distinct yet 
overlapping categories: those that are involved in the mitogenic response to Src activation 
and those that are involved in mediating the effects of Src on the actin-based 
cytoskeleton.   
The MAP kinase pathway, as illustrated in Figure 6, is one of the most well-
characterized pathways activated in response to Src and is involved in the induction of a 
mitogenic response (Gupta et al., 1992; Howe et al., 1992; Cowley et al., 1994; 
Whitmarsh and Davis, 1996; Klein and Schneider, 1997).  The first step in the activation 
of the MAP kinase pathway downstream of Src is the formation of stable complex 
between Shc and Grb2 (Rozakis-Adcock et al., 1992).  Thus in order to assess the effects 
of the c-Yes amino terminus on the ability of Src to induce activation of the MAP kinase 
pathway, we first assayed complex formation between Shc and Grb2.  CEF lysates were 
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immunoprecipitated with an anti-Shc monoclonal antibody, and the immunoprecipitates 
were resolved by SDS-PAGE.  Western blot analysis was performed using an anti-Grb2 
monoclonal antibody.  Blots were stripped and re-probed with the anti-Shc antibody to 
demonstrate that equal amounts of Shc were immunoprecipitated (Figure 7A, bottom 
panel).  Minimal complex formation was detected between Shc and Grb2 in lysates from 
mock-transfected cells.  Robust complex formation was detected between Shc and Grb2 
in Src527F-transformed cells (Figure 7A, top panel).  Cells expressing Y4U32527F 
displayed increased Shc/Grb2 complex formation over mock-transfected CEF 
(approximately 2.5 fold); however, levels were almost 2-fold lower than those detected in 
Src-expressing cells (Figure 7A, top panel).  Cells expressing Y4U527F displayed levels of 
Shc/Grb2 complex formation more closely approximating those induced by Src527F (1.2 
fold lower) (Figure 7A, top panel).  Similar results were obtained when 
immunoprecipitating with the anti-Grb2 antibody and probing with the anti-Shc antibody 
(data not shown). These data indicate that the c-Yes amino terminus alone is not 
sufficient to abrogate Src-induced Grb2/Shc complex formation.   
We next looked further downstream at c-Raf activation.  c-Raf activation was 
assessed by western blot analysis using an antibody against the phosphorylated form of c-
Raf.  CEF lysates from mock-transfected cells, or cells expressing Src527F, Y4U32527F, or 
Y4U527F were separated by SDS-PAGE, and western blots were probed with the anti-
phospho-Raf antibody.  As seen in Figure 7B, no phosphorylation of c-Raf was detected 
in mock-transfected cells; however, lysates from cells expressing Src527F were strongly 
immunoreactive with the anti-phospho-Raf antibody (Figure 7B, top panel).  Y4U32527F 
lysates were weakly immunoreactive with the anti-phospho-Raf antibody in comparison 
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to Src527F; however, Y4U527F-induced c-Raf phosphorylation more closely approximated 
levels induced by Src527F.   (Figure 7B, top panel).  Blots were additionally probed with 
an anti-c-Raf antibody in order to determine relative levels of c-Raf present in the cell 
lysates (Figure 7B, bottom panel).  The markedly lower levels of phospho-c-Raf present 
in Y4U32527F lysates were somewhat surprising.  We have, however, previously noted 
functional differences in the SH3 and SH2 domains of c-Src and c-Yes, and thus the 
reduced c-Raf activation induced by Y4U32527F may be due to one or both of these 
domains (Summy et al., 2000).  Nevertheless, these results indicate that the c-Yes amino 
terminus alone is not sufficient to prevent the activation of c-Raf downstream of Src.   
We next assessed the effects of the c-Yes amino terminus on the ability of Src to 
induce activation of the MAP kinases Erk 1/2.  In order to assess the activation of Erk 
1/2, western blot analysis was performed on lysates from mock-transfected CEF or cells 
expressing Src527F, Y4U32527F, or Y4U527F using an anti-phospho-ERK 1/2 antibody, 
immunoreactive against the activated forms of Erk 1 and 2.  As seen in Figure 7C, 
Src527F, Y4U32527F, and Y4U527F each induced significant Erk activation above levels 
detected in mock-transfected cells (Figure 7C, top panel).  Western blots were 
additionally probed with an anti-MAP kinase antibody, specific for Erk 1/2, to ensure that 
equal levels of protein were present in the lysates (Figure 7C, bottom panel).  These 
results indicate that the presence of the c-Yes amino terminus is insufficient to abrogate 
Erk activation downstream of Src527F.  Thus the inability of chimeric proteins with the c-
Yes amino terminus to induce rearrangement of the actin cytoskeleton and changes in 
cellular morphology do not correlate with an inability to activate the MAP kinase 
pathway. 
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Src527F/c-Yes chimeras with the c-Yes amino terminus fail to activate the PI3K/Akt 
pathway.  
While many proteins are known to be important for Src-mediated actin filament 
rearrangement, the precise pathway that regulates this process has not been defined.  
Phosphatidylinositol-3-kinase (PI3K), a lipid and protein kinase named for its ability to 
phosphorylate the 3’ hydroxyl group of inositol phospholipids, may potentially mediate 
the effects of Src on the actin cytoskeleton, as it functions downstream of Src and is 
known to be involved in actin filament rearrangements (Penuel and Martin, 1999; 
Krasilnikov, 2000; Odajima et al., 2000; Sohara et al., 2001).  We first assessed the 
activation of PI3 kinase indirectly, using the activation state of Akt as an indicator of PI3 
kinase activity.  Akt is a ser/thr kinase that is activated downstream of PI3K and an 
important mediator of cellular survival signals (Krasilnikov, 2000).  In order to evaluate 
Akt activation, western blot analysis was performed, using an antibody against the 
phosphorylated and active form of Akt, on lysates from cells that were mock-transfected 
or expressing Src527F, Y4U32527F, or Y4U527F.  As seen in Figure 8A, no Akt 
phosphorylation was detected in lysates of mock-transfected CEF; however, strong anti-
phospho-Akt immunoreactivity was detected in cell lysates expressing Src527F (Figure 
8A, top panel).  Levels of anti-phospho-Akt reactivity from cells expressing Y4U32527F 
or Y4U527F were only slightly higher than background (Figure 8A, top panel).  These 
results indicate that the presence of the c-Yes amino terminus was sufficient to ablate the 
ability of Src527F to induce activation of Akt, presumably through PI3K.  In order to 
directly assess the ability of these proteins to induce PI3 kinase activity, cell lysates were 
immunoprecipitated with an antibody against the 85 kDa subunit of PI3K, and the 
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immunoprecipitated proteins were subjected to a PI3 kinase assay.  The radio-labeled 
kinase assay products were then spotted on thin layer chromatography plates for 
separation.  The results were visualized using phosphorimager analysis.  As can be seen 
in Figure 8B, little PI3 kinase activity was detected in lysates from mock-transfected 
cells, while PI3 kinase activity was readily detected in Src527F-transfected cells (Figure 
8B, top panel).  Cells expressing Y4U32527F, however, displayed levels of PI3 kinase 
activity that were equivalent to background (Figure 8B, top panel).  Western blot analysis 
of PI3K immunoprecipitates using an anti-PI3K p85 antibody revealed that equivalent 
amounts of PI3K were present (Figure 8B, bottom panel).  These results indicate that 
Y4U32527F is unable to induce activation of PI3K.  Thus, the inability of this protein to 
induce the rearrangements of the actin cytoskeleton and the morphological changes that 
are characteristic of Src transformation may be due to an inability to activate PI3K. 
 
 
 
 
 
 
 
 
 
 
 
 110 
Discussion 
 c-Yes and c-Src are two of the most highly homologous members of the Src 
family of non-receptor tyrosine kinases, yet despite their significant similarity, specificity 
exists between the two proteins.  The c-src and c-yes gene knockout mice and cells 
derived from them have proved useful in uncovering cellular processes and pathways in 
which these proteins function distinctly from one another.  As mentioned above, several 
studies carried out in cells derived from the c-src -/- mice have indicated deficiencies in 
cellular processes that are dependent on dynamic regulation of the actin cytoskeleton.  c-
Yes, despite normal expression in these cells, is unable to compensate for c-Src in the 
regulation of these processes.   
The experiments described in this report were undertaken in an effort to gain an 
understanding of the roles of the c-Yes functional domains in the apparent inability of c-
Yes to regulate actin cytoskeletal rearrangements.  In these experiments, the cytoskeletal 
and morphological changes that occur concomitantly with Src527F-induced transformation 
of CEF were used as a model system.  We discovered that replacement of the Src SH4, 
Unique, SH3, and SH2 domains with the corresponding c-Yes domains resulted in a loss 
of actin repositioning from stress fibers to punctate rosettes and actin-based membranous 
motility structures such as lamellipodia and filopodia.  The inability to induce 
morphological and cytoskeletal changes was associated primarily with the c-Yes amino 
terminus (SH4 and Unique domains), as the Y32527F chimera was able to induce these 
phenotypic changes.  However, replacement of the c-Src amino terminus with that of c-
Yes eliminated the ability of Src527F to induce the phenotypic changes that are typically 
observed upon overexpression of the protein.  
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 Having identified the c-Yes amino terminus as the region responsible for the 
failure of these chimeric proteins to induce morphological and cytoskeletal changes, the 
focus shifts to the determination of why this is true.  Failure to activate the appropriate 
signaling pathway or pathways would seem to be an obvious answer, but that raises the 
more difficult issue of identifying the pathway or pathways responsible.  This is a 
particularly vexing issue, as there are many proteins that are important for Src-mediated 
actin filament rearrangement, and they do not necessarily act in one linear pathway.  In 
fact, it is likely that the effectors of Src transformation act through multiple pathways, 
both parallel and overlapping.   
One pathway that is activated downstream of Src and is essential for cell 
transformation by oncogenic Src is the MAP kinase pathway (Cowley et al., 1994).  Erk 
1/2 MAP kinases are activated downstream of Src through a pathway that can be initiated 
through Shc/Grb2 interaction (Rozakis-Adcock et al., 1992). Shc/Grb2 complex 
formation allows the Grb2/SOS complex to activate Ras, which is followed by activation 
of Raf, MEK1/2, and finally the MAP kinases themselves (Klein and Schneider, 1997).  
In these studies, the ability of Src527F to induce activation of the MAP kinase pathway 
was not ablated by the presence of the c-Yes amino terminus.  Although Y4U32527F did 
not induce the robust activation of members of the MAPK pathway that Src527F did, 
differences mediated by Src527F and Y4U527F were less pronounced.  The reduced levels 
of MAPK pathway activation induced by Y4U32527F may be due to the presence of the c-
Yes SH3 and SH2 domains, which, as noted above, have been previously demonstrated to 
differ in their ligand-binding, and hence signaling, capacities (Sparks et al., 1996; 
Summy et al., 2000).  While activation of MAP kinases are important for the mitogenic 
 112 
response to Src activation, the role that MAP kinase activation plays in rearrangement of 
the actin cytoskeleton downstream of Src is unclear.  Fincham and colleagues 
demonstrated that inactivation of Rho, a key modulator of the actin cytoskeleton, 
downstream of Src may be independent of mitogenesis, thus indicating that separate 
pathways may be involved in inducing the cytoskeletal and mitogenic responses 
(Fincham et al., 1999).  
PI3K is an important downstream mediator of Src and is involved in directing 
actin cytoskeletal rearrangements (Toker and Cantley, 1997; Penuel and Martin, 1999; 
Krasilnikov, 2000; Odajima et al., 2000; Sohara et al., 2001).  It has been reported 
previously that PI3K may function in parallel with the MAP kinase pathway (Penuel and 
Martin, 1999; Susa et al., 2000; Odajima et al., 2000).  The 85 kDa subunit of PI3K is 
both a substrate and SH3 domain binding partner of Src, and the ability of Src to 
associate with PI3K correlates with its ability to induce cell transformation (Hamaguchi 
et al., 1993; Catling et al., 1994; Pleiman et al., 1994; Krasilnikov, 2000).  Fincham et al. 
recently demonstrated that binding of the v-Src SH3 domain to PI3K is important in 
targeting Src to focal adhesion structures (Fincham et al., 2000).  The exact mechanism 
by which PI3K exerts its influence on the actin cytoskeleton remains unclear; however, it 
may be involved in the regulation of Rho family members, such as Rac-1, Cdc42, and 
RhoA (Reif et al., 1996).  Preliminary data obtained in our laboratory indicate that 
Src527F/c-Yes amino terminal chimeras fail to inactivate, and in fact may induce 
activation of RhoA, which is responsible for formation of actin stress fibers (Summy and 
Qian, unpublished data).  Additionally, activation of PI3K results in activation of the 
Ser/Thr kinase Akt (Krasilnikov, 2000).  Akt activation contributes to cell survival and 
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may also play a role in cell transformation (Krasilnikov, 2000).  Our data indicate that 
Src527F/c-Yes amino terminal chimeras are incapable of efficiently inducing activation of 
Akt, as demonstrated by western blot analysis with the anti-phospho-Akt antibody.  This 
result correlates with the inability of Y4U32527F to induce activation of PI3K.  We feel 
that the inability of Src527F/c-Yes amino terminal chimeras to activate the PI3K/Akt 
pathway may be responsible for their inability to induce actin filament rearrangement. 
The investigation of one question invariably leads to the uncovering of another: in 
this case, why are Src527F/c-Yes amino terminal chimeras unable to induce activation of 
PI3K?  Traditionally, Src has been hypothesized to induce PI3K activation through direct 
binding and/or tyrosine phosphorylation (Pleiman et al., 1994; Krasilnikov, 2000).  
Binding of Src to PI3K occurs through an interaction between the Src SH3 domain and 
the 85 kDa subunit of PI3K (Pleiman et al., 1994; Mak et al., 1996).  Mutants of v-Src 
that fail to bind PI3K also fail to induce cell transformation (Catling et al., 1994).  While 
there is no previous evidence of direct interaction between c-Yes and PI3K, there is little 
reason to believe that the c-Yes SH3 domain would be unable to bind to p85, as the SH3 
domain residues that have been reported to be essential for p85 binding in other Src 
family members are conserved in c-Yes (Mak et al., 1996), and v-Yes is able to induce 
elevated PI3K activity (Fukui et al., 1991).  Additionally, the Y4U527F chimera, which 
expresses the c-Src SH3 domain, was unable to induce efficient activation of Akt.  This 
suggests that it is the c-Yes amino terminus itself that is responsible for the inability of 
these chimeras to induce activation of the PI3K/Akt pathway. 
As mentioned above, the c-Yes amino terminus is composed of the SH4 and 
Unique domains.  The c-Yes SH4 domain contains a palmitoylation site at Cys 3 that is 
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not present in the c-Src SH4 domain (Resh, 1994).  Palmitoylation is important for 
targeting Src family kinases to detergent-resistant membrane microdomains, or lipid rafts 
(Shenoy-Scaria et al., 1994; Resh, 1994; Robbins et al., 1995).  It is possible that 
sequestration to the lipid raft fraction may be responsible for the inability of Src527F/c-Yes 
amino terminal chimeras to activate the PI3K pathway and thus induce morphological 
and cytoskeletal changes.  This explanation would be in agreement with the ability of v-
Yes to induce PI3K activation and cell transformation, as v-Yes is an N-terminal fusion 
of the Yes protein with the retroviral Gag protein and is not palmitoylated, relying instead 
on the Gag protein for membrane targeting (Ghysdael et al., 1981; Fukui et al., 1991).   
Raft localization cannot be the full explanation, however, as the palmitoylation 
site is sufficient for localization of Src family kinases to lipid rafts (Shenoy-Scaria et al., 
1994), yet Y4527F is able to induce actin filament rearrangement and morphological 
changes.   It is possible that the Unique domain contributes to membrane 
compartmentalization, as occurs with Lck (Bijlmakers et al., 1997), or targets the kinase 
to proteins with which it would not normally interact.  Conversely, the c-Yes Unique 
domain may prevent the interaction of Src527F with substrates or binding partners, such as 
PI3K, that are necessary for repositioning of cellular actin and induction of 
morphological changes.  However, the ability of the YU527F chimera to induce actin 
filament rearrangement and morphological changes suggests that this is also not the 
complete story and that both the SH4 and Unique domains contribute to the inability of 
Src527F/c-Yes amino terminal chimeras to induce morphological changes and actin 
filament rearrangement.  The SH4 and Unique domains may act synergistically, both 
through sequestration to lipid raft fractions and through altered protein/protein and/or 
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protein/substrate interactions.  The function of the c-Yes Unique domain has not been 
previously explored. 
  It should also be noted that the inability of Y4U527F and Y4U32527F to activate 
the PI3K/Akt pathway in CEF may be unrelated to direct interaction between the 
chimeric proteins and PI3K.  Hakak et al. demonstrated that in Shp-2 knockout cells, the 
PI3K/Akt pathway was inefficiently activated by v-Src, and this correlated with reduced 
complex formation between Cbl and p85 (Hakak et al., 2000).  The reason behind the 
reduced activation of the PI3K/Akt pathway by Src527F/c-Yes amino terminal chimeras is 
currently under investigation.   
 In summary, we have demonstrated that fully activated Src/Yes chimeras with the 
c-Yes amino terminus are unable to induce the cytoskeletal and morphological changes 
normally associated with expression of Src527F in CEF.  The deficiency in actin 
cytoskeleton rearrangement correlates strongly with the inability of these chimeras to 
induce activation of the PI3K/Akt pathway.  These results may provide insight into why 
c-Yes is unable to compensate for c-Src in the regulation of several cytoskeletal 
processes in c-Src knockout cells. Future studies, in which these chimeras are expressed 
in c-src -/-cells, may provide further insight into this problem. 
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Figure 1.  Src527F/c-Yes chimeric constructs.  Src527F/c-Yes chimeras are depicted 
subdivided into the following functional domains: SH4 domain, Unique domain, SH3 
domain, SH2 domain, protein tyrosine kinase domain, and regulatory sequence.  Gray 
boxes represent domains from c-Yes; white boxes represent domains from Src527F.  The 
generation of the Y3527F, Y2527F, Y32527F, Y4U32527F, Y4U527F, Y4527F, and YU527F 
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chimeric constructs was described previously.  All proteins were expressed in CEF via 
the Rous Sarcoma Virus (RSV) vector. 
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Figure 2.  Effects of Src527F/c-Yes chimeras on cellular phosphotyrosine, cell 
morphology, and the actin cytoskeleton.  (A) Thirty µg of day 12 RIPA lysates from 
mock-transfected CEF or cells expressing Src527F, Y3527F, Y2527F, Y32527F, or Y4U32527F 
were separated by 8% SDS PAGE.  Lysates were transferred to PVDF membrane, 
CEF Src527F 
Y32527F Y4U32527F 
C 
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blocked in 1% BSA, and probed with a rabbit anti-phosphotyrosine antibody (top panel), 
rabbit anti-phospho-Y416 (middle panel), or rabbit anti-Src (bottom panel).  Lane 1 = 
CEF; Lane 2 = Src527F; Lane 3 = Y3527F; Lane 4 = Y2527F; Lane 5 = Y32527F; Lane 6 = 
Y4U32527F. (B) Confluent CEF expressing Src527F, Y3527F, Y2527F, Y32527F, or Y4U32527F 
were photographed at day 12 post-transfection in 100 mm tissue culture plates (Falcon).  
Cells were photographed at 40x total magnification using a Plan 2 filter.  Mock-
transfected CEF and cells expressing Src527F, Y32527F, and Y4U32527F are shown.  (C) 
Mock-transfected CEF and cells expressing Src527F, Y3527F, Y2527F, Y32527F, or 
Y4U32527F were fixed at 50% confluence on cover slips in 3.7% formaldehyde, 
permeablized in 0.4 % triton X-100, and stained with rhodamine-phalloidin (2 µg/ml).  
Cells were visualized via Zeiss LSM 510 confocal microscopy (63x objective).  Mock 
transfected CEF and cells expressing Src527F, Y32527F, or Y4U32527F are shown.  Bars 
represent 10 µm.  (A-C) Results are representative of three independent experiments. 
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Figure 3.  Expression of Src527F/c-Yes amino terminal chimeras in CEF and their effects 
on cell morphology and the actin cytoskeleton.  (A) Thirty µg of day 12 RIPA lysates 
from mock-transfected CEF or cells expressing Src527F, Y4U32527F, Y4U527F, Y4527F, or 
YU527F were separated via 8% SDS PAGE.  Lysates were transferred to PVDF 
10 µm 
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C 
 124 
membrane, blocked in 5% milk/TBS-T, and probed with rabbit anti-Src.  Lane 1 = CEF; 
Lane 2 = Src527F; Lane 3 = Y4U32527F; Lane 4 = Y4U527F; Lane 5 = Y4527F; Lane 6 = 
YU527F.  (B) Confluent CEF expressing Y4U527F, Y4527F or YU527F were photographed at 
day 12 post-transfection in 100 mm tissue culture plates (Falcon).  Cells were 
photographed at 40x total magnification using a Plan 2 filter. (C) CEF expressing 
Y4U527F, Y4527F, or YU527F were fixed at 50% confluence on cover slips in 3.7% 
formaldehyde, permeablized in 0.4 % triton X-100, and stained with rhodamine-
phalloidin (2 µg/ml).  Cells were visualized via Zeiss LSM 510 confocal microscopy 
(63x objective).  Bars represent 10 µm.  (A-C) Results are representative of three 
independent experiments. 
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Figure 4.  Y4U32527F is expressed at higher steady state levels than LA29 v-Src.  Fifty µg 
of day 12 RIPA lysates from mock-transfected CEF or cells expressing Src527F, 
Y4U32527F, or LA29 v-Src were resolved by 8% SDS PAGE, transferred to PVDF 
membrane, blocked in 5% milk/TBS-T, and probed with rabbit anti-phospho-Y416.  Lane 
1 = CEF; Lane 2 = Src527F; Lane 3 = Y4U32527F; Lane 4 = LA29 v-Src.  Results are 
representative of two independent experiments. 
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Figure 5.  Y4U32527F is associated with the triton X-100 insoluble cytoskeletal fraction.  
Mock-transfected CEF or cells expressing c-Src, Src527F, Y4U32527F, or Y4U527F were 
grown to confluence in 100 mm dishes.  Cells were incubated in 1 ml of CSK buffer for 
1, 4, or 10 min.  The triton-soluble fractions were collected, and the triton-insoluble 
material at each time-point was solublized in RIPA buffer.  Fifty µg of cell lysates from 
each fraction were separated by 8% SDS PAGE, transferred to PVDF membrane, blocked 
with 5% milk/TBS-T, and probed with rabbit anti-Src.  Results are shown for mock-
transfected CEF (top left panel), c-Src (top right panel), Src527F (bottom left panel), and 
Y4U32527F (bottom right panel).  C = CSK buffer; R = RIPA buffer. 
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Figure 6.  Src can activate the MAP kinase pathway.  Activation of the MAPK pathway 
by Src begins with phosphorylation of the adaptor protein Shc.  Phosphorylated Shc 
forms a stable complex with Grb2, which binds to the guanine nucleotide exchange factor 
SOS.  SOS facilitates exchange of GTP for GDP, thereby resulting in activation of Ras.   
Activated Ras binds to and contributes to the activation of c-Raf.  Activated c-Raf 
phosphorylates and activates MEK1/ 2, which in turn phosphorylate and activate Erk 1/2 
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MAP kinases.  The MAP kinases phosphorylate and activate nuclear transcription factors 
such as Elk 1 (Klein and Schneider, 1997). 
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Figure 7.  Activation of the MAP kinase pathway by Src527F and Src527F/c-Yes chimeras.   
(A) Five hundred µg of RIPA lysates from mock-transfected CEF or cells expressing 
IP: Anti-Shc 
Anti-Grb2 
Anti-Shc 
1 2 3 4 
Western Blot Western Blot 
Anti-Phospho-Raf 
Anti-c-Raf-1 
1 2 3 4 
A B 
Western Blot 
Anti-Phospho-Erk 
Anti-MAPK 
1 2 3 4 
C 
 130 
Src527F, Y4U32527F, or Y4U527F were immunoprecipitated with an anti-Shc antibody and 
separated by 10% SDS PAGE.  Immunoprecipitated proteins were transferred to PVDF 
membrane, blocked in 5% milk/TBS-T and probed with an anti-Grb2 antibody (top 
panel).   The blots were stripped and re-probed with the anti-Shc antibody, 
immunoreactive against the 46, 52, and 66 kDa isoforms of Shc (bottom panel).  Results 
are representative of two independent experiments.  (B) Fifty µg of RIPA lysates from 
mock-transfected CEF or cells expressing Src527F, Y4U32527F, or Y4U527F were resolved 
by 8% SDS PAGE, transferred to PVDF membrane, blocked in 5% milk/TBS-T and 
probed with an anti-phospho-Raf antibody (top panel).  Western blot analysis was also 
performed with an anti-c-Raf antibody to determine relative protein levels (bottom 
panel).  Results are representative of two independent experiments.  (C) Fifty µg of RIPA 
lysates from mock-transfected CEF or cells expressing Src527F, Y4U32527F, or Y4U527F 
were processed for western blot analysis as described above.  Membranes were probed 
with an anti-phospho-Erk antibody (top panel) or an anti-p42/44 MAPK antibody to 
determine relative protein levels (bottom panel).  Results are representative of two 
independent experiments.  (A-C)  Lane 1 = CEF; Lane 2 = Src527F; Lane 3 = Y4U32527F; 
Lane 4 = Y4U527F. 
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Figure 8.  Src527F/c-Yes chimeras with the c-Yes amino terminus are unable to activate 
the PI3K/Akt pathway.  (A) Fifty µg of RIPA lysates from mock-transfected CEF or cells 
expressing Src527F, Y4U32527F, or Y4U527F were resolved by 8% SDS PAGE, transferred 
to PVDF membrane, blocked with 5% milk/TBS-T, and probed with an anti-phospho-Akt 
antibody (top panel) or with an anti-Akt antibody to determine relative protein levels 
(bottom panel).  Lane 1 = CEF; Lane 2 = Src527F; Lane 3 = Y4U32527F; Lane 4 = Y4U527F.  
Results are representative of two independent blots.  (B) Four hundred µg of lysates from 
mock-transfected CEF or cells expressing Src527F or Y4U32527F were immunoprecipitated 
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with an anti-PI3K antibody and subjected to PI3 kinase assay as described in materials 
and methods.  Kinase assay products were resolved by thin layer chromatography and 
visualized by Phosphorimager analysis (top panel).  Anti-PI3K immunoprecipitates were 
also resolved by 8% SDS PAGE, transferred to PVDF membrane, blocked in 5% 
milk/TBS-T, and probed with an anti-PI3K p85 antibody to verify equal amounts of PI3K 
in the lysates (bottom panel).  Lane 1 = CEF; Lane 2 = Src527F; Lane 3 = Y4U32527F. 
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Src family tyrosine kinases are expressed in virtually all vertebrate tissues, and 
are involved in signal transduction pathways that govern a variety of biological 
processes, including cell cycle, cell spreading, motility, differentiation, survival, and 
death (Thomas and Brugge, 1997).  While there is a wealth of data available on the 
functions of Src family kinases, the issue of specificity in signaling between Src family 
members has only been lightly addressed.  With the exception of c-Src, c-Yes, and Fyn, 
Src family kinases are expressed only in limited subsets of hematopoietic cells (Thomas 
and Brugge, 1997).  These kinases, including Lyn, Lck, Hck, Blk, Fgr, and Yrk, are well 
positioned to serve specific functions in signaling pathways unique to these cells.  
Examples of this include Fgr and Hck in the development and differentiation of 
monocytic cells and Lck in T-cell receptor signaling (Katagiri et al., 1991; Katagiri et al., 
1992; Wong et al., 1998).  Even in these cells, however, there are frequently multiple Src 
family kinases present, indicating that they either perform redundant functions, or that 
individual Src family kinases expressed in the same cells carry out unique functions.  It 
should be noted, however, that these two possibilities are not mutually exclusive, and 
evidence exists to support both redundancy and specificity of function between Src 
family kinases (Brown and Cooper, 1996; Page et al., 1997).   
The primary goal of these studies was the investigation of how c-Src and c-Yes 
are capable of sending specific signals.  c-Src and c-Yes are two of the most highly 
homologous members of the Src family of tyrosine kinases.  They share over 80% amino 
acid homology outside of their Unique domains and are expressed across a wide range of 
cells and tissues (Kitamura et al., 1982; Sudol et al., 1988; Zhao et al., 1990; Sugawara et 
al., 1991).  The studies outlined in this thesis have focused on the contributions of the 
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functional domains to signaling specificity between c-Src and c-Yes.  All Src family 
kinases share a common functional domain architecture.  These domains, with the 
exception of the amino terminal region (SH4 and Unique domains), each take on a known 
three-dimensional conformation and thus contribute, in a well-established fashion, to the 
overall fold of the protein (Sicheri et al., 1997; Xu et al., 1997).  The independent folding 
of the functional domains permits exchange of homologous functional domains between 
Src family members without disrupting the overall protein conformation.  Additionally, 
with the exception of the Unique domain, the functions of these domains, and thus their 
general contributions to Src family kinase signaling, have been well characterized.    
The experiments described in this thesis have focused primarily on the roles of the 
non-catalytic functional domains in signaling specificity between c-Src and c-Yes.  The 
non-catalytic domains were chosen for study due to the high homology between the 
kinase domains themselves. c-Src and c-Yes share 90% amino acid homology in their 
kinase domains, including virtually complete identity in 11 sub-regions important for 
tyrosine kinase activity (Kitamura et al., 1982; Brickell, 1992).  Additionally, there is 
little data available in the literature to suggest that substrate selectivity exists between the 
catalytic domains of Src family kinases.  Thus the focus of this thesis was placed on the 
non-catalytic domains, including the SH4, Unique, SH3, and SH2 domains.  Utilizing 
chimeras in which the c-Src or Src527F functional domains were replaced by the 
corresponding domains of c-Yes, signaling specificity between c-Src and c-Yes was 
studied at three interrelated yet distinct levels: protein/protein interactions, transcriptional 
activation, and cell biology.  
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 In comparison to c-Src, little is known of the function of c-Yes, thus the studies 
outlined in this thesis evolved into an assessment of the effects of the c-Yes functional 
domains on the signaling capacity of activated c-Src, at the three levels mentioned above.  
In the course of these experiments, each of the non-catalytic functional domains was 
implicated in signaling specificity.  Src family kinase signaling is initiated at the level of 
protein/protein interactions.  Upon kinase activation, the conformation shifts from the 
closed or assembled form to the open conformation, in which the intramolecular 
interactions between the SH3 domain and kinase linker and between the SH2 domain and 
the phosphorylated carboxy-terminal tyrosine are displaced (Xu et al., 1999).  The kinase 
active site is then readily accessible for ATP and substrates.  Substrate interactions may 
include both stable and transient associations with binding partners and phosphorylation 
of target proteins.  It was in hypothesized in Chapter 2 that differences in the binding 
specificity of the SH3 and/or SH2 domains would result in differential protein/protein 
interactions at the level of stable complex formation and substrate selection.  It has been 
demonstrated previously that functional SH3 and SH2 domains are necessary for efficient 
phosphorylation of SH3 and SH2 domain binding partners, and SH2 domain swapping 
can alter the profile of proteins phosphorylated by a tyrosine kinase (Kanner et al., 1991; 
Mayer and Baltimore, 1994; Weng et al., 1994; Guappone and Flynn, 1997).  
Collectively, these data indicate that SH3 and SH2 domains are able to select substrates 
through initiation of complex formation and presentation of bound proteins for 
phosphorylation.  In the case of the SH2 domain, initial phosphorylation is a prerequisite 
for binding; however, this brings the kinase and substrate in closer proximity, facilitating 
subsequent phosphorylation events.  Processive phosphorylation of Src family kinase 
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SH2 domain binding partners has been demonstrated previously (Pellicena et al., 1998; 
Scott and Miller, 2000).  
Kanner and colleagues observed that v-Yes, in comparison to v-Src, induced 
significantly lower levels of tyrosine-phosphorylation of several v-Src substrates (Kanner 
et al., 1990).  These proteins included the SH3 and SH2 domain binding partners AFAP-
110 and p130 CAS, thus our selection of these proteins for study in Chapter 2.  It was 
also demonstrated previously that mutants of activated Src deficient in SH3 domain 
binding were unable to efficiently induce tyrosine phosphorylation of AFAP-110, while 
SH2 domain mutants were deficient in phosphorylation of p130 CAS (Kanner et al., 
1991).  Hence our hypothesis that the inability of v-Yes to induce efficient 
phosphorylation of these proteins was due to deficiencies in SH3- or SH2-mediated 
substrate presentation.   
According to this hypothesis, replacement of the Src527F SH3 domain with that of 
c-Yes was expected to disrupt the ability of active Src to associate with and select AFAP-
110 for phosphorylation, while the replacement of the Src527F SH2 domain with that of c-
Yes would do the same for interactions with p130 CAS.  As reported in Chapter 2, the 
results did not support the hypothesis in regard to substrate selection.  Replacement of the 
Src527F SH3 and/or SH2 domains did not impede its ability to induce phosphorylation of 
either AFAP-110 or p130 CAS (Chapter 2, Figure 4A and 4B).  The phosphorylation of 
several other unidentified Src SH3 and SH2 domain binding partners was also not 
affected by replacement of the Src527F SH3 or SH2 domain with the corresponding 
domain from c-Yes, as determined by anti-pTyr western blot analysis of SH3 or SH2 
domain affinity absorptions from lysates of cells expressing Src527F, Y3527F, or Y2527F 
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(Figure 2, A and B).  Additionally, neither the c-Yes SH3 nor SH2 domain, in the context 
of Src527F, enhanced phosphorylation of proteins capable of binding specifically to either 
domain (Figure 2, A and B).  These results indicate that there is functional redundancy 
between the c-Src and c-Yes SH3 and SH2 domains at the level of substrate selection; 
however it does not address the issue of specificity in protein binding.   
Evidence for protein binding specificity was detected between both the SH3 and 
SH2 domains of c-Src and c-Yes.  In vitro affinity absorptions indicated that AFAP-110 
bound the c-Yes SH3 domain with much lower affinity than the c-Src SH3 domain 
(Chapter 2, Figure 1A).  The c-Yes SH3 domain also failed to bind six tyrosine-
phosphorylated proteins (approximate molecular weights of 137, 108, 97, 91, 77, and 72 
kDa) that were affinity absorbed by the c-Src SH3 domain from lysates expressing 
Src527F or Src527F/c-Yes chimeras (Figure 2A). The c-Yes SH3 domain selectively bound 
to the 65 kDa Yes associated protein (YAP 65) (Sudol, 1994), indicating that the GST-
SH3Yes fusion protein was functional (Chapter 2, Figure 1B).  Additionally, as mentioned 
above, chimeric proteins with the c-Yes SH3 domain, in contrast to Src527F, did not 
efficiently co-immunoprecipitate with AFAP-110, however the c-Yes SH2 domain did 
not inhibit the co-immunoprecipitation of Src527F/c-Yes chimeras with AFAP-110 
(Chapter 2, Figure 4D).  Neither the c-Yes SH3 nor SH2 domain affected the ability of 
chimeric constructs to co-immunoprecipitate with p130 CAS.  The c-Yes SH2 domain 
appeared to facilitate association of Src527F/c-Yes chimeras with an unidentified 87 kDa 
tyrosine-phosphorylated protein (pp87), as only those chimeras with the c-Yes SH2 
domain were found to efficiently co-immunoprecipitate with pp87 (Chapter 2, Figure 5).  
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Differential protein binding between the c-Src and c-Yes SH3 domains was not 
unexpected.  Differences in SH3 domain ligand specificity, to the amino or carboxy 
terminal sides of the core PXXP motif, between Src family members, including c-Src and 
c-Yes, have been shown previously using in vitro peptide binding studies (Rickles et al., 
1994; Rickles et al., 1995; Sparks et al., 1996).  The c-Src and c-Yes SH3 domains are 
very similar, however, differing at only 11 amino acid positions (Sudol et al., 1988; Xu et 
al., 1997), and these have not been definitively identified as crucial for ligand binding.  In 
lieu of the homology between the c-Src and c-Yes SH3 domains, it is of little surprise 
that ligand specificity detected between the two was subtle (LXXRPLPXΨP for Src, 
ΨXXRPLPXLP, where Ψ represents an aliphatic residue, and X represents any amino 
acid) (Sparks et al., 1996).  It was not determined if these differences in ligand specificity 
corresponded to actual differences in the ability of the c-Src and c-Yes SH3 domains to 
associate with full-length polypeptides, either in vitro or in vivo.  The SH3 domains of c-
Src, Fyn, and Lyn have previously demonstrated differential protein binding capacities in 
vitro (Weng et al., 1994), however this was not observed for the c-Src and c-Yes SH3 
domains.   
The data presented in Chapter 2 indicate that the differences in specificity 
between the c-Src and c-Yes SH3 domains are sufficient for differential protein/protein 
interactions both in vitro and in vivo.  The individual amino acids responsible for ligand 
specificity, however, remain to be determined.  Although systematic mutagenesis was not 
carried out to identify the individual residues responsible for imparting ligand specificity, 
they are likely to be localized to regions harboring non-homologous amino acid changes 
between the two SH3 domains.  Glu97 and Thr98 in the c-Src SH3 domain, which 
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correspond to Thr105 and Asp106 in the c-Yes SH3 domain, represent two non-
homologous amino acid differences between the c-Src and c-Yes SH3 domains.  These 
residues lie within the RT loop, a region that connects two of the core beta sheets and 
contributes to ligand specificity (Noble et al., 1993; Erpel et al., 1995), thus identifying 
these amino acids as potentially important for directing SH3 domain specificity between 
c-Src and c-Yes.  Further studies, in which these residues in the c-Src and c-Yes SH3 
domains are mutated, will be necessary to fully assess their importance for ligand 
specificity between the two proteins. 
While differences in ligand specificity were expected between the c-Src and c-
Yes SH3 domains, the evidence for differential protein binding between the c-Src and c-
Yes SH2 domains was a surprise.  In vitro binding assays indicate that Src family kinases 
select the same cognate peptide ligand sequences (Songyang et al., 1993).  The c-Src and 
c-Yes SH2 domains in particular have been demonstrated to bind the same sites within 
their cognate ligands (Alonso et al., 1995; Muthuswamy and Muller, 1995). While no 
significant differences in ligand specificity were detected between the c-Src and c-Yes 
SH2 domains in vitro (Figure 2B), an 87 kDa tyrosine-phosphorylated protein (pp87) was 
observed to co-immunoprecipitate preferentially with Src527F/c-Yes chimeras with the c-
Yes SH2 domain.  This is strongly suggestive that pp87 represents either a direct or 
indirect SH2 domain binding partner.  Again, the question remains as to which amino 
acids dictate SH2 domain specificity between c-Src and c-Yes.   
The SH2 domain is composed of two binding pockets separated by a large central 
beta sheet (Waksman et al., 1992; Eck et al., 1993).  The two binding pockets 
accommodate phosphotyrosine and downstream residues within the cognate ligand 
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respectively (Waksman et al., 1992; Eck et al., 1993).  In the case of Src family kinases, 
the second ligand-binding pocket is typically occupied by a hydrophobic amino acid three 
residues downstream of the phosphotyrosine (pY+3) (Eck et al., 1993).  As 
phosphotyrosine binding is a conserved feature of all SH2 domains, and differences in the 
downstream binding pocket dictate ligand specificity between the various SH2 domain 
sub-classes, the pY+3 pocket initially seemed the more attractive candidate for directing 
specificity between Src family kinases.   
There are 27 amino acid differences between the c-Src and c-Yes SH2 domains, 
however, the most notable non-homologous differences between the SH2 domains, 
within the pY+3 pocket, occur in the B helix, which forms the bottom of the pocket.  
These differences occur at Gln223, Ala228, and Tyr229 in Src527F, corresponding to Lys, 
Lys, and His in c-Yes.  However, the existing crystal structures of Src family SH2 
domains (Sicheri et al., 1997; Xu et al., 1997) suggest that only His237 is likely to be 
directed toward the interior of the ligand-binding pocket (Waksman et al., 1992).  
Unfortunately, mutation of this residue to tyrosine did not affect the ability of Y2527F to 
associate with pp87 (Figure 3, top panel).  In a recent paper by Bradshaw et al., it was 
reported that Cys185 in the c-Src SH2 domain phosphotyrosine pocket, occupied by serine 
in all other Src family kinases (Ser193 in c-Yes), imparts a reduced affinity for 
phosphotyrosine relative to serine (Bradshaw et al., 1999).  Differences in 
phosphotyrosine affinity may represent a mechanism for dictating ligand specificity 
between the c-Src and c-Yes SH2 domains, as a non-consensus SH2 domain binding 
partner may be more readily accommodated by a higher affinity for phosphotyrosine.  
Mutation of this Ser, Ser185 in Y2527F, resulted in a mild loss of pp87 co-
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immunoprecipitation (Figure 3, top panel), however, this consistently corresponded with 
a decrease in the amount of Y2527FS185C immunoprecipitated relative to the other Src527F/c-
Yes SH2 chimeric constructs (Figure 3, bottom panel), thus making it impossible to attribute 
the decreased co-immunoprecipitation of pp87 to mutation of residue 185 from Ser to 
Cys.   
Differential phosphotyrosine affinity between the c-Src and c-Yes SH2 domains 
may also have implications for the relative abilities of these kinases to be activated in 
response to cellular signals.  A higher affinity for phosphotyrosine may allow more 
efficient association between the phosphorylated tail and the SH2 domain, thus 
stabilizing the inactive, closed conformation.  Interestingly, it was observed that c-Src/c-
Yes chimeras with the c-Yes SH2 domain induced much lower levels of cellular 
phosphotyrosine and autophosphorylation than corresponding constructs with the c-Src 
SH2 domain (Figure 4).  Mutation of Ser185 to Cys in Y2, however, did not increase 
cellular phosphotyrosine or autophosphorylation of this kinase (Figure 5A and data not 
shown).   
In an effort to determine why c-Src/c-Yes chimeric constructs with the c-Yes SH2 
domain displayed reduced levels of cellular phosphotyrosine and autophosphorylation, 
the possibility that the closed conformation was stabilized by an ionic interaction between 
a positive-charged amino acid in the c-Yes SH2 domain (His229 in Y2) and a negative-
charged residue in the regulatory tail (Glu531 in c-Src, Asp539 in c-Yes) was explored.  
Again, however, mutation of these residues to uncharged amino acids (His229 to Tyr, as in 
c-Src and Glu531 to Gln) did not result in increased kinase activation, as evidenced by 
autophosphorylation (Figure 5A, top panel) and phosphorylation of the regulatory 
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tyrosine Tyr527 (Figure 5B, top panel).  It thus appears that additional residues are 
involved in directing specificity between the c-Src and c-Yes SH2 domains; however, 
with no clues as to which amino acids might be responsible for SH2 domain specificity 
between the two kinases, a systematic series of SH2 domain mutations was deemed 
beyond the scope of these studies.  Nevertheless, the results obtained in these studies 
indicate that the c-Src and c-Yes SH2 domains may contribute to signaling specificity 
between these proteins and may play a larger role in directing signaling specificity 
between Src family kinases than previously believed. 
What are the functional implications of ligand specificity between the c-Src and c-
Yes SH3 and SH2 domains?  The results presented here do not suggest a strong influence 
on substrate selection.  The tyrosine phosphorylation of AFAP-110 and other tyrosine-
phosphorylated SH3 domain binding partners induced by Y3527F was surprising given the 
inefficient co-immunoprecipitation and in vitro binding between these proteins.  As 
mentioned above, SH3 domain interactions are necessary for Src-induced tyrosine 
phosphorylation of AFAP-110 and other SH3 domain binding partners (Kanner et al., 
1991; Weng et al., 1994; Guappone and Flynn, 1997).  Mutations in either the SH3 
domain binding site of AFAP-110 or the Src SH3 domain impair the ability of Src527F to 
induce tyrosine phosphorylation of AFAP-110 (Kanner et al., 1991; Guappone and 
Flynn, 1997).  Due to the failure of the c-Yes SH3 domain to bind AFAP-110 efficiently 
in vitro or in vivo, a corresponding deficiency in the ability of Y3527F to induce AFAP-
110 tyrosine phosphorylation was expected.  This was not the case, however, as Y3527F 
and Src527F induced comparable levels of AFAP-110 tyrosine phosphorylation.  How are 
these seemingly contradictory results explained?  One possible explanation is that the c-
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Yes SH3 domain, as opposed to a c-Src SH3 domain in which residues critical for ligand 
binding have been mutated, is capable of low-level association with AFAP-110.  As seen 
in Chapter 2, there is modest association of the c-Yes SH3 domain with AFAP-110 in 
vitro, and this correlates with inefficient yet still detectable co-immunoprecipitation 
between Y3527F and AFAP-110 in RIPA lysates.  This relatively weak association 
between the c-Yes SH3 domain and AFAP-110 may allow a transient association 
between AFAP-110 and Y3527F that is sufficient to permit tyrosine phosphorylation of 
AFAP-110 but not detectable co-immunoprecipitation between the two proteins.  
 The benefit of the more stable association between the c-Src or Src527F SH3 
domain and AFAP-110 remains unclear, as it does not result in a significant enhancement 
in tyrosine phosphorylation.  Higher affinity association between the c-Src SH3 domain 
and AFAP-110 may allow formation of longer lived signaling complexes with distinct 
functions, including sub-cellular targeting, recruitment of signaling molecules, or 
alterations in the multimeric status of AFAP-110 itself.  AFAP-110 has an intrinsic 
ability to bind actin filaments (Qian et al., 2000), and phosphorylation of AFAP-110 by 
PKC activates the ability of AFAP-110 to induce actin filament bundling in vitro (Qian et 
al., submitted).  Thus, AFAP-110 may play a key role in remodeling the actin filament 
cytoskeleton in response to cellular signals, as occurs during embryonic development, 
cell division, and metastasis of cancer cells.  Src527F/c-Yes chimeras with the c-Yes SH3 
domain are capable of inducing actin filament remodeling in CEF comparable to Src527F, 
thus it does not appear that stable association between Src527F and AFAP-110 is a 
requirement for induction of actin filament rearrangement.  AFAP-110 association with 
active Src is also not sufficient to target Src to focal adhesion structures, as Fincham et al. 
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demonstrated that mutants of Src that failed to localize to focal adhesions were still able 
to associate with AFAP-110 (Fincham et al., 2000).   
Regardless of the biological importance of stable association between activated c-
Src and AFAP-110, the inefficient association of c-Yes with AFAP-110 would 
presumably preclude the involvement of c-Yes in these signaling pathways. Conversely, 
stable association between pp87 and Src527F/c-Yes chimeras with the c-Yes SH2 domain, 
and theoretically activated c-Yes itself, may allow these proteins to participate in 
signaling pathways that do not involve c-Src.  This may occur, as described above for 
Src/AFAP-110 interactions, through sub-cellular localization or formation of c-Yes-
specific signaling complexes.  Unfortunately, in comparison to c-Src, little is known 
about the biological functions of c-Yes, and there are few intermolecular interactions 
between c-Yes and its cellular binding partners that have demonstrated definitive 
functional implications.  Association of c-Yes with YAP65 may facilitate localization of 
c-Yes to the apical surface in airway epithelial cells (Mohler et al., 1999), and it was 
recently demonstrated that recruitment of c-Yes to a signaling complex including beta-
arrestin 1 and the endothelin type-A receptor might allow c-Yes to participate in 
endothelin-stimulated glucose transport (Imamura et al., 2001).  The only phenotype 
reported thus far as a result of loss of the c-yes gene is a deficiency in transcytosis 
mediated by the polyimmunoglobulin (pIg) receptor (Luton et al., 1999).  Expression of 
the Src527F/c-Yes chimeras in c-yes -/- cells may prove useful in uncovering why c-Src is 
unable to compensate for c-Yes in pIg receptor function and what role pp87 may play in 
this pathway.   
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The affinity of the c-Src and c-Yes SH3 and SH2 domains for their cognate 
ligands also has implications for the activation of these kinases in response to cellular 
signals.  The HIV-1 Nef protein is able to bind and activate Hck through SH3 domain 
interactions (Moarefi et al., 1997).  Greenway and colleagues found that SH3 domain 
specificity between Src family kinases allows HIV-2 and SIV Nef to target the SH3 
domains of Src and Fyn, as opposed to Hck (Greenway et al., 1999).  Baisden et al. 
demonstrated that a mutant of AFAP-110 in which the leucine zipper motif is deleted is 
able to activate c-Src in an SH3 domain-dependent fashion, most likely through 
displacement of the intramolecular interaction between the SH3 domain and the kinase 
linker (Baisden et al., submitted).  The low affinity interaction between AFAP-110 and 
the c-Yes SH3 domain may be insufficient to permit AFAP-110-induced activation of c-
Yes in response to cellular signals.  The functions of AFAP-110, both downstream and 
upstream of Src, remain the subject of ongoing investigations by others.  It remains 
possible that pp87 binding contributes to the activation of c-Yes in a similar fashion, 
however, this will be difficult to determine experimentally until pp87 is cloned and 
identified.   
In summary, the proteins studied in these experiments, including the known c-Src 
substrates p130 CAS and AFAP-110, as well as several unidentified tyrosine 
phosphorylated SH3 and SH2 domain binding partners, did not provide evidence for SH3 
or SH2 domain-mediated substrate specificity between activated c-Src and c-Yes.  While 
these results should not be over-interpreted to imply that SH3 and SH2 domain-mediated 
substrate selection between c-Src and c-Yes do not exist, the results imply that they may 
not be the primary means of generating signaling specificity.  The SH3- and SH2-
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mediated specificity in protein binding observed in these experiments may contribute 
more to overall signaling specificity through differential signaling complex formation 
than through substrate selection.   
In contrast to the differences in protein/protein interactions, differences in 
transcriptional activation and cell biology were primarily found to be due to differences 
in the Src527F and c-Yes amino terminal regions, including the SH4 and Unique domains.  
Chimeric proteins with the c-Yes amino terminus, Y4U32527Fand Y4U527F, were deficient 
in upregulation of the heme oxygenase 1 (HO-1) gene product (Chapter 3, Figure 3B and 
Figure 6) and induction of the morphological and cytoskeletal changes that occur 
concomitant with overexpression of constitutively activated c-Src (Chapter 4, Figure 2B, 
2C, 3B, 3C) despite the fact that they were fully active, as evidenced by anti-
phosphotyrosine and anti-phospho-Y416 western blot analysis (Chapter 4, Figure 2A).  
The decreased HO-1 induction and failure of these chimeras to induce rearrangement of 
the actin cytoskeleton was attributed to the presence of the c-Yes amino terminus, as 
Y32527F was fully functional in regard to both of these processes.  Both the SH4 and 
Unique domains were necessary in order to obtain these results, as chimeric proteins in 
which only the SH4 or Unique domain of Src527F was replaced by that of c-Yes induced 
actin filament rearrangement and efficient upregulation of HO-1 expression in CEF.   
In recent years, it has become clear that the amino terminal regions of Src family 
kinases do not simply localize these proteins to cellular membranes; they also regulate 
the compartmentalization of these kinases within cellular membranes.  Specifically, it has 
been demonstrated that palmitoylation of Src family members dictates their inclusion into 
triton X-100 resistant membrane fractions, referred to as lipid rafts (Robbins et al., 1995).  
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These are formed by aggregates of bulky lipids, including sphingolipids and cholesterol, 
and glycosylphosphatidyl inositol (GPI)-linked proteins (Brown and London, 1997).  
Several acylated signaling proteins, including many Src family kinases, are recruited to 
lipid raft fractions by virtue of their long chain fatty acid modifications.  Fatty acylation 
is not necessarily a requirement for inclusion into lipid raft fractions, however, as several 
transmembrane receptors localize to lipid rafts, including the PDGF and Fcε receptors 
(Brown and London, 1997; Honda et al., 2000).   
As mentioned in Chapter 4, recruitment to lipid rafts is important for the 
participation of Src family kinases in several signaling pathways.  The detection of c-Yes 
in caveolae, a sub-class of lipid rafts that are defined by the presence of caveolin, was 
among the first reports of Src family kinases in lipid rafts (Sugawara et al., 1991).  The 
importance of c-Yes localization to caveolae, however, was not determined.  Shenoy-
Scaria et al. were among the first to observe that association between Src family kinases 
and a cellular binding partner was dependent on palmitoylation and localization to lipid 
rafts (Arreaza et al., 1994; Shenoy-Scaria et al., 1994).  At a functional level, co-
localization of the Fcε receptor and Src family kinases in lipid raft fractions is essential 
for Fcε receptor signaling (Honda et al., 2000; Suzuki et al., 2000).  In this system, it was 
demonstrated that raft localization serves as a means of achieving signaling specificity, as 
c-Src was unable to reconstitute Fcε receptor signaling unless a palmitoylation signal was 
included in the amino terminus (Honda et al., 2000; Suzuki et al., 2000).  Palmitoylation-
dependent signaling is also observed for Lck, which is unable to transmit signals from the 
T-cell receptor in the absence of palmitoylation (Yurchak and Sefton, 1995).   
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The results obtained in the present studies were particularly novel, in that the 
entire amino terminal region, including both the SH4 palmitoylation signal and the 
Unique domain, was required in order to achieve the differential effects on transcription 
and the actin cytoskeleton.  This is of note in that previous studies have traditionally 
reported the functions of the SH4 and Unique domains individually, with little 
consideration given to the possibility that these domains may act in concert.  The 
heterogeneity of the Unique domain across the Src family renders it virtually impossible 
to assign a generalized function.  Lck associates with the CD4 and CD8 T cell co-
receptors by virtue of its Unique domain (Shaw et al., 1989; Campbell et al., 1995), 
whereas the Unique domain of Lyn is responsible for mediating its association with the 
Fcε receptor (Vonakis et al., 1997).  The Unique domains of Fyn, c-Src, and c-Yes harbor 
phosphorylation sites that demonstrate some correlation with activation, however, the full 
importance of these phosphorylations remains unknown (Gould and Hunter, 1988; 
Morgan et al., 1989; Shenoy et al., 1989; Ariki et al., 1997; Hansen et al., 1997).  
Bijlmakers and colleagues reported that the Unique domain of Lck is sufficient for 
membrane localization, however, the construct used in those studies included the Lck 
SH4 domain (Bijlmakers et al., 1997).   
Unlike the Unique domain, the function of the SH4 domain has been well 
established.  Myristoylation, in conjunction with either palmitoylation or positive-
charged amino acids, localize Src family kinases to cellular membranes (Resh, 1994).  
Palmitoylation then localizes Src family kinases to lipid raft fractions, allowing them to 
participate in signaling pathways originating in these membrane microenvironments.  The 
requirement of the c-Yes SH4 domain for the inability of Src527F/c-Yes chimeras to 
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induce actin filament rearrangement and elevated HO-1 expression suggests that 
localization to lipid rafts is important in these results.  However, the additional 
requirement for the c-Yes Unique domain complicates the issue.  These results indicate 
that either the Unique domain participates in localization or that it, in conjunction with 
the SH4 domain, facilitates interaction with a protein or proteins that inhibit the ability of 
Y4U32527F and Y4U527F to influence signaling pathways that induce HO-1 expression and 
actin filament rearrangement.  Alternatively, the c-Yes Unique domain, again in 
conjunction with the SH4 domain, may prevent interaction with a Src substrate or binding 
partner that is necessary for initiation of these signaling events.  Regardless, it is clear 
that both the c-Yes SH4 and Unique domains are required for the inability of proteins 
with the c-Yes amino terminus to efficiently induce elevated HO-1 expression and actin 
filament rearrangement.  Thus, evidence is presented for a synergistic effect of the SH4 
and Unique domains in c-Yes signaling. 
What do these results reveal about the biological functions of c-Yes and the 
signaling pathways it utilizes?  Unfortunately, they suggest more about what activated c-
Yes cannot do than what it can.  However, they may also provide insight as to why c-Yes 
is frequently unable to compensate for the absence of c-Src in c-src -/- cells.  The c-Yes 
amino terminal region is necessary and sufficient to inhibit the ability of Src527F/c-Yes 
chimeras to participate in pathways that effect elevated induction of HO-1 and 
rearrangement of actin stress fibers into rosettes, lamellipodia, and filopodia.  These 
results correlate well with data in the literature that indicate that c-Yes is unable to 
participate in related signaling pathways. Heme oxygenase 1 is an enzyme that cleaves 
the heme molecule into iron, carbon monoxide, and biliverdin (Maines, 1997; 
 158 
Montellano, 2000).  HO-1 is expressed in a wide range of tissues in response to diverse 
cellular stimuli, including hypoxia (Maines, 1997), heavy metals (Masuya et al., 1998), 
Ras (Seko et al., 1996), MAP kinases (Koong et al., 1994; Seko et al., 1997), NFκB 
(Koong et al., 1994), Hypoxia-Inducible Transcription Factor 1 (HIF-1) (Lee et al., 
1997), and, was shown in Chapter 3, Src activation.  The ability of activated Src to induce 
HO-1 expression was not surprising in lieu of the fact that tyrosine kinase inhibitors 
block HO-1 induction in response to heavy metals (Masuya et al., 1998) and given the 
ability of v-Src to induce HIF-1 expression (Jiang et al., 1997).  In fact, the reduced 
induction of HO-1 by Y4U32527F and Y4U527F may be due to a failure to induce 
expression of HIF-1.   
It was demonstrated in Chapter 4 that chimeric proteins with the c-Yes amino 
terminus failed to induce activation of the PI3K/Akt pathway (Chapter 4, Figure 8A and 
8B).  Several recent studies have indicated that activation of PI3K and/or Akt are 
necessary for induction of HIF-1 (Sandau et al., 2000; Zhong et al., 2000; Jiang et al., 
2001).  Failure to activate PI3K may prevent Y4U32527F and Y4U527F from efficiently 
activating an oxidative stress response pathway that involves HIF-1 expression and 
subsequent expression of HO-1.  These results suggest that c-Yes, by virtue of its amino 
terminal region, may not participate in this oxidative stress response pathway.  In 
agreement with this hypothesis, it was previously observed that c-Src, but not c-Yes, is 
activated in response to hypoxia, and results in expression of vascular endothelial growth 
factor, which is also induced in response to HIF-1 (Mukhopadhyay et al., 1995).       
The inability of Y4U32527F and Y4U527F to induce actin cytoskeletal 
rearrangement and morphological changes is also in agreement with results reported 
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previously.  As mentioned in Chapters 1 and 4, cells lacking the c-src gene are deficient 
in several processes that are dependent on the dynamic regulation of the actin 
cytoskeleton.  These include cell migration (Hall et al., 1996), cell spreading (Kaplan et 
al., 1995), neurite extension (Ignelzi, Jr. et al., 1994), membrane ruffle and ring 
formation (Boyce et al., 1992), and osteoclast-mediated bone resorption (Soriano et al., 
1991).  The results reported in Chapter 4 suggest that the c-Yes amino terminus may 
prevent Y4U32527F and Y4U527F, and by extension activated c-Yes, from inducing 
remodeling of the actin cytoskeleton.  Cells transfected with Y4U32527F or Y4U527F 
retained a normal CEF morphology, characterized by intact focal adhesions and long 
actin stress fibers.  In contrast, cells expressing Src527F and the other activated Src527F/c-
Yes chimeras displayed a fully transformed morphology and a repositioning of actin from 
stress fibers into rosettes and actin-based membranous motility structures, such as 
lamellipodia and filopodia.   
Investigation of signaling pathways downstream of activated Src revealed that 
Src527F/c-Yes amino terminal chimeras were able to induce activation of the MAPK 
pathway, as evidenced by Shc/Grb2 complex formation and activation of Raf-1 and Erk.  
These results are in agreement with published data that indicate that the mitogenic effects 
of Src activation may be separable from the effects on the actin cytoskeleton (Fincham et 
al., 1999).  In contrast to their effects on the MAPK pathway, Src527F/c-Yes amino 
terminal chimeras were unable to induce activation of the PI3K/Akt pathway, as 
determined by activation-specific Akt phosphorylation and PI3K assay.  Interestingly, 
Y4U32527F was able to induce a transformed morphology and cytoskeletal 
rearrangements in a chemically immortalized CEF cell line (Figure 6A).  In these cells, 
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activation-specific Akt phosphorylation levels were comparable to those detected in cells 
expressing Src527F (Figure 6B).  These data indicate a strong correlation between the 
ability of Src527F/c-Yes chimeras to induce activation of the PI3K/Akt pathway and their 
ability to cause disruption of actin filament structures.   
PI3K is an important mediator of actin cytoskeletal rearrangement in Src-
transformed cells and in response to a variety of other stimuli, however, it is not clear 
how PI3K mediates its effects on the cytoskeleton (Penuel and Martin, 1999; Krasilnikov, 
2000; Odajima et al., 2000; Sohara et al., 2001).  Akt may play a role in actin 
rearrangement mediated through PI3K, as may members of the Rho family of small 
GTPases, including RhoA, Rac-1 and Cdc42 (Krasilnikov, 2000).  Although there is still 
controversy as to where Rho family members fall in the pathway leading to actin filament 
rearrangement in response to activated c-Src or PI3K, they appear to play a key role in 
these processes (Reif et al., 1996; Ren and Schwartz, 1998; Mackay and Hall, 1998; 
Aspenstrom, 1999; Cantrell, 2001).  RhoA induces actin filament stress fibers; Rac-1 
activation results in lamellipodia formation; and Cdc42 causes the formation of filopodia 
(Mackay and Hall, 1998).  The loss of actin stress fibers in Src-transformed cells is 
accompanied by activation of p190 Rho-GAP, a GTPase activating protein and negative 
regulator of the RhoA G protein (Fincham et al., 1999).  In preliminary results from CEF 
expressing Y4U32527F and Y4U527F, RhoA activity was not decreased, but in fact 
increased by a factor of approximately 1.5 (Figure 7).  Thus, the inability of Y4U32527F 
and Y4U527F to induce disruption and rearrangement of actin stress fibers may be due to a 
failure to activate PI3K and to inactivate RhoA.  Whether RhoA acts downstream or 
upstream of PI3K in these cells is at this point unknown.  Regardless, our results suggest 
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the possibility that the amino terminal region prevents c-Yes from participating in 
dynamic regulation of the actin cytoskeleton by preventing activation of PI3K and 
inactivation of RhoA.  This explanation is in agreement with the ability of v-Yes to 
induce cell transformation and activation of PI3K (Fukui et al., 1991), as the v-Yes 
amino terminus is fused with the viral Gag sequence and is not palmitoylated (Beemon 
and Mattingly, 1986).  Expression of these chimeric constructs in c-src -/- cells may aid 
in the determination of the validity of this model outside of the chicken embryo fibroblast 
system.  As mentioned above, the only observed defect in c-yes -/- cells is a deficiency in 
transcytosis of IgA mediated by the pIg receptor (Luton et al., 1999).  Expression of these 
chimeras in c-yes -/- cells may aid in the determination of why c-Src is unable to 
compensate for c-Yes in this pathway and whether this may also be attributed to amino 
terminal differences between the two proteins.       
The results obtained in these experiments raise questions about the relative 
contributions of c-Src and c-Yes to the onset and progression of human cancers.  The 
transition of a cell from the normal to the cancerous state is a multi-step process, and 
while the biochemical pathways utilized to achieve full transformation may vary, there 
are certain phenotypic changes that are almost universally present.  The experiments 
outlined in these studies directly and indirectly touch on four of these: cell proliferation, 
resistance to apoptosis, rearrangement of the cytoskeletal architecture, and the ability to 
survive in the face of oxidative stress.  Cancerous cells are characterized by unchecked 
cell division (Molinari, 2000), and remodeling of the actin cytoskeleton allows them to 
invade surrounding tissue and metastasize (Pawlak and Helfman, 2001). Resistance to 
apoptosis allows the continued survival of the tumor in the face of DNA damage and 
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removal from its normal cellular milieu (Howell, 2000).  Resistance to oxidative damage 
allows cancerous cells to survive oxidative threats from the body’s defense system and 
hypoxic conditions encountered in the interior of a tumor in the absence of 
vascularization (Pugh et al., 2001).  The studies presented in this thesis, along with those 
in the literature, either directly demonstrate or suggest that c-Src activation is able to 
induce all of these effects.   
In Chapter 4, it was demonstrated that Src527F expression results in activation of 
the MAPK pathway, which in turn induces cell cycle progression (Roussel, 1998).  It was 
also shown that Src527F induces efficient rearrangement of the actin cytoskeleton, 
repositioning actin from stress fibers to actin based motility structures. c-Src activation 
also induces activation of the Akt/PI3K pathway, which in addition to its effects on the 
cytoskeleton, is an important mediator of cell survival and resistance to apoptosis 
(Krasilnikov, 2000).  Finally, it was demonstrated that Src527F induces high levels of HO-
1 expression, a protein that is involved in the resistance to hypoxic stress (Maines, 1997).  
 In the present studies, proteins with the c-Yes amino terminus were only able to 
induce one of the effects mentioned above, at levels that approached those achieved by 
Src527F: activation of the MAPK pathway.  Unfortunately, due to the lack of a 
constitutively activated c-Yes, there is currently no data available in the literature on the 
phenotype of cells expressing this protein and how they differ from cells expressing 
active c-Src.  Y4U32527F should functionally approximate constitutively active c-Yes 
(Yes535F), as the only differences between the two proteins occur in their highly 
homologous tyrosine kinase domains.  c-Yes is frequently activated in a subset of human 
cancers, most notably colon carcinoma and melanoma (Loganzo, Jr. et al., 1993; Park et 
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al., 1993; Pena et al., 1995; Marchetti et al., 1998).  In these cancers, the level of c-Yes 
activation correlates with the metastatic potential of the cells.  How then does activated c-
Yes contribute to the cancerous phenotype?  Activation of the MAPK pathway may allow 
c-Yes to induce mitogenesis and thereby contribute to cell transformation.  Tsygankova 
et al. demonstrated the importance of c-Yes in activation of the MAPK pathway in 
response to angiotensin II treatment of liver epithelial cells (Tsygankova et al., 1998).  
Recent evidence also suggests that c-Yes may be important in regulation of cell 
adhesions (Owens et al., 2000) and VEGF-induced vascular permeability (Eliceiri et al., 
1999).  c-Yes is most frequently activated in cancers of epithelial origin, thus c-Yes 
activation may contribute to metastasis through disruption of tight junctions and/or 
through an increase in vascular permeability that would enhance angiogenesis.   
While the data presented in this thesis suggest that the c-Yes amino terminus 
prevents its participation in pathways that regulate actin filament rearrangement, it should 
be noted that palmitoylation of Src family kinases is a reversible process (Yurchak and 
Sefton, 1995; Bano et al., 1998).  As the SH4 domain is essential for the loss of function 
associated with the c-Yes amino terminus, regulated de-palmitoylation of c-Yes in 
cancerous cells may allow the protein to move out of lipid raft fractions and participate in 
signaling pathways that were previously inaccessible.  As mentioned above, v-Yes is not 
palmitoylated and is capable of inducing PI3K activation, CEF transformation, and tumor 
formation in chickens (Beemon and Mattingly, 1986; Toyoshima et al., 1987; Fukui et 
al., 1991).  The palmitoylation status of activated c-Yes in cancerous cells has not been 
reported.  Nevertheless, the results presented here indicate that the c-Yes amino terminus, 
including the SH4 palmitoylation signal and the Unique domain, are crucial for the 
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inability of activated Src/Yes chimeras to induce actin filament rearrangement, activation 
of the PI3K/Akt pathway, and induction of HO-1 expression.  The amino terminal region 
may thus limit the ability of c-Yes itself to contribute to the onset and progression of the 
metastatic phenotype. 
The experiments outlined in this thesis have examined the contributions of the 
non-catalytic functional domains to signaling specificity between the c-Src and c-Yes 
tyrosine kinases.  The results indicate that each non-catalytic functional domain 
contributes to some aspect of signaling specificity.  These results allow the proposal of a 
working model for specificity in signaling between c-Src and c-Yes (Figure 8).  In this 
model, after synthesis, the two proteins are rapidly localized to cellular membranes.  
Upon membrane localization, c-Src and c-Yes differentially partition into detergent 
soluble and insoluble regions, respectively, as dictated by differences in their amino 
termini.  This may be the most important contribution to signaling specificity between c-
Src and c-Yes, as it determines the subset of proteins available for intermolecular 
interactions.  Protein/protein interactions mediated by the Unique domain may contribute 
to membrane compartmentalization or stable complex formation with intermolecular 
binding partners that allow initiation of downstream signaling events.  Protein/protein 
interactions or phosphorylation events mediated by the Unique domains may also 
contribute to differential activation of c-Src and c-Yes, through destabilization of the 
closed conformation.  Signaling specificity is further fine-tuned through intermolecular 
interactions mediated by the SH3 and SH2 domains.  These regions serve to select 
substrates, and perhaps more importantly, direct stable associations with protein binding 
partners that may influence sub-cellular localization, activation state, and formation of 
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multi-protein signaling complexes through which specific signals are sent.  This model 
for signaling specificity does not exclude the ability of c-Src and c-Yes to function 
redundantly.  Src family kinases are rapidly (5 min) localized to cellular membranes after 
synthesis, however, it was observed for Fyn that localization to detergent resistant lipid 
rafts occurs after a 10-20 min lag time (van't Hof and Resh, 1997).  c-Yes and c-Src may 
thus interact with overlapping subsets of proteins before c-Yes partitions into lipid rafts. 
Additionally, regulated de-palmitoylation of c-Yes, and partitioning of other proteins 
between raft and non-raft fractions, may bring c-Src and c-Yes into contact with 
overlapping sets of proteins.    
This model for signaling specificity between c-Src and c-Yes may be more 
broadly applicable to signaling specificity between Src family kinases in general.  
Understanding how these kinases are capable of sending specific signals will be 
important in the overall understanding of the function of these proteins, and in their 
possible usage as targets for rational drug design.  Src family kinase inhibitors have 
shown promise as anti-cancer drugs due to their ability to block cell proliferation, 
however, most of these compounds do not distinguish between Src family members 
(Lawrence and Niu, 1998; Moasser et al., 1999; Al Obeidi and Lam, 2000).  Studies in 
mice lacking one or more Src family members have revealed that loss of individual Src 
family kinases is more readily tolerated than loss of multiple Src family members (Stein 
et al., 1994).  Thus, non-specific inhibition of Src family kinases may have deleterious 
effects as a result of disruption of multiple signaling pathways.  A more ideal treatment 
strategy would involve inhibition of only the kinase or kinases that were abnormally 
activated in a particular tumor.  A comprehensive knowledge of the roles of the 
 166 
functional domains in generating signaling specificity may allow the design of drugs 
specific for individual Src family kinases that would avoid the potentially deleterious 
effects of global Src family kinase inhibition.    
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Figure 1.  Src family kinase activation.  (A) In the inactive state, Src family kinases exist 
in the closed or assembled conformation.  This structure is stabilized primarily by two 
intramolecular interactions: association of the SH2 domain with the phosphorylated tail 
tyrosine (Y527 in c-Src) and binding of the SH3 domain to the SH2/kinase linker, which 
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forms a left-handed type II helix in the closed conformation.  (B) SH3 and SH2 domain 
binding partners may displace the SH3/linker and/or SH2/carboxy terminal tyrosine 
interactions, thus shifting the conformation of the protein from closed to open.  The 
transition to the open conformation allows access of ATP and substrates to the kinase 
active site.  (C) Activation of the kinase is accompanied and enhanced by 
autophosphorylation at a key tyrosine residue (Y416 in c-Src) in the activation loop.  
(Cartoon provided by Amanda Gatesman). 
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Figure 2.  The c-Yes SH3 and SH2 domains do not affect tyrosine phosphorylation of c-
Src SH3 and SH2 domain binding partners.  (A) Mock-transfected CEF or cells 
expressing Src527F, Y3527F, Y2527F, Y32527F, or Y4U32527F were lysed in RIPA buffer, and 
five hundred µg of cell lysates were absorbed with GST, GST-SH3Src, or GST-SH3Yes 
bound to glutathione-sepharose beads.  Bound proteins were eluted by boiling in 
Laemmli’s sample buffer (LSB), and resolved by 8% SDS-PAGE.  After transfer to 
PVDF membrane, proteins were blocked in 1% BSA/TBS-T and probed with a rabbit 
anti-phosphotyrosine antibody.  Results are shown for mock-transfected CEF and cells 
expressing Src527F and Y3527F.  Lanes 1, 4, 8 = GST; Lanes 2, 5, 9 = GST-SH3Src; Lanes 
3, 6, 10 = GST-SH3Yes; Lane 7 = Molecular weight marker.  (B) Experiments were 
performed as in (A), however, lysates were absorbed with GST, GST-SH2Src, or GST-
SH2Yes.  Results are shown for mock-transfected CEF and cells expressing Src527F and 
Y2527F.  Lanes 1, 4, 7 = GST; Lanes 2, 5, 8 = GST-SH2Src; Lanes 3, 6, 9 = GST-SH2Yes. 
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Figure 3.  Association of Src527F and Y2527F mutants with pp87.  Y2S185C, Y2H229Y, and 
Y2E531Q mutants were generated via mutation of Ser185 to Cys (TCC → TGC), His229 to 
Tyrosine (CAC → TAC), or Glu531 to Gln (GAG → CAG) in Y2.  Mutagenesis was 
verified via DNA sequencing.  Constitutive activation of the Y2S185C and Y2H229Y mutants 
was achieved via replacement of the c-Src tyrosine kinase domain coding-sequence with 
that of Src527F as described in Chapter 2.  Mock-transfected CEF or cells expressing 
Src527F, Y2527F, Y2527FS185C, or Y2527FH229Y were lysed in RIPA, and 500 µg of lysates 
were immunoprecipitated with the rabbit anti-Src antibody.  Co-immunoprecipitated 
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proteins were eluted via boiling in LSB and resolved by 8% SDS-PAGE.  Proteins were 
transferred to PVDF, blocked in 1% BSA/TBS-T and probed with a rabbit anti-
phosphotyrosine antibody.  Blots were stripped and re-probed with rabbit anti-Src to 
assess the relative levels of immunoprecipitated protein.  Lane 1 = CEF; Lane 2 = Src527F; 
Lane 3 = Y2527F; Lane 4 = Y2527FS185C; Lane 5 = Y2527FH229Y.  Western blots are 
representative of three independent experiments. 
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Figure 4.  Induction of cellular phosphotyrosine and autophosphorylation of c-Src/c-Yes 
chimeras.  Mock-transfected CEF or cells expressing c-Src, c-Yes, Y3, Y2, Y32, or 
Y4U32 were lysed in RIPA buffer, and 30 µg of lysates were resolved by 8% SDS-
PAGE, transferred to PVDF, blocked in 1% BSA/TBS-T, and probed with a rabbit anti-
phosphotyrosine antibody.  Lane 1 = CEF; Lane 2 = c-Src; Lane 3 = c-Yes; Lane 4 = Y3; 
Lane 5 = Y2; Lane 6 = Y32; Lane 7 = Y4U32.  In the bottom panel, CEF, c-Src, Y3, Y2, 
Y32, or Y4U32 lysates were prepared for western blot analysis as described above and 
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probed with a rabbit anti-phospho-Y416 antibody.  Lane 1 = CEF; Lane 2 = c-Src; Lane 3 
= Y3; Lane 4 = Y2; Lane 5 = Y32; Lane 6 = Y4U32.  Western blots are representative of 
three independent experiments. 
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Figure 5.  Activation state of c-Src, Y2, and Y2 mutants in CEF.  Mock-transfected CEF 
or cells expressing c-Src, Y2, Y2S185C, Y2H229Y, or Y2E531Q were lysed in RIPA buffer, 
and 50 µg of lysates were resolved by 8% SDS-PAGE, transferred to PVDF, blocked in 
5% milk/TBS-T, and probed with either a rabbit anti-phospho-Y416 antibody (A, top 
panel) or a rabbit anti-phospho-Y529 antibody (B, top panel).  In the bottom panels, blots 
were stripped and re-probed with rabbit anti-Src.  (A)  Lane 1 = CEF; Lane 2 = c-Src; 
Lane 3 = Y2; Lane 4 = Y2S185C; Lane 5 = Y2H229Y; Lane 6 = Y2E531Q.  (B)  Lane 1 = CEF; 
Lane 2 = Y2; Lane 3 = Y2S185C; Lane 4 = Y2H229Y; Lane 5 = Y2E531Q. 
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Figure 6.  Y4U32527F induces actin filament rearrangement and Akt activation in DF-1 
cells.  (A) Mock-transfected DF-1 or cells expressing Src527F or Y4U32527F were fixed at 
50% confluence on cover slips for 15 min in 3.7% formaldehyde, followed by three 
washes in PBS.  Cells were permeablized via incubation for 4 min with 0.4% triton X-
100.  After three PBS washes, cells were stained with FITC-phalloidin (5 µg/ml), 
mounted on slides, and visualized via Zeiss LSM 510 confocal microscopy (63x 
objective).  These results are representative of two independent experiments.  (B) Mock-
transfected DF-1 or cells expressing Src527F, Y4U32527F, or Y4U527F were lysed in RIPA, 
and 50 µg of lysates were resolved by 8% SDS-PAGE, transferred to PVDF, blocked 
with 5% milk/TBS-T, and probed with an anti-phospho-Akt antibody (Upstate 
Biotechnology).  Lane 1 = Mock-transfected DF-1; Lane 2 = Src527F; Lane 3 = 
Y4U32527F; Lane 4 = Y4U527F.   
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Figure 7.  Src527F/c-Yes chimeras with the c-Yes amino terminus fail to inactivate Rho.  
The Rho activation assay kit was obtained from Upstate Biotechnology and performed as 
described in the protocol.  Briefly, mock-transfected CEF, or cells expressing Src527F, 
Y32527F, Y4U32527F, or Y4U527F were lysed in Rho lysis buffer, and quantitated for total 
protein content.   Fifty µl of Rhotekin Rho binding domain-conjugated agarose beads 
were added for each 500 µl of cell lysates, followed by gentle rocking for 45 min at 4°C.  
Beads were collected by centrifugation, and bound proteins were eluted by boiling in 
sample buffer.  Bound proteins were separated by 12 % SDS-PAGE, transferred to 
PVDF, blocked in 3% milk/PBS, and probed with an anti-Rho antibody (Upstate 
Biotechnology).  Lane 1 = Anti-Rho immunoprecipitation from CEF lysates; Lane 2 = 
CEF; Lane 3 = Src527F; Lane 4 = Y32527F; Lane 5 = Y4U32527F; Lane 6 = Y4U527F. 
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Figure 8.  Model for Signaling Specificity between c-Src and c-Yes.  In this model, after 
synthesis, c-Src and c-Yes are rapidly localized to cellular membranes.  At the 
membrane, subtle differences in signaling between the two proteins may be mediated by 
differential protein/protein interactions through the SH3, SH2, and Unique domains.  
These protein/protein interactions may serve to affect subcellular localization, direct 
stable signaling complex formation, or select substrates for phosphorylation.  The SH3, 
SH2, and SH1 domains may also serve to transmit overlapping signals between the 
kinases.  After membrane localization, c-Yes partitions into lipid raft fractions.  The 
reversible nature of palmitoylation may allow c-Yes to traffic in and out of lipid rafts. 
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Sequestration into lipid rafts may contribute significantly to c-Yes specific signaling by 
dictating the sub-set of proteins available for intermolecular interactions.  The Unique 
domain may also contribute to localization.  Once inside lipid rafts, c-Yes-specific signals 
may be dictated by protein/protein interactions mediated through the Unique, SH3, and 
SH2 domains.  (Membrane cartoon provided by Amanda Gatesman). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Y-527 
SH2 
N-Kinase 
Fragment 
P 
X 
X P Y-416 SH2 Y-527 
P 
X 
X P 
 182 
References 
 
Al Obeidi,F.A., Lam,K.S. (2000). Development of inhibitors for protein tyrosine kinases. 
Oncogene 19, 5690-5701. 
Alonso,G., Koegl,M., Mazurenko,N., Courtneidge,S.A. (1995). Sequence requirements 
for binding of Src family tyrosine kinases to activated growth factor receptors. 
J.Biol.Chem. 270, 9840-9848. 
Ariki,M., Tanabe,O., Usui,H., Hayashi,H., Inoue,R., Nishito,Y., Kagamiyama,H., 
Takeda,M. (1997). Identification of autophosphorylation sites in c-Yes purified from rat 
liver plasma membranes. J.Biochem.(Tokyo) 121, 104-111. 
Arreaza,G., Melkonian,K.A., LaFevre-Bernt,M., Brown,D.A. (1994). Triton X-100-
resistant membrane complexes from cultured kidney epithelial cells contain the Src 
family protein tyrosine kinase p62yes. J.Biol.Chem. 269, 19123-19127. 
Aspenstrom,P. (1999). Effectors for the Rho GTPases. Curr.Opin.Cell Biol. 11, 95-102. 
Bano,M.C., Jackson,C.S., Magee,A.I. (1998). Pseudo-enzymatic S-acylation of a 
myristoylated yes protein tyrosine kinase peptide in vitro may reflect non-enzymatic S-
acylation in vivo. Biochem.J. 330 ( Pt 2), 723-731. 
Beemon,K., Mattingly,B. (1986). Avian sarcoma virus gag-fps and gag-yes transforming 
proteins are not myristylated or palmitylated. Virology 155, 716-720. 
Bijlmakers,M.J., Isobe-Nakamura,M., Ruddock,L.J., Marsh,M. (1997). Intrinsic signals 
in the unique domain target p56(lck) to the plasma membrane independently of CD4. 
J.Cell Biol. 137, 1029-1040. 
Boyce,B.F., Yoneda,T., Lowe,C., Soriano,P., Mundy,G.R. (1992). Requirement of 
pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. 
J.Clin.Invest 90, 1622-1627. 
Bradshaw,J.M., Mitaxov,V., Waksman,G. (1999). Investigation of phosphotyrosine 
recognition by the SH2 domain of the Src kinase. J.Mol.Biol. 293, 971-985. 
Brickell,P.M. (1992). The p60c-src family of protein-tyrosine kinases: structure, 
regulation, and function. Crit Rev.Oncog. 3, 401-446. 
Brown,D.A., London,E. (1997). Structure of detergent-resistant membrane domains: does 
phase separation occur in biological membranes? Biochem.Biophys.Res.Commun. 240, 
1-7. 
Brown,M.T., Cooper,J.A. (1996). Regulation, substrates and functions of src. 
Biochim.Biophys.Acta 1287, 121-149. 
 183 
Campbell,K.S., Buder,A., Deuschle,U. (1995). Interactions between the amino-terminal 
domain of p56lck and cytoplasmic domains of CD4 and CD8 alpha in yeast. 
Eur.J.Immunol. 25, 2408-2412. 
Cantrell,D.A. (2001). Phosphoinositide 3-kinase signalling pathways. J.Cell Sci. 114, 
1439-1445. 
Eck,M.J., Shoelson,S.E., Harrison,S.C. (1993). Recognition of a high-affinity 
phosphotyrosyl peptide by the Src homology-2 domain of p56lck. Nature 362, 87-91. 
Eliceiri,B.P., Paul,R., Schwartzberg,P.L., Hood,J.D., Leng,J., Cheresh,D.A. (1999). 
Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular 
permeability. Mol.Cell 4, 915-924. 
Erpel,T., Superti-Furga,G., Courtneidge,S.A. (1995). Mutational analysis of the Src SH3 
domain: the same residues of the ligand binding surface are important for intra- and 
intermolecular interactions. EMBO J. 14, 963-975. 
Fincham,V.J., Brunton,V.G., Frame,M.C. (2000). The SH3 domain directs acto-myosin-
dependent targeting of v-Src to focal adhesions via phosphatidylinositol 3-kinase. 
Mol.Cell Biol. 20, 6518-6536. 
Fincham,V.J., Chudleigh,A., Frame,M.C. (1999). Regulation of p190 Rho-GAP by v-Src 
is linked to cytoskeletal disruption during transformation. J.Cell Sci. 112 ( Pt 6), 947-956. 
Fukui,Y., Saltiel,A.R., Hanafusa,H. (1991). Phosphatidylinositol-3 kinase is activated in 
v-src, v-yes, and v-fps transformed chicken embryo fibroblasts. Oncogene 6, 407-411. 
Gould,K.L., Hunter,T. (1988). Platelet-derived growth factor induces multisite 
phosphorylation of pp60c-src and increases its protein-tyrosine kinase activity. Mol.Cell 
Biol. 8, 3345-3356. 
Greenway,A.L., Dutartre,H., Allen,K., McPhee,D.A., Olive,D., Collette,Y. (1999). 
Simian immunodeficiency virus and human immunodeficiency virus type 1 nef proteins 
show distinct patterns and mechanisms of Src kinase activation. J.Virol. 73, 6152-6158. 
Guappone,A.C., Flynn,D.C. (1997). The integrity of the SH3 binding motif of AFAP-110 
is required to facilitate tyrosine phosphorylation by, and stable complex formation with, 
Src. Mol.Cell Biochem. 175, 243-252. 
Hall,C.L., Lange,L.A., Prober,D.A., Zhang,S., Turley,E.A. (1996). pp60(c-src) is 
required for cell locomotion regulated by the hyaluronanreceptor RHAMM. Oncogene 
13, 2213-2224. 
Hansen,K., Alonso,G., Courtneidge,S.A., Ronnstrand,L., Heldin,C.H. (1997). PDGF-
induced phosphorylation of Tyr28 in the N-terminus of Fyn affects Fyn activation. 
Biochem.Biophys.Res.Commun. 241, 355-362. 
 184 
Honda,Z., Suzuki,T., Kono,H., Okada,M., Yamamoto,T., Ra,C., Morita,Y., 
Yamamoto,K. (2000). Sequential requirements of the N-terminal palmitoylation site and 
SH2 domain of Src family kinases in the initiation and progression of FcepsilonRI 
signaling. Mol.Cell Biol. 20, 1759-1771. 
Howell,S.B. (2000). Resistance to apoptosis in prostate cancer cells. Mol.Urol. 4, 225-
229. 
Ignelzi,M.A., Jr., Miller,D.R., Soriano,P., Maness,P.F. (1994). Impaired neurite 
outgrowth of src-minus cerebellar neurons on the cell adhesion molecule L1. Neuron 12, 
873-884. 
Imamura,T., Huang,J., Dalle,S., Ugi,S., Usui,I., Luttrell,L.M., Miller,W.E., 
Lefkowitz,R.J., Olefsky,J.M. (2001). {beta}-arrestin-mediated recruitment of the Src 
family kinase Yes mediates endothelin-1-stimulated glucose transport. J.Biol.Chem. 
Jiang,B.H., Agani,F., Passaniti,A., Semenza,G.L. (1997). V-SRC induces expression of 
hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular 
endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. 
Cancer Res. 57, 5328-5335. 
Jiang,B.H., Jiang,G., Zheng,J.Z., Lu,Z., Hunter,T., Vogt,P.K. (2001). 
Phosphatidylinositol 3-kinase signaling controls levels of hypoxia- inducible factor 1. 
Cell Growth Differ. 12, 363-369. 
Kanner,S.B., Reynolds,A.B., Vines,R.R., Parsons,J.T. (1990). Monoclonal antibodies to 
individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine 
kinases. Proc.Natl.Acad.Sci.U.S.A 87, 3328-3332. 
Kanner,S.B., Reynolds,A.B., Wang,H.C., Vines,R.R., Parsons,J.T. (1991). The SH2 and 
SH3 domains of pp60src direct stable association with tyrosine phosphorylated proteins 
p130 and p110. EMBO J. 10, 1689-1698. 
Kaplan,K.B., Swedlow,J.R., Morgan,D.O., Varmus,H.E. (1995). c-Src enhances the 
spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes 
Dev. 9, 1505-1517. 
Katagiri,K., Katagiri,T., Kajiyama,K., Uehara,Y., Yamamoto,T., Yoshida,T. (1992). 
Modulation of monocytic differentiation of HL-60 cells by inhibitors of protein tyrosine 
kinases. Cell Immunol. 140, 282-294. 
Katagiri,K., Katagiri,T., Koyama,Y., Morikawa,M., Yamamoto,T., Yoshida,T. (1991). 
Expression of src family genes during monocytic differentiation of HL- 60 cells. 
J.Immunol. 146, 701-707. 
Kitamura,N., Kitamura,A., Toyoshima,K., Hirayama,Y., Yoshida,M. (1982). Avian 
sarcoma virus Y73 genome sequence and structural similarity of its transforming gene 
product to that of Rous sarcoma virus. Nature 297, 205-208. 
 185 
Koong,A.C., Chen,E.Y., Mivechi,N.F., Denko,N.C., Stambrook,P., Giaccia,A.J. (1994). 
Hypoxic activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling 
pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Res. 54, 5273-
5279. 
Krasilnikov,M.A. (2000). Phosphatidylinositol-3 kinase dependent pathways: the role in 
control of cell growth, survival, and malignant transformation. Biochemistry (Mosc.) 65, 
59-67. 
Lawrence,D.S., Niu,J. (1998). Protein kinase inhibitors: the tyrosine-specific protein 
kinases. Pharmacol.Ther. 77, 81-114. 
Lee,P.J., Jiang,B.H., Chin,B.Y., Iyer,N.V., Alam,J., Semenza,G.L., Choi,A.M. (1997). 
Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 
gene in response to hypoxia. J.Biol.Chem. 272, 5375-5381. 
Loganzo,F., Jr., Dosik,J.S., Zhao,Y., Vidal,M.J., Nanus,D.M., Sudol,M., Albino,A.P. 
(1993). Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human 
malignant melanoma. Oncogene 8, 2637-2644. 
Luton,F., Verges,M., Vaerman,J.P., Sudol,M., Mostov,K.E. (1999). The SRC family 
protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo. Mol.Cell 4, 
627-632. 
Mackay,D.J., Hall,A. (1998). Rho GTPases. J.Biol.Chem. 273, 20685-20688. 
Maines,M.D. (1997). The heme oxygenase system: a regulator of second messenger 
gases. Annu.Rev.Pharmacol.Toxicol. 37, 517-554. 
Marchetti,D., Parikh,N., Sudol,M., Gallick,G.E. (1998). Stimulation of the protein 
tyrosine kinase c-Yes but not c-Src by neurotrophins in human brain-metastatic 
melanoma cells. Oncogene 16, 3253-3260. 
Masuya,Y., Hioki,K., Tokunaga,R., Taketani,S. (1998). Involvement of the tyrosine 
phosphorylation pathway in induction of human heme oxygenase-1 by hemin, sodium 
arsenite, and cadmium chloride. J.Biochem.(Tokyo) 124, 628-633. 
Mayer,B.J., Baltimore,D. (1994). Mutagenic analysis of the roles of SH2 and SH3 
domains in regulation of the Abl tyrosine kinase. Mol.Cell Biol. 14, 2883-2894. 
Moarefi,I., LaFevre-Bernt,M., Sicheri,F., Huse,M., Lee,C.H., Kuriyan,J., Miller,W.T. 
(1997). Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. 
Nature 385, 650-653. 
Moasser,M.M., Srethapakdi,M., Sachar,K.S., Kraker,A.J., Rosen,N. (1999). Inhibition of 
Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 59, 
6145-6152. 
 186 
Mohler,P.J., Kreda,S.M., Boucher,R.C., Sudol,M., Stutts,M.J., Milgram,S.L. (1999). Yes-
associated protein 65 localizes p62(c-Yes) to the apical compartment of airway epithelia 
by association with EBP50. J.Cell Biol. 147, 879-890. 
Molinari,M. (2000). Cell cycle checkpoints and their inactivation in human cancer. Cell 
Prolif. 33, 261-274. 
Montellano,P.R. (2000). The mechanism of heme oxygenase. Curr.Opin.Chem.Biol. 4, 
221-227. 
Morgan,D.O., Kaplan,J.M., Bishop,J.M., Varmus,H.E. (1989). Mitosis-specific 
phosphorylation of p60c-src by p34cdc2-associated protein kinase. Cell 57, 775-786. 
Mukhopadhyay,D., Tsiokas,L., Zhou,X.M., Foster,D., Brugge,J.S., Sukhatme,V.P. 
(1995). Hypoxic induction of human vascular endothelial growth factor expression 
through c-Src activation. Nature 375, 577-581. 
Muthuswamy,S.K., Muller,W.J. (1995). Activation of Src family kinases in Neu-induced 
mammary tumors correlates with their association with distinct sets of tyrosine 
phosphorylated proteins in vivo. Oncogene 11, 1801-1810. 
Noble,M.E., Musacchio,A., Saraste,M., Courtneidge,S.A., Wierenga,R.K. (1993). Crystal 
structure of the SH3 domain in human Fyn; comparison of the three-dimensional 
structures of SH3 domains in tyrosine kinases and spectrin. EMBO J. 12, 2617-2624. 
Odajima,J., Matsumura,I., Sonoyama,J., Daino,H., Kawasaki,A., Tanaka,H., Inohara,N., 
Kitamura,T., Downward,J., Nakajima,K., Hirano,T., Kanakura,Y. (2000). Full oncogenic 
activities of v-Src are mediated by multiple signaling pathways. Ras as an essential 
mediator for cell survival. J.Biol.Chem. 275, 24096-24105. 
Owens,D.W., McLean,G.W., Wyke,A.W., Paraskeva,C., Parkinson,E.K., Frame,M.C., 
Brunton,V.G. (2000). The catalytic activity of the Src family kinases is required to 
disrupt cadherin-dependent cell-cell contacts. Mol.Biol.Cell 11, 51-64. 
Page,S.T., van Oers,N.S., Perlmutter,R.M., Weiss,A., Pullen,A.M. (1997). Differential 
contribution of Lck and Fyn protein tyrosine kinases to intraepithelial lymphocyte 
development. Eur.J.Immunol. 27, 554-562. 
Park,J., Meisler,A.I., Cartwright,C.A. (1993). c-Yes tyrosine kinase activity in human 
colon carcinoma. Oncogene 8, 2627-2635. 
Pawlak,G., Helfman,D.M. (2001). Cytoskeletal changes in cell transformation and 
tumorigenesis. Curr.Opin.Genet.Dev. 11, 41-47. 
Pellicena,P., Stowell,K.R., Miller,W.T. (1998). Enhanced phosphorylation of Src family 
kinase substrates containing SH2 domain binding sites. J.Biol.Chem. 273, 15325-15328. 
 187 
Pena,S.V., Melhem,M.F., Meisler,A.I., Cartwright,C.A. (1995). Elevated c-yes tyrosine 
kinase activity in premalignant lesions of the colon. Gastroenterology 108, 117-124. 
Penuel,E., Martin,G.S. (1999). Transformation by v-Src: Ras-MAPK and PI3K-mTOR 
mediate parallel pathways. Mol.Biol.Cell 10, 1693-1703. 
Pugh,C.W., Gleadle,J., Maxwell,P.H. (2001). Hypoxia and oxidative stress in breast 
cancer. Hypoxia signalling pathways. Breast Cancer Res. 3, 313-317. 
Qian,Y., Baisden,J.M., Zot,H.G., Van Winkle,W.B., Flynn,D.C. (2000). The carboxy 
terminus of AFAP-110 modulates direct interactions with actin filaments and regulates its 
ability to alter actin filament integrity and induce lamellipodia formation. Exp.Cell Res. 
255, 102-113. 
Reif,K., Nobes,C.D., Thomas,G., Hall,A., Cantrell,D.A. (1996). Phosphatidylinositol 3-
kinase signals activate a selective subset of Rac/Rho-dependent effector pathways. 
Curr.Biol. 6, 1445-1455. 
Ren,X.D., Schwartz,M.A. (1998). Regulation of inositol lipid kinases by Rho and Rac. 
Curr.Opin.Genet.Dev. 8, 63-67. 
Resh,M.D. (1994). Myristylation and palmitylation of Src family members: the fats of the 
matter. Cell 76, 411-413. 
Rickles,R.J., Botfield,M.C., Weng,Z., Taylor,J.A., Green,O.M., Brugge,J.S., Zoller,M.J. 
(1994). Identification of Src, Fyn, Lyn, PI3K and Abl SH3 domain ligands using phage 
display libraries. EMBO J. 13, 5598-5604. 
Rickles,R.J., Botfield,M.C., Zhou,X.M., Henry,P.A., Brugge,J.S., Zoller,M.J. (1995). 
Phage display selection of ligand residues important for Src homology 3 domain binding 
specificity. Proc.Natl.Acad.Sci.U.S.A 92, 10909-10913. 
Robbins,S.M., Quintrell,N.A., Bishop,J.M. (1995). Myristoylation and differential 
palmitoylation of the HCK protein- tyrosine kinases govern their attachment to 
membranes and association with caveolae. Mol.Cell Biol. 15, 3507-3515. 
Roussel,M.F. (1998). Key effectors of signal transduction and G1 progression. 
Adv.Cancer Res. 74, 1-24. 
Sandau,K.B., Faus,H.G., Brune,B. (2000). Induction of hypoxia-inducible-factor 1 by 
nitric oxide is mediated via the PI 3K pathway. Biochem.Biophys.Res.Commun. 278, 
263-267. 
Scott,M.P., Miller,W.T. (2000). A peptide model system for processive phosphorylation 
by Src family kinases. Biochemistry 39, 14531-14537. 
Seko,Y., Takahashi,N., Tobe,K., Kadowaki,T., Yazaki,Y. (1997). Hypoxia and 
hypoxia/reoxygenation activate p65PAK, p38 mitogen- activated protein kinase (MAPK), 
 188 
and stress-activated protein kinase (SAPK) in cultured rat cardiac myocytes. 
Biochem.Biophys.Res.Commun. 239, 840-844. 
Seko,Y., Tobe,K., Takahashi,N., Kaburagi,Y., Kadowaki,T., Yazaki,Y. (1996). Hypoxia 
and hypoxia/reoxygenation activate Src family tyrosine kinases and p21ras in cultured rat 
cardiac myocytes. Biochem.Biophys.Res.Commun. 226, 530-535. 
Shaw,A.S., Amrein,K.E., Hammond,C., Stern,D.F., Sefton,B.M., Rose,J.K. (1989). The 
lck tyrosine protein kinase interacts with the cytoplasmic tail of the CD4 glycoprotein 
through its unique amino-terminal domain. Cell  59, 627-636. 
Shenoy-Scaria,A.M., Dietzen,D.J., Kwong,J., Link,D.C., Lublin,D.M. (1994). Cysteine3 
of Src family protein tyrosine kinase determines palmitoylation and localization in 
caveolae. J.Cell Biol. 126, 353-363. 
Shenoy,S., Choi,J.K., Bagrodia,S., Copeland,T.D., Maller,J.L., Shalloway,D. (1989). 
Purified maturation promoting factor phosphorylates pp60c-src at the sites 
phosphorylated during fibroblast mitosis. Cell 57, 763-774. 
Sicheri,F., Moarefi,I., Kuriyan,J. (1997). Crystal structure of the Src family tyrosine 
kinase Hck. Nature 385, 602-609. 
Sohara,Y., Ishiguro,N., Machida,K., Kurata,H., Thant,A.A., Senga,T., Matsuda,S., 
Kimata,K., Iwata,H., Hamaguchi,M. (2001). Hyaluronan activates cell motility of v-Src-
transformed cells via Ras- mitogen-activated protein kinase and phosphoinositide 3-
kinase-Akt in a tumor-specific manner. Mol.Biol.Cell 12, 1859-1868. 
Songyang,Z., Shoelson,S.E., Chaudhuri,M., Gish,G., Pawson,T., Haser,W.G., King,F., 
Roberts,T., Ratnofsky,S., Lechleider,R.J., . (1993). SH2 domains recognize specific 
phosphopeptide sequences. Cell 72, 767-778. 
Soriano,P., Montgomery,C., Geske,R., Bradley,A. (1991). Targeted disruption of the c-
src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693-702. 
Sparks,A.B., Rider,J.E., Hoffman,N.G., Fowlkes,D.M., Quillam,L.A., Kay,B.K. (1996). 
Distinct ligand preferences of Src homology 3 domains from Src, Yes, Abl, Cortactin, 
p53bp2, PLCgamma, Crk, and Grb2. Proc.Natl.Acad.Sci.U.S.A 93, 1540-1544. 
Stein,P.L., Vogel,H., Soriano,P. (1994). Combined deficiencies of Src, Fyn, and Yes 
tyrosine kinases in mutant mice. Genes Dev. 8, 1999-2007. 
Sudol,M. (1994). Yes-associated protein (YAP65) is a proline-rich phosphoprotein that 
binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 9, 2145-2152. 
Sudol,M., Kieswetter,C., Zhao,Y.H., Dorai,T., Wang,L.H., Hanafusa,H. (1988). 
Nucleotide sequence of a cDNA for the chick yes proto-oncogene: comparison with the 
viral yes gene. Nucleic Acids Res. 16, 9876. 
 189 
Sugawara,K., Sugawara,I., Sukegawa,J., Akatsuka,T., Yamamoto,T., Morita,M., Mori,S., 
Toyoshima,K. (1991). Distribution of c-yes-1 gene product in various cells and tissues. 
Br.J.Cancer 63, 508-513. 
Suzuki,T., Kono,H., Hirose,N., Okada,M., Yamamoto,T., Yamamoto,K., Honda,Z. 
(2000). Differential involvement of Src family kinases in Fc gamma receptor- mediated 
phagocytosis. J.Immunol. 165, 473-482. 
Thomas,S.M., Brugge,J.S. (1997). Cellular functions regulated by Src family kinases. 
Annu.Rev.Cell Dev.Biol. 13, 513-609. 
Toyoshima,K., Yamamoto,T., Kawai,S., Yoshida,M. (1987). Viral oncogenes, v-yes and 
v-erbB, and their cellular counterparts. Adv.Virus Res. 32, 97-127. 
Tsygankova,O.M., Peng,M., Maloney,J.A., Hopkins,N., Williamson,J.R. (1998). 
Angiotensin II induces diverse signal transduction pathways via both Gq and Gi proteins 
in liver epithelial cells. J.Cell Biochem. 69, 63-71. 
van't Hof,W., Resh,M.D. (1997). Rapid plasma membrane anchoring of newly 
synthesized p59fyn: selective requirement for NH2-terminal myristoylation and 
palmitoylation at cysteine-3. J.Cell Biol. 136, 1023-1035. 
Vonakis,B.M., Chen,H., Haleem-Smith,H., Metzger,H. (1997). The unique domain as the 
site on Lyn kinase for its constitutive association with the high affinity receptor for IgE. 
J.Biol.Chem. 272, 24072-24080. 
Waksman,G., Kominos,D., Robertson,S.C., Pant,N., Baltimore,D., Birge,R.B., 
Cowburn,D., Hanafusa,H., Mayer,B.J., Overduin,M., . (1992). Crystal structure of the 
phosphotyrosine recognition domain SH2 of v- src complexed with tyrosine-
phosphorylated peptides. Nature 358, 646-653. 
Weng,Z., Thomas,S.M., Rickles,R.J., Taylor,J.A., Brauer,A.W., Seidel-Dugan,C., 
Michael,W.M., Dreyfuss,G., Brugge,J.S. (1994). Identification of Src, Fyn, and Lyn 
SH3-binding proteins: implications for a function of SH3 domains. Mol.Cell Biol. 14, 
4509-4521. 
Wong,J., Straus,D., Chan,A.C. (1998). Genetic evidence of a role for Lck in T-cell 
receptor function independent or downstream of ZAP-70/Syk protein tyrosine kinases. 
Mol.Cell Biol. 18, 2855-2866. 
Xu,W., Doshi,A., Lei,M., Eck,M.J., Harrison,S.C. (1999). Crystal structures of c-Src 
reveal features of its autoinhibitory mechanism. Mol.Cell 3, 629-638. 
Xu,W., Harrison,S.C., Eck,M.J. (1997). Three-dimensional structure of the tyrosine 
kinase c-Src. Nature 385, 595-602. 
 190 
Yurchak,L.K., Sefton,B.M. (1995). Palmitoylation of either Cys-3 or Cys-5 is required 
for the biological activity of the Lck tyrosine protein kinase. Mol.Cell Biol. 15, 6914-
6922. 
Zhao,Y.H., Krueger,J.G., Sudol,M. (1990). Expression of cellular-yes protein in 
mammalian tissues. Oncogene 5, 1629-1635. 
Zhong,H., Chiles,K., Feldser,D., Laughner,E., Hanrahan,C., Georgescu,M.M., 
Simons,J.W., Semenza,G.L. (2000). Modulation of hypoxia-inducible factor 1alpha 
expression by the epidermal growth factor/phosphatidylinositol 3-
kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor 
angiogenesis and therapeutics. Cancer Res. 60, 1541-1545. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 191 
 
CURRICULUM VITAE 
Justin Summy, Ph.D. (anticipated, December 2001) 
 
Personal and Professional 
 
Personal 
 
 Born: Mount Pleasant, PA 
 Marital Status: Single 
 Citizenship:  US citizen.  SSN: 457-81-5256 
 Current Home: 113 Mountaineer Village, Morgantown WV, 26508 
 Current Work: 2813 MBR Cancer Center, West Virginia University, Morgantown, 
WV 26506-9300, phone: 304-293-0501 
 
Education 
 
 1992-1996 - West Virginia University    B.S., Biology.  With honors, summa cum    
      laude. 
 1996-2001 - West Virginia University   Ph.D., Microbiology & Immunology 
 Thesis: Specificity in signaling by cYes (mentor, Daniel C. Flynn, Ph.D.). 
 
Professional Experience 
 
1994-1995: Undergraduate Research Fellow, Lisa Salati, PhD. West Virginia 
University 
1996-1997: Teaching Assistant, Department of Microbiology & Immunology, West 
Virginia University 
1997-2001: Research Assistant, Mary Babb Randolph Cancer Center, West Virginia 
University 
2001 - present: Post-doctoral fellow, Dr. Gary Gallick, MD Anderson Cancer Center. 
 
Active Society Membership 
 
1. American Society for Cell Biology (ASCB): Student Member. 
 
Honors 
 
1. Presidential Scholar (full scholarship). West Virginia University. 1992-1996. 
2. Golden Key Honor Society.  1994 
3. Beta Beta Beta, National Biology Honor Society.  1995 
4. Phi Beta Kappa.  1996 
5. Swiger Graduate Student Fellowship.  1997-2000. 
6. Outstanding Graduate Student Award - WVU Health Sciences Center.  1997. 
 192 
7. Student Travel Award - American Society for Cell Biology, 38th National Meeting, 
San Francisco, CA December 1998. 
 
Area of Research Expertise: Cancer, signal transduction, tyrosine kinases. 
 
RESEARCH 
Funding Obtained: 
Active/Pending/Expired expired 
Project Number (Principal Investigator): (Justin M. Summy) 
Source: Swiger Foundation 
Title of Project (and/or Subproject): Specificity in signaling by cYes 
Dates of Approved/Proposed Project: 8/1/1997 to 7/31/00 
Annual Direct Costs / Percent Effort: $15,000 / 100% effort 
The major goals of this project are...A graduate student fellowship award that paid the 
salary for JMS.  
 
 
Active/Pending/Expired expired 
Project Number (Principal Investigator): (Daniel C. Flynn, PhD) 
Source: Emmet G. and Brownie E. McDowell Fund 
Title of Project (and/or Subproject): Activation of telomerase by Src, Yes and Myb 
proto-oncogenes 
Dates of Approved/Proposed Project: 3/1/98 to 2/28/99 
Annual Direct Costs / Percent Effort: $20,000 / 100% effort 
The major goals of this project are...This grant supported the research project of J.M. 
Summy.  Proposal was written by JMS and submitted on his behalf by DCF.  
 
   
PUBLICATIONS 
  
1. Qian, Y., A.C. Guappone, J.M. Baisden, M.W. Hill, J.M. Summy, and D.C. Flynn. 
1999. Monoclonal Antibodies Directed Against AFAP-110 Recognize Species-
specific and Conserved Epitopes. Hybridoma 18:167-175. 
2. Summy, J.M.., A.C. Guappone, M.Sudol, and D.C. Flynn. 2000. SH2 and SH3 
interactions can dictate specificity in substrate selection between cSrc and cYes. 
Oncogene, 19:155-160. 
3. Summy J.M., J. Hoey, and D.C. Flynn. 2000. Chimeric constructs containing the 
SH4/Unique domains of cYes can restrict the ability of Src527F to efficiently 
upregulate Heme Oxygenase-1 expression. Cell. Signaling, 12:887-897. 
4. Summy, J. M. D.C. Flynn and M. Sudol.  Src family tyrosine kinases in growth 
control.  Invited Review, Frontiers in Biochemistry, Submitted. 
 193 
5. Baisden J.M., L. Cherezova, Y. Qian, J.M. Summy, A. Guappone-Koay, B. Han, M. 
Liu, X. Shi and D.C. Flynn.  PKC alters actin filament integrity and directs activation 
of cSrc through interactions with the Src-binding partner, AFAP-110.  Submitted. 
6. Summy, J.M., B.-H. Jiang and D.C. Flynn.  The c-Yes amino terminal SH4 and 
Unique domains prevent actin filament rearrangement and Phosphatidylinositol-3-
kinase activation by Src527F/c-Yes chimeric proteins.  Manuscript in preparation.  
7. Summy J.M. and D.C. Flynn.  Differential responses to activated cYes in CEF and 
DF-1 cells.  Manuscript in preparation. 
 
                                                       ABSTRACTS 
 
      1.  J.M. Summy and D.C. Flynn.  Role of the functional domains in directing  
           signaling specificity between Src and Yes.  American Society for Cell Biology,   
           1998. 
     2.  J.M. Summy, A.C. Guappone, and D.C. Flynn.  Roles of the c-Src and c-Yes  
           functional domains in directing signaling specificity.  American Association for 
           Cancer Research, 1998. 
     3.  J.M. Summy and D.C. Flynn.   The c-Yes amino terminus inhibits the ability of  
           fully activated c-Src/c-Yes chimeras to induce cell transformation in chicken 
           embryo fibroblasts.  Meeting on Oncogenes, 2000. 
 
 
 
Research statement:  
  
         Src family kinases represent key components of a wide variety of cellular signal 
transduction pathways, contributing to the regulation of such diverse events as vesicular 
trafficking, cell division, survival, motility, adhesion, and spreading.  Two of these 
kinases, c-Src and c-Yes are abnormally activated in a variety of human cancers, and thus 
may contribute to tumor development or progression.   c-Src and c-Yes may in turn 
represent potential targets for anti-tumor therapy.  However, as many tumors only harbor 
abnormal activation of one of these proteins, it may be beneficial to target the proteins 
individually.  In order to accomplish this, one must have an understanding of how these 
proteins are different and able to send specific signals.  We have sought to understand the 
contributions of the functional domains to specificity in signaling between Src and Yes.   
In order to shed light on this issue, we have generated Src/Yes chimeras in which 
the SH3, SH2, SH3 and SH2, or SH4, Unique, SH3, and SH2 domains of c-Src or fully 
activated Src527F were replaced by the corresponding domains from c-Yes.  Upon 
expressing these constructs in chicken embryo fibroblasts (CEF), we have determined 
that, while the Yes SH3 and SH2 domains do not appear to affect Src substrate selection, 
they do alter the profile of proteins with which Src is able to form stable complexes in 
vivo.  Replacement of the Src SH3 domain with that of Yes results in a loss of ability of 
Src to co-immunoprecipitate with AFAP-110.  Replacement of the Src SH2 domain with 
that of c-Yes results in a gain of ability of Src to co-immunoprecipitate with an unknown 
87 kDa phosphoprotein.  pp87 may represent an important component of a heretofore 
unidentified Yes-specific signaling pathway.  
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Replacement of the Src amino terminus (SH4 and Unique domains) with those of 
c-Yes results in a loss of ability of Src527F to induce CEF transformation.  This loss of 
transformation capacity seems to require both the SH4 and Unique domains, as 
replacement of either domain individually still allows for cell transformation.  We 
hypothesize that the c-Yes SH4 and Unique domains may cooperatively serve to sequester 
Src away from key substrates or signaling partners necessary for activation of a pathway 
necessary for cell transformation. 
 Understanding the roles of the functional domains in allowing these extremely 
homologous kinases to send specific signals will be important in understanding the 
biology of these proteins and may contribute to the overall understanding of signaling 
specificity between Src family members.  In addition, knowledge of how Src and Yes are 
able to generate unique signals may facilitate the design of compounds that can 
selectively inhibit signals sent by each kinase individually.  Such compounds would 
further our understanding of the biological roles of these proteins and may prove useful 
as chemotherapeutic agents for cancers in which an individual Src family kinase is 
abnormally activated. 
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